<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Vortioxetine for depression in adults - Koesters, M - 2017 | Cochrane Library</title> <meta content="Vortioxetine for depression in adults - Koesters, M - 2017 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011520.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Vortioxetine for depression in adults - Koesters, M - 2017 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011520.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD011520.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Vortioxetine for depression in adults" name="citation_title"/> <meta content="Markus Koesters" name="citation_author"/> <meta content="Ulm University" name="citation_author_institution"/> <meta content="markus.koesters@uni-ulm.de" name="citation_author_email"/> <meta content="Giovanni Ostuzzi" name="citation_author"/> <meta content="University of Verona" name="citation_author_institution"/> <meta content="Giuseppe Guaiana" name="citation_author"/> <meta content="Western University" name="citation_author_institution"/> <meta content="Johanna Breilmann" name="citation_author"/> <meta content="Ulm University" name="citation_author_institution"/> <meta content="Corrado Barbui" name="citation_author"/> <meta content="University of Verona" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="7" name="citation_issue"/> <meta content="10.1002/14651858.CD011520.pub2" name="citation_doi"/> <meta content="2017" name="citation_date"/> <meta content="2017/07/05" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011520.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011520.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011520.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Antidepressive Agents [*therapeutic use]; Depressive Disorder, Major [*drug therapy]; Duloxetine Hydrochloride [therapeutic use]; Patient Dropouts [statistics &amp; numerical data]; Piperazines [*therapeutic use]; Placebos [therapeutic use]; Randomized Controlled Trials as Topic; Remission Induction; Serotonin and Noradrenaline Reuptake Inhibitors [therapeutic use]; Sulfides [*therapeutic use]; Venlafaxine Hydrochloride [therapeutic use]; Vortioxetine" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011520.pub2&amp;doi=10.1002/14651858.CD011520.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011520.pub2&amp;doi=10.1002/14651858.CD011520.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011520.pub2&amp;doi=10.1002/14651858.CD011520.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011520.pub2&amp;doi=10.1002/14651858.CD011520.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011520.pub2&amp;doi=10.1002/14651858.CD011520.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011520.pub2&amp;doi=10.1002/14651858.CD011520.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011520.pub2&amp;doi=10.1002/14651858.CD011520.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011520.pub2&amp;doi=10.1002/14651858.CD011520.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011520.pub2&amp;doi=10.1002/14651858.CD011520.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011520.pub2&amp;doi=10.1002/14651858.CD011520.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011520.pub2&amp;doi=10.1002/14651858.CD011520.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011520.pub2&amp;doi=10.1002/14651858.CD011520.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011520.pub2&amp;doi=10.1002/14651858.CD011520.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011520.pub2&amp;doi=10.1002/14651858.CD011520.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011520.pub2&amp;doi=10.1002/14651858.CD011520.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011520.pub2&amp;doi=10.1002/14651858.CD011520.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011520.pub2&amp;doi=10.1002/14651858.CD011520.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011520.pub2&amp;doi=10.1002/14651858.CD011520.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011520.pub2&amp;doi=10.1002/14651858.CD011520.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011520.pub2&amp;doi=10.1002/14651858.CD011520.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011520.pub2&amp;doi=10.1002/14651858.CD011520.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011520.pub2&amp;doi=10.1002/14651858.CD011520.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011520.pub2&amp;doi=10.1002/14651858.CD011520.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774054000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774081000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000"}};Liferay.authToken="zCmos3jT";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD011520\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD011520\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011520\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011520\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1559916434000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","zh_HANS","ru","ms","hr","pl","fa"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD011520.pub2",title:"Vortioxetine for depression in adults",firstPublishedDate:"Jul 5, 2017 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Common Mental Disorders Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738735355000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=zCmos3jT&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011520.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD011520.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD011520.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD011520.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011520.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD011520.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD011520.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD011520.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD011520.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD011520.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;Abstract&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;pl&quot;,&quot;title&quot;:&quot;Streszczenie prostym językiem&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;Plain language summary&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD011520.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD011520.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD011520.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD011520.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>11757 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD011520.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011520.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011520.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011520.pub2/full#CD011520-abs-0004"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011520.pub2/full#CD011520-sec-0140"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011520.pub2/full#CD011520-sec-0022"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011520.pub2/full#CD011520-sec-0023"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011520.pub2/full#CD011520-sec-0028"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011520.pub2/full#CD011520-sec-0029"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011520.pub2/full#CD011520-sec-0071"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011520.pub2/full#CD011520-sec-0129"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD011520.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011520.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011520.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011520.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD011520.pub2/media/CDSR/CD011520/table_n/CD011520StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD011520.pub2/media/CDSR/CD011520/table_n/CD011520StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011520.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011520.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011520.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD011520.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD011520.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD011520.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2017 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD011520.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Vortioxetine for depression in adults</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011520.pub2/information#CD011520-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Markus Koesters</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011520.pub2/information#CD011520-cr-0003">Giovanni Ostuzzi</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011520.pub2/information#CD011520-cr-0004">Giuseppe Guaiana</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011520.pub2/information#CD011520-cr-0005">Johanna Breilmann</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011520.pub2/information#CD011520-cr-0006">Corrado Barbui</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD011520.pub2/information/en#CD011520-sec-0149">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 05 July 2017 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD011520.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD011520.pub2">https://doi.org/10.1002/14651858.CD011520.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD011520-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD011520-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD011520-abs-0003">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD011520-abs-0011">فارسی</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD011520-abs-0002">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD011520-abs-0001" lang="en"> <section id="CD011520-sec-0001"> <h3 class="title" id="CD011520-sec-0001">Background</h3> <p>Major depressive disorder is a common mental disorder affecting a person's mind, behaviour and body. It is expressed as a variety of symptoms and is associated with substantial impairment. Despite a range of pharmacological and non‐pharmacological treatment options, there is still room for improvement of the pharmacological treatment of depression in terms of efficacy and tolerability. The latest available antidepressant is vortioxetine. It is assumed that vortioxetine's antidepressant action is related to a direct modulation of serotonergic receptor activity and inhibition of the serotonin transporter. The mechanism of action is not fully understood, but it is claimed to be novel. Vortioxetine was placed in the category of "Other" antidepressants and may therefore provide an alternative to existing antidepressant drugs. </p> </section> <section id="CD011520-sec-0002"> <h3 class="title" id="CD011520-sec-0002">Objectives</h3> <p>To assess the efficacy and acceptability of vortioxetine compared with placebo and other antidepressant drugs in the treatment of acute depression in adults. </p> </section> <section id="CD011520-sec-0003"> <h3 class="title" id="CD011520-sec-0003">Search methods</h3> <p>We searched Cochrane's Depression, Anxiety and Neurosis Review Group's Specialised Register to May 2016 without applying any restrictions to date, language or publication status. We checked reference lists of relevant studies and reviews, regulatory agency reports and trial databases. </p> </section> <section id="CD011520-sec-0004"> <h3 class="title" id="CD011520-sec-0004">Selection criteria</h3> <p>We included randomised controlled trials comparing the efficacy, tolerability, or both of vortioxetine versus placebo or any other antidepressant agent in the treatment of acute depression in adults. </p> </section> <section id="CD011520-sec-0005"> <h3 class="title" id="CD011520-sec-0005">Data collection and analysis</h3> <p>Two review authors independently selected the studies and extracted data. We extracted data on study characteristics, participant characteristics, intervention details and outcome measures in terms of efficacy, acceptability and tolerability. We analysed intention‐to‐treat (ITT) data only and used risk ratios (RR) as effect sizes for dichotomous data and mean differences (MD) for continuous data with 95% confidence intervals (CI). Meta‐analyses used random‐effects models. </p> </section> <section id="CD011520-sec-0006"> <h3 class="title" id="CD011520-sec-0006">Main results</h3> <p>We included 15 studies (7746 participants) in this review. Seven studies were placebo controlled; eight studies compared vortioxetine to serotonin‐norepinephrine reuptake inhibitors (SNRIs). We were unable to identify any study that compared vortioxetine to antidepressant drugs from other classes, such as selective serotonin reuptake inhibitors (SSRIs). </p> <p>Vortioxetine may be more effective than placebo across the three efficacy outcomes: response (Mantel‐Haenszel RR 1.35, 95% CI 1.22 to 1.49; 14 studies, 6220 participants), remission (RR 1.32, 95% CI 1.15 to 1.53; 14 studies, 6220 participants) and depressive symptoms measured using the Montgomery‐Åsberg Depression Scale (MADRS) (score range: 0 to 34; higher score means worse outcome: MD ‐2.94, 95% CI ‐4.07 to ‐1.80; 14 studies, 5566 participants). The quality of the evidence was low for response and remission and very low for depressive symptoms. We found no evidence of a difference in total dropout rates (RR 1.05, 95% CI 0.93 to 1.19; 14 studies, 6220 participants). More participants discontinued vortioxetine than placebo because of adverse effects (RR 1.41, 95% CI 1.09 to 1.81; 14 studies, 6220 participants) but fewer discontinued due to inefficacy (RR 0.56, 95% CI 0.34 to 0.90, P = 0.02; 14 studies, 6220 participants). The quality of the evidence for dropouts was moderate.The subgroup and sensitivity analyses did not reveal factors that significantly influenced the results. </p> <p>In comparison with other antidepressants, very low‐quality evidence from eight studies showed no clinically significant difference between vortioxetine and SNRIs as a class for response (RR 0.91, 95% CI 0.82 to 1.00; 3159 participants) or remission (RR 0.89, 95% CI 0.77 to 1.03; 3155 participants). There was a small difference favouring SNRIs for depressive symptom scores on the MADRS (MD 1.52, 95% CI 0.50 to 2.53; 8 studies, 2807 participants). Very low quality evidence from eight studies (3159 participants) showed no significant differences between vortioxetine and the SNRIs as a class for total dropout rates (RR 0.89, 95% CI 0.73 to 1.08), dropouts due to adverse events (RR 0.74, 95% CI 0.51 to 1.08) and dropouts due to inefficacy (RR 1.52, 95% CI 0.70 to 3.30). </p> <p>Against individual antidepressants, analyses suggested that vortioxetine may be less effective than duloxetine in terms of response rates (RR 0.86, 95% CI 0.79 to 0.94; 6 studies, 2392 participants) and depressive symptoms scores on the MADRS scale (MD 1.99, 95% CI 1.15 to 2.83; 6 studies; 2106 participants). Against venlafaxine, meta‐analysis of two studies found no statistically significant differences (response: RR 1.03, 95% CI 0.85 to 1.25; 767 participants; depressive symptom scores: MD 0.02, 95% CI ‐2.49 to 2.54; 701 participants). In terms of number of participants reporting at least one adverse effect (tolerability), vortioxetine was better than the SNRIs as a class (RR 0.90, 95% CI 0.86 to 0.94; 8 studies, 3134 participants) and duloxetine (RR 0.89, 95% CI 0.84 to 0.95; 6 studies; 2376 participants). However, the sensitivity analysis casts some doubts on this result, as only two studies used comparable dosing. </p> <p>We judged none of the studies to have a high risk of bias for any domain, but we rated all studies to have an unclear risk of bias of selective reporting and other biases. </p> </section> <section id="CD011520-sec-0007"> <h3 class="title" id="CD011520-sec-0007">Authors' conclusions</h3> <p>The place of vortioxetine in the treatment of acute depression is unclear. Our analyses showed vortioxetine may be more effective than placebo in terms of response, remission and depressive symptoms, but the clinical relevance of these effects is uncertain. Furthermore, the quality of evidence to support these findings was generally low. In comparison to SNRIs, we found no advantage for vortioxetine. Vortioxetine was less effective than duloxetine, but fewer people reported adverse effects when treated with vortioxetine compared to duloxetine. However, these findings are uncertain and not well supported by evidence. A major limitation of the current evidence is the lack of comparisons with the SSRIs, which are usually recommended as first‐line treatments for acute depression. Studies with direct comparisons to SSRIs are needed to address this gap and may be supplemented by network meta‐analyses to define the role of vortioxetine in the treatment of depression. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD011520-abs-0004" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD011520-abs-0004">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD011520-abs-0010">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD011520-abs-0012">فارسی</a> </li> <li class="section-language"> <a class="" href="full/hr#CD011520-abs-0008">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/ms#CD011520-abs-0007">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/pl#CD011520-abs-0009">Polski</a> </li> <li class="section-language"> <a class="" href="full/ru#CD011520-abs-0006">Русский</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD011520-abs-0005">简体中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD011520-abs-0004" lang="en"> <h3>Vortioxetine for the treatment of depression in adults</h3> <p><b>Why is this review important?</b> </p> <p>Many people suffer from major depression. Major depression is a serious illness that can cause significant distress both to patients and their families. Major depression affects people's work and relationships, but can also affect people physically, for example by changing concentration or appetite. Available antidepressant medicines are not always effective in treating major depression and may also have unpleasant side effects. This review compares a new antidepressant, vortioxetine, to placebo (a pretend treatment, e.g. sugar tablet) and other antidepressants. It is assumed that vortioxetine works differently from other available antidepressants and it is important to know if it is an effective treatment and a possible alternative for already available treatments. </p> <p><b>Who will be interested in this review?</b> </p> <p>People affected by major depression and their families, general practitioners (GPs), psychiatrists, and pharmacists and other professionals working in adult mental health services. </p> <p><b>What questions does this review aim to answer?</b> </p> <p>Is vortioxetine more effective than placebo in treating individual with an episode of major depression?<br/> Is vortioxetine more or less effective than other available antidepressant treatments?<br/> Do more or fewer people stay in treatment when treated with vortioxetine compared to placebo or other antidepressants?<br/> Do more or fewer people have side effects when treated with vortioxetine compared to other antidepressants? </p> <p><b>Which studies were included in the review?</b> </p> <p>In May 2016, we searched electronic medical databases to find trials that compared vortioxetine to placebo or other antidepressants. We included only studies that used a randomised controlled design (where people were randomly put into one of two or more treatment groups) and had adults (aged over 18 years) with a diagnosis of major depression. We included 15 trials, involving 7746 participants in the review. </p> <p><b>What does the evidence from the review tell us?</b> </p> <p>The quality of the evidence ranged from very low to moderate, depending on the outcome (what symptom or effect was measured) and the comparison. Vortioxetine was more effective than placebo, but it was not more effective than other commonly used antidepressants. The studies found no difference in people stopping their treatment compared to placebo or other antidepressants. Vortioxetine was only compared to one type of medicine (called SNRIs) and not compared to the most frequently prescribed antidepressants. The outcomes varied markedly across studies. </p> <p><b>What should happen next?</b> </p> <p>No firm conclusion on vortioxetine can be made. Vortioxetine was effective in treating acute major depression, but did not show a clear advantage in comparison with some treatments which are already available. Conclusions are also made difficult because comparisons to the most frequently prescribed antidepressants (called SSRIs) are lacking. Furthermore, it is unclear if vortioxetine has an advantage in specific side effects associated with commonly prescribed antidepressants, for example sexual problems. These questions should be addressed in future studies. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD011520-sec-0140" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD011520-sec-0140"></div> <h3 class="title" id="CD011520-sec-0141">Implications for practice</h3> <section id="CD011520-sec-0141"> <p>The place of vortioxetine in the treatment of acute depression is unclear. Our analysis showed vortioxetine to be more effective than placebo in terms of response, remission and depressive symptoms, but the clinical relevance of these effects is uncertain, because of the small magnitude of effect, the poor quality of evidence and the highly selected participants enrolled In comparison to serotonin‐norepinephrine reuptake inhibitor (SNRI), there was no advantage for vortioxetine, and no studies compared vortioxetine with any of the selective serotonin reuptake inhibitor (SSRIs). Therefore, the available data leave uncertainty on whether vortioxetine is similarly effective, more effective or even less effective in comparison with these reference antidepressants. Vortioxetine might be less effective than duloxetine, but may have advantages over the SNRIs in terms of tolerability profile, as fewer participants reported adverse effects when treated with vortioxetine compared to SNRIs. According to the US Food and Drug Administration (FDA), the adverse effect profile might be similar to that of the SSRIs (<a href="./references#CD011520-bbs2-0089" title="ZhangJ , MathisMV , SellersJW , KordzakhiaG , JacksonAJ , DowA , et al. The US Food and Drug Administration's perspective on the new antidepressant vortioxetine. Journal of Clinical Psychiatry2015;76(1):8‐14. ">Zhang 2015</a>). </p> </section> <h3 class="title" id="CD011520-sec-0142">Implications for research</h3> <section id="CD011520-sec-0142"> <p>A major limitation of the current evidence is the lack of comparisons with the SSRIs, which are usually recommended as first‐line treatments for acute depression. Therefore, direct comparisons to these agents may help better determine the place of vortioxetine in the treatment of depression. Two studies that compared vortioxetine to an SSRI have recently been completed and may cushion the limitations, although both trials focus on the effects on cognition (see <a href="./references#CD011520-bbs1-0003" title="">Studies awaiting classification</a>). Future studies should also address and report adverse effects of competitive treatment options using more standardised approaches, to ascertain if vortioxetine is better tolerated than other antidepressants. Furthermore, advanced meta‐analytical approaches, such as individual participant data meta‐analyses should be conducted to investigate whether a dose‐response effect exists, and whether efficacy is moderated by trial characteristics, including countries and settings, a challenging issue which received little attention so far (<a href="./references#CD011520-bbs2-0089" title="ZhangJ , MathisMV , SellersJW , KordzakhiaG , JacksonAJ , DowA , et al. The US Food and Drug Administration's perspective on the new antidepressant vortioxetine. Journal of Clinical Psychiatry2015;76(1):8‐14. ">Zhang 2015</a>). The paucity of direct head‐to‐head comparisons between vortioxetine and other antidepressants would suggest a requirement for multiple‐treatment meta‐analyses attempting to address how this new antidepressant compares, in terms of efficacy and tolerability, with SSRIs. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD011520-sec-0022" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD011520-sec-0022"></div> <div class="table" id="CD011520-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Vortioxetine compared to Placebo for adults with Major Depressive Disorder</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Vortioxetine compared to Placebo for adults with Major Depressive Disorder</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> adults with Major Depressive Disorder<br/> <b>Setting:</b> Inpatients and outpatients<br/> <b>Intervention:</b> Vortioxetine<br/> <b>Comparison:</b> Placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with Placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with Vortioxetine</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Response<br/> assessed with: reduction of at least 50% on the HAMD scale or MADRS scale, or any other score 1 or 2 on CGI‐I<br/> follow up: range 6 weeks to 8 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.35<br/> (1.22 to 1.49) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>6220<br/> (14 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>All studies were sponsored by the pharmaceutical companies that manufacture vortioxetine. Small difference favouring vortioxetine. </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>356 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>480 per 1,000<br/> (434 to 530) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Total number of drop‐outs<br/> follow up: range 6 weeks to 8 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.05<br/> (0.93 to 1.19) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>6220<br/> (14 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>No difference between vortioxetine and placebo.</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>160 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>168 per 1,000<br/> (149 to 190) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Remission<br/> assessed with: 7 points or less on the 17‐item HAM‐D and 8 points or less for longer HAM‐D versions; 10 or less points on the MADRS; score 1 or 2 on CGI‐S<br/> follow up: range 6 weeks to 8 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.33<br/> (1.15 to 1.53) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>6217<br/> (14 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Small difference favouring vortioxetine.</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>224 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>299 per 1,000<br/> (258 to 343) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Depressive Symptoms<br/> assessed with: MADRS score (score range: 0‐34; higher score means worse outcome)<br/> follow up: range 6 weeks to 8 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The change in depressive symptoms score ranged from 10.8 to 15.9 points</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The change was 2.94 points higher<br/> (1.8 higher to 4.07 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5566<br/> (14 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>1 3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Small difference favouring vortioxetine.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Drop‐out due to adverse events<br/> follow up: range 6 weeks to 8 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.41<br/> (1.09 to 1.81) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>6220<br/> (14 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Small difference favouring placebo.</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>38 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>53 per 1,000<br/> (41 to 68) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Drop‐out due to inefficacy<br/> follow up: range 6 weeks to 8 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.56<br/> (0.34 to 0.90) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>6220<br/> (14 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Small difference favouring vortioxetine.</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>31 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>18 per 1,000<br/> (11 to 28) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Tolerability</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.12<br/> (1.07 to 1.16) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>6182<br/> (14 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Small difference favouring placebo</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>564 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>632 per 1,000<br/> (603 to 654) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; <b>OR:</b> Odds ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> A serious risk of bias is present, as about 30% of the studies showed an overall dropout rate above 20%, evidence was downgraded by one level </p> <p><sup>2</sup> A moderate degree of heterogeneity (I‐squared 30‐60%) is present, evidence was downgraded by one level </p> <p><sup>3</sup> A substantial degree of heterogeneity (I‐squared 60‐90%) is present, evidence was downgraded by two levels </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD011520-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Vortioxetine compared to SNRIs for adults with Major Depressive Disorder</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Vortioxetine compared to SNRIs for adults with Major Depressive Disorder</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> adults with Major Depressive Disorder<br/> <b>Setting:</b> Inpatients and outpatients<br/> <b>Intervention:</b> Vortioxetine<br/> <b>Comparison:</b> SNRIs </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with SNRIs</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with Vortioxetine</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Response<br/> assessed with: assessed with: reduction of at least 50% on the HAMD scale or MADRS scale, or any other score 1 or 2 on CGI‐I<br/> follow up: range 6 weeks to 8 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.91<br/> (0.82 to 1.00) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>3159<br/> (8 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>1 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>All studies were sponsored by the pharmaceutical companies that manufacture vortioxetine. No difference between vortioxetine and SNRIs. </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>577 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>525 per 1,000<br/> (473 to 577) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Total number of drop‐outs<br/> follow up: range 6 weeks to 8 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.89<br/> (0.73 to 1.08) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>3159<br/> (8 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>1 3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>No difference between vortioxetine and SNRIs.</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>212 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>189 per 1,000<br/> (155 to 229) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Remission<br/> assessed with: 7 points or less on the 17‐item HAM‐D and 8 points or less for longer HAM‐D versions; 10 or less points on the MADRS; score 1 or 2 on CGI‐S<br/> follow up: range 6 weeks to 8 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.89<br/> (0.77 to 1.03) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>3155<br/> (8 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>1 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>No difference between vortioxetine and SNRIs.</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>370 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>329 per 1,000<br/> (285 to 381) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Depressive Symptoms<br/> assessed with: MADRS score (score range: 0‐34; higher score means worse outcome)<br/> follow up: range 6 weeks to 8 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The change in depressive symptoms score ranged from 14.1 to 23.4 points</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The change was 1.52 points lower<br/> (0.5 lower to 2.53 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2807<br/> (8 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>1 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Small difference favouring SNRIs.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Drop‐out due to adverse events<br/> follow up: range 6 weeks to 8 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.74<br/> (0.51 to 1.08) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>3159<br/> (8 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>1 2 3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>No difference between vortioxetine and SNRIs.</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>97 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>72 per 1,000<br/> (50 to 105) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Drop‐out due to inefficacy<br/> follow up: range 6 weeks to 8 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.52<br/> (0.70 to 3.30) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>3159<br/> (8 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>1 4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>No difference between vortioxetine and SNRIs.</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>14 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>21 per 1,000<br/> (10 to 45) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Tolerability</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.90<br/> (0.86 to 0.94) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>3134<br/> (8 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Small difference favouring vortioxetine</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>690 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>621 per 1,000<br/> (593 to 648) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; <b>OR:</b> Odds ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> A very serious risk of bias is present as 60% of the studies had more than 20% dropouts overall, evidence was downgraded by two levels </p> <p><sup>2</sup> A moderate degree of heterogeneity (I‐squared 30‐60%) is present, evidence was downgraded by one level </p> <p><sup>3</sup> The 95% CI crossed both 1 (no differences) and 0.75 (appreciable benefit for vortioxetine), evidence was downgraded by one level </p> <p><sup>4</sup> The 95% CI crossed 1 (no differences), 0.75 (appreciable benefit for vortioxetine) and 1.25 (appreciable benefit for SNRIs). Outcome is very imprecise: evidence was downgraded by two levels </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD011520-sec-0023" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD011520-sec-0023"></div> <section id="CD011520-sec-0024"> <h3 class="title" id="CD011520-sec-0024">Description of the condition</h3> <p>Major depressive disorder (MDD) affects a person's mind, behaviour and body and is expressed in a variety of symptoms. The core features are depressed mood and loss of interest or pleasure. Other diagnostic criteria include significant changes in bodyweight, decreased or increased appetite, sleep disturbances, psychomotor agitation or retardation, fatigue, feelings of worthlessness or guilt, reduced concentration and suicidal ideation (<a href="./references#CD011520-bbs2-0031" title="American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders: DSM‐5. 5th Edition. Washington (DC): American Psychiatric Association, 2013. ">APA 2013</a>). According to the fourth edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM‐IV), a person must have symptoms for at least two weeks (<a href="./references#CD011520-bbs2-0031" title="American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders: DSM‐5. 5th Edition. Washington (DC): American Psychiatric Association, 2013. ">APA 2013</a>). The core features of major depression have not been changed from DSM‐IV to DSM‐5. Although there are some differences in the diagnosis of depression between DSM and International Classification of Diseases (ICD), diagnoses of major depression according to DSM‐IV seems to be congruent with severe or moderate depressive episodes according to ICD‐10 (<a href="./references#CD011520-bbs2-0078" title="SaitoM , IwataN , KawakamiN , MatsuyamaY , OnoY , NakaneY , et al. Evaluation of the DSM‐IV and ICD‐10 criteria for depressive disorders in a community population in Japan using item response theory. International Journal of Methods in Psychiatric Research2010;19(4):211‐22. ">Saito 2010</a>). </p> <p>MDD is a common mental disorder, but prevalence rates vary markedly across countries. Lifetime prevalence was estimated at 14.6% on average in high‐income countries and 11.1% in low‐income countries, with a female:male ratio of about 2:1 (<a href="./references#CD011520-bbs2-0036" title="BrometE , AndradeL , HwangI , SampsonNA , AlonsoJ , deGirolamoG , et al. Cross‐national epidemiology of DSM‐IV major depressive episode. BMC Medicine2011;9:90. ">Bromet 2011</a>). MDD is associated with substantial impairment. According to the Global Burden of Disease study, MDD is the second leading cause of disability worldwide (<a href="./references#CD011520-bbs2-0084" title="VosT , FlaxmanAD , NaghaviM , LozanoR , MichaudC , EzzatiM , et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990‐2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet2012; Vol. 380, issue 9859:2163‐96. ">Vos 2012</a>). </p> </section> <section id="CD011520-sec-0025"> <h3 class="title" id="CD011520-sec-0025">Description of the intervention</h3> <p>A variety of pharmacological and non‐pharmacological treatment options is available for the treatment of MDD. Pharmacological treatment options comprise monoamine oxidase inhibitors (MAOIs), tricyclic antidepressants (TCAs) or heterocyclic antidepressants, selective serotonin re‐uptake inhibitors (SSRIs), serotonin‐norepinephrine (‐noradrenaline) reuptake inhibitors (SNRIs), and other antidepressant agents (e.g. mirtazapine, bupropion, reboxetine, agomelatine), as well herbal products (e.g. hypericum). Current guidelines for depression recommend the use of an antidepressant or psychological treatment for people with moderate depression (<a href="./references#CD011520-bbs2-0030" title="American Psychiatric Association. American Psychiatric Association Practice Guidelines for the Treatment of Patients with Major Depressive Disorder. 3rd Edition. Arlington (VA): American Psychiatric Publishing, Inc, 2010. ">APA 2010</a>; <a href="./references#CD011520-bbs2-0074" title="National Institute for Health and Care Excellence. Depression in Adults. CG90. London (UK): National Institute for Health and Care Excellence, 2009. ">NICE 2009</a>) as first‐line treatment. According to these guidelines, the effectiveness between classes of antidepressants is similar. However, SSRIs are recommended over TCAs and MAOIs due to their favourable adverse effect profile (<a href="./references#CD011520-bbs2-0030" title="American Psychiatric Association. American Psychiatric Association Practice Guidelines for the Treatment of Patients with Major Depressive Disorder. 3rd Edition. Arlington (VA): American Psychiatric Publishing, Inc, 2010. ">APA 2010</a>; <a href="./references#CD011520-bbs2-0074" title="National Institute for Health and Care Excellence. Depression in Adults. CG90. London (UK): National Institute for Health and Care Excellence, 2009. ">NICE 2009</a>). SSRIs have now become the most prescribed antidepressant class in most parts of the world (<a href="./references#CD011520-bbs2-0034" title="BauerM , MonzBU , MontejoAL , QuailD , DantchevN , DemyttenaereK , et al. Prescribing patterns of antidepressants in Europe: results from the Factors Influencing Depression Endpoints Research (FINDER) study. European Psychiatry2008;23(1):66‐73. ">Bauer 2008</a>; <a href="./references#CD011520-bbs2-0059" title="GroverS , AvasthA , KalitaK , DalalPK , RaoGP , ChaddaRK , et al. IPS multicentric study: antidepressant prescription patterns. Indian Journal of Psychiatry2013;55(1):41‐5. ">Grover 2013</a>; <a href="./references#CD011520-bbs2-0088" title="ZhangY , BeckerT , KöstersM . Preliminary study of patterns of medication use for depression treatment in China. Asia‐Pacific Psychiatry: Official Journal of the Pacific Rim College of Psychiatrists2013;5(4):231‐6. ">Zhang 2013</a>). </p> <p>Vortioxetine was licensed for the treatment of depression by the Food and Drugs Administration (FDA) in September 2013 in the USA (<a href="./references#CD011520-bbs2-0048" title="Us.Food , DrugAdministration . Novel New Drugs 2013 Summary. https://www.fda.gov/downloads/drugs/developmentapprovalprocess/druginnovation/ucm381803.pdf 2014, (accessed 21 June 2017). ">FDA 2014</a>) and by the European Medicines Agency (EMA) in December 2013 for the EU (<a href="./references#CD011520-bbs2-0045" title="European Medical Agency. Brintellix: EPAR‐Summary for the public. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_‐_Summary_for_the_public/human/002717/WC500159448.pdf 2014, (accessed 21 June 2017). ">EMA 2014</a>). Despite the similarities to SSRIs, the mechanism of action of vortioxetine is claimed to be novel (see <a href="#CD011520-sec-0026">How the intervention might work</a>). According to the ATC classification of the World Health Organization (WHO), vortioxetine is placed in the category of "Other" antidepressants (<a href="./references#CD011520-bbs2-0087" title="WHO Collaborating Centre for Drug Statistics Methodology. ATC/DDD Index 2017. https://www.whocc.no/atc_ddd_index/?code=N06AX26 2016 (accessed 21 June 2017). ">WHO 2016</a>). Due to the recent marketing authorisation, clinical experience and data on clinical use of vortioxetine is very limited at this time. </p> </section> <section id="CD011520-sec-0026"> <h3 class="title" id="CD011520-sec-0026">How the intervention might work</h3> <p>The mechanism of action of vortioxetine is not fully understood, but it is assumed to be related to a direct modulation of serotonergic receptor activity and inhibition of the serotonin transporter. Vortioxetine is an antagonist to 5‐HT<sub>3</sub>, 5‐HT<sub>1D</sub> and 5‐HT<sub>7</sub> receptors, a partial agonist to the 5‐HT<sub>1B</sub> receptor and a 5‐HT<sub>1A</sub> receptor agonist (<a href="./references#CD011520-bbs2-0046" title="European Medicines Agency. Brintellix EPAR ‐ public assessment report 2014. www.ema.europa.eu/docs/en_GB/document_library/EPAR_‐_Public_assessment_report/human/002717/WC500159447.pdf (accessed 2 February 2015). ">EMA 2014a</a>). However, it is unclear if and how these mechanism contribute to an antidepressant effect. It is hypothesised that serotonin transporter inhibition, combined with the several other actions of vortioxetine at 5‐HT receptors, mainly at 5‐HT<sub>3</sub> receptors, enhances the release of serotonin and modulates the release of other neurotransmitters within various brain circuits (enhanced release of norepinephrine, dopamine, histamine, acetylcholine and glutamate; reduced gamma‐aminobutyric acid (GABA) signalling). These actions could improve the efficiency of information processing in malfunctioning brain circuits by facilitating long‐term potentiation, neuroplasticity and increased firing of pyramidal neurons (<a href="./references#CD011520-bbs2-0044" title="Du JardinKG , LiebenbergN , MullerHK , ElfvingB , SanchezC , WegenerG . Differential interaction with the serotonin system by S‐ketamine, vortioxetine, and fluoxetine in a genetic rat model of depression. Psychopharmacology2016;233(14):2813‐25. ">Du Jardin 2016</a>; <a href="./references#CD011520-bbs2-0075" title="PehrsonAL , JeyarajahT , SanchezC . Regional distribution of serotonergic receptors: a systems neuroscience perspective on the downstream effects of the multimodal‐acting antidepressant vortioxetine on excitatory and inhibitory neurotransmission. CNS Spectrums2016;21(2):162‐83. ">Pehrson 2016</a>; <a href="./references#CD011520-bbs2-0082" title="StahlSM . Modes and nodes explain the mechanism of action of vortioxetine, a multimodal agent (MMA): blocking 5HT3 receptors enhances release of serotonin, norepinephrine, and acetylcholine. CNS Spectrums2015;20(5):455‐9. ">Stahl 2015</a>). </p> </section> <section id="CD011520-sec-0027"> <h3 class="title" id="CD011520-sec-0027">Why it is important to do this review</h3> <p>Despite the common use of antidepressants and the variety of available treatment options, there is still an ongoing debate about the use of antidepressants in general as some studies show modest effects compared to placebo (<a href="./references#CD011520-bbs2-0066" title="KirschI , DeaconBJ , Huedo‐MedinaTB , ScoboriaA , MooreTJ , JohnsonBT . Initial severity and antidepressant benefits: a meta‐analysis of data submitted to the Food and Drug Administration. PLoS Medicine2008;5(2):e45. ">Kirsch 2008</a>). A significant proportion of people do not achieve remission with current treatments (<a href="./references#CD011520-bbs2-0076" title="PigottHE . STAR*D: a tale and trail of bias. Ethical Human Psychology and Psychiatry2011;13(1):6‐28. ">Pigott 2011</a>). Furthermore, although the adverse effect profile of SSRIs is in general judged favourable over TCAs or MAOIs, many people are dropping out of antidepressant treatment (<a href="./references#CD011520-bbs2-0076" title="PigottHE . STAR*D: a tale and trail of bias. Ethical Human Psychology and Psychiatry2011;13(1):6‐28. ">Pigott 2011</a>), mainly due to adverse effects (<a href="./references#CD011520-bbs2-0037" title="BullSA , HunkelerEM , LeeJY , RowlandCR , WilliamsonTE , SchwabJR , et al. Discontinuing or switching selective serotonin‐reuptake inhibitors. Annals of Pharmacotherapy2002;36(4):578‐84. ">Bull 2002</a>). Thus, there is still room for improvement of the pharmacological treatment of depression. </p> <p>Another subject of debate is the comparative effects of modern antidepressants. One multiple‐treatment meta‐analysis of 12 new‐generation antidepressant drugs concluded that sertraline and escitalopram may be more favourable in terms of efficacy and acceptability compared to the other included antidepressants (<a href="./references#CD011520-bbs2-0041" title="CiprianiA , FurukawaTA , SalantiG , GeddesJR , HigginsJPT , ChurchillR , et al. Comparative efficacy and acceptability of 12 new‐generation antidepressants: a multiple‐treatments meta‐analysis. Lancet2009;373(9665):746‐58. ">Cipriani 2009</a>). Notably, this finding could not be replicated in another comprehensive review (<a href="./references#CD011520-bbs2-0055" title="GartlehnerG , HansenRA , MorganLC , ThalerK , LuxL , vanNoordM , et al. Comparative benefits and harms of second‐generation antidepressants for treating major depressive disorder: an updated meta‐analysis. Annals of Internal Medicine2011;155(11):772‐85. ">Gartlehner 2011</a>). The latter review concluded that there are no substantial differences in efficacy between the antidepressants, but that antidepressants differ in onset of action and adverse events (<a href="./references#CD011520-bbs2-0055" title="GartlehnerG , HansenRA , MorganLC , ThalerK , LuxL , vanNoordM , et al. Comparative benefits and harms of second‐generation antidepressants for treating major depressive disorder: an updated meta‐analysis. Annals of Internal Medicine2011;155(11):772‐85. ">Gartlehner 2011</a>). </p> <p>Vortioxetine was approved in late 2013 for the USA and EU and is currently the latest available antidepressant. Randomised controlled trials (RCTs) comparing vortioxetine to placebo or other antidepressants have been published. Several systematic reviews and meta‐analyses have been published on the efficacy and tolerability on vortioxetine. The first meta‐analysis included seven studies comparing vortioxetine to placebo (<a href="./references#CD011520-bbs2-0035" title="BerhanA , BarkerA . Vortioxetine in the treatment of adult patients with major depressive disorder: a meta‐analysis of randomized double‐blind controlled trials. BMC Psychiatry2014;14:276. ">Berhan 2014</a>). One systematic narrative review gave an overview of the vortioxetine studies and reported results of 10 RCTs in adults with major depression without pooling the results (<a href="./references#CD011520-bbs2-0042" title="CitromeL . Vortioxetine for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antidepressant ‐ what is the number needed to treat, number needed to harm and likelihood to be helped or harmed?. International Journal of Clinical Practice2014;68(1):60‐82. ">Citrome 2014</a>). Two meta‐analyses did not conduct a systematic review of the data. The first pooled analysis selected 11 short‐term placebo‐controlled trials and five long‐term open‐label studies to evaluate the safety and tolerability of vortioxetine (<a href="./references#CD011520-bbs2-0032" title="BaldwinDS , ChronesL , FloreaI , NielsenR , NomikosGg , PaloW , et al. The safety and tolerability of vortioxetine: analysis of data from randomized placebo‐controlled trials and open‐label extension studies. Journal of Psychopharmacology (Oxford, England)2016;30(3):242‐52. ">Baldwin 2016</a>). The second pooled analysis analysed a selected subset of five studies to examine the effect of vortioxetine on quality of life (<a href="./references#CD011520-bbs2-0050" title="FloreaI , LoftH , DanchenkoN , RiveB , BrignoneM , MerikleE , et al. Vortioxetine effects on overall patient functioning in patients with major depressive disorder. 28th European College of Neuropsychopharmacology, ECNP Congress; 2015 Aug 29 to Sep 1; Amsterdam, Netherlands. 2015:S436. ">Florea 2015</a>). Furthermore, 11 studies were included in an indirect comparison of vortioxetine, duloxetine, sertraline, vilazodone, levomilnacipram and escitalopram (<a href="./references#CD011520-bbs2-0043" title="CitromeL . Vortioxetine for major depressive disorder: an indirect comparison with duloxetine, escitalopram, levomilnacipran, sertraline, venlafaxine, and vilazodone, using number needed to treat, number needed to harm, and likelihood to be helped or harmed. Journal of Affective Disorders2016;196:225‐33. ">Citrome 2016</a>). Two other meta‐analyses focused on a subset of a specific dose of vortioxetine 5 mg (<a href="./references#CD011520-bbs2-0051" title="FuJ , ChenY . The efficacy and safety of 5 mg/d Vortioxetine compared to placebo for major depressive disorder: a meta‐analysis. Psychopharmacology2015;232(1):7‐16. ">Fu 2015</a>) or 10 mg (<a href="./references#CD011520-bbs2-0070" title="LiG , WangX , MaD . The efficacy and safety of 10 mg vortioxetine in the treatment of major depressive disorder: a meta‐analysis of randomized controlled trials. Neuropsychiatric Disease and Treatment2016;12:523‐31. ">Li 2016</a>) compared to placebo. However, another meta‐analysis, based on an analysis of 11 studies, found no effect differences related to dosing (<a href="./references#CD011520-bbs2-0071" title="MeekerAS , HerinkMC , HaxbyDG , HartungDM . The safety and efficacy of vortioxetine for acute treatment of major depressive disorder: a systematic review and meta‐analysis. Systematic Reviews2015;4:21. ">Meeker 2015</a>). This meta‐analysis included comparisons of vortioxetine and placebo as well as vortioxetine and active comparators, but it included subtherapeutic doses below 5 mg. In sum, these reviews agree that vortioxetine has a significant advantage compared to placebo in terms of efficacy, but found no advantage compared to other available antidepressants. </p> <p>A summary of the FDA review of vortioxetine is also available (<a href="./references#CD011520-bbs2-0089" title="ZhangJ , MathisMV , SellersJW , KordzakhiaG , JacksonAJ , DowA , et al. The US Food and Drug Administration's perspective on the new antidepressant vortioxetine. Journal of Clinical Psychiatry2015;76(1):8‐14. ">Zhang 2015</a>). The FDA review included 10 short‐term placebo‐controlled trials and concluded that vortioxetine demonstrated efficacy in six of the included trials, but reported that only vortioxetine 20 mg/day showed superiority over placebo in US trials and showed smaller effects in general in US populations. The most recent meta‐analysis, which was co‐authored by employees of the manufacturers of vortioxetine, analysed an almost identical dataset and included data from treatment arms in the approved dose range of 11 short‐term studies which had results published on ClinicalTrials.gov (<a href="./references#CD011520-bbs2-0083" title="ThaseME , MahableshwarkarAR , DragheimM , LoftH , VietaE . A meta‐analysis of randomized, placebo‐controlled trials of vortioxetine for the treatment of major depressive disorder in adults. European Neuropsychopharmacology2016;26(6):979‐93. ">Thase 2016</a>). Most analyses were conducted with aggregated data, but additional individual participant data were used. Apparently, the analyses did not follow an a priori defined protocol. However, the analyses are in line with the findings from previous reviews, showing a statistically significant advantage of vortioxetine compared to placebo, but a clear dose‐response relationship could not be established. It also confirms the findings of smaller effects in US studies. Thus, despite several attempts to synthesise available literature on vortioxetine, a practical interpretation of data from current systematic reviews may be limited by comprehensiveness issues (lack of thorough search for unpublished data, selective inclusion of trials in the analyses), and possible conflicts of interest. Our review provides an independent, comprehensive and up‐to‐date summary of the available evidence of the efficacy and acceptability of vortioxetine compared to placebo and other active pharmacological treatment options. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD011520-sec-0028" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD011520-sec-0028"></div> <p>To assess the efficacy and acceptability of vortioxetine compared with placebo and other antidepressant drugs in the treatment of acute depression in adults. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD011520-sec-0029" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD011520-sec-0029"></div> <section id="CD011520-sec-0030"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD011520-sec-0031"> <h4 class="title">Types of studies</h4> <p>We included RCTs but excluded quasi‐RCTs. For trials with a cross‐over design, we considered only the results from the first randomisation period. We included cluster‐RCTs if sufficient information was available to account for the clustering (see <a href="#CD011520-sec-0060">Unit of analysis issues</a>). </p> </section> <section id="CD011520-sec-0032"> <h4 class="title">Types of participants</h4> <section id="CD011520-sec-0033"> <h5 class="title">Characteristics</h5> <p>Participants of both sexes, of any ethnicity, and aged 18 years and older.</p> </section> <section id="CD011520-sec-0034"> <h5 class="title">Diagnosis</h5> <p>Participants with a primary diagnosis of unipolar major depression according to DSM‐III (<a href="./references#CD011520-bbs2-0026" title="American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM‐III). 3rd Edition. Washington (DC): American Psychiatric Association, 1980. ">APA 1980</a>), DSM‐ III‐R (<a href="./references#CD011520-bbs2-0027" title="American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM‐III‐R). 3rd Edition. Washington (DC): American Psychiatric Association, 1987. ">APA 1987</a>), DSM‐IV (<a href="./references#CD011520-bbs2-0028" title="American Psychiatric Association. .. Diagnostic and Statistical Manual of Mental Disorders (DSM‐IV). 4th Edition. Washington (DC): American Psychiatric Association, 1994. ">APA 1994</a>), DSM‐IV‐TR (<a href="./references#CD011520-bbs2-0029" title="American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM‐IV‐TR). 4th Edition. Washington (DC): American Psychiatric Association, 2000. ">APA 2000</a>), DSM‐5 (<a href="./references#CD011520-bbs2-0031" title="American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders: DSM‐5. 5th Edition. Washington (DC): American Psychiatric Association, 2013. ">APA 2013</a>), ICD‐10 (<a href="./references#CD011520-bbs2-0086" title="World Health Organization (WHO). The ICD‐10 Classification of Mental and Behavioural Disorders. Geneva (Switzerland): WHO, 1992. ">WHO 1992</a>), Feighner (<a href="./references#CD011520-bbs2-0049" title="FeighnerJP , RobinsE , GuzeSB , WoodruffRA , WinokurG , MunozR . Diagnostic criteria for use in psychiatric research. Archives of General Psychiatry1972;26(1):57‐63. ">Feighner 1972</a>) or Research Diagnostic Criteria (<a href="./references#CD011520-bbs2-0081" title="SpitzerRL , EndicottJ , RobinsE . Research diagnostic criteria: rationale and reliability. Archives of General Psychiatry1978;35(6):773‐82. ">Spitzer 1978</a>), and Chinese Classification of Mental Disorders (CCMD‐3, <a href="./references#CD011520-bbs2-0040" title="Chinese Society of Psychiatry. The Chinese Classification and Diagnostic Criteria of Mental Disorders Version 3 (CCMD‐3) 2001. www.21jk.com.cn/english/ (accessed 2 February 2015). ">Chinese Society of Psychiatry 2001</a>). We excluded studies of people with treatment‐resistant depression, defined as inadequate treatment response to at least four weeks of adequate antidepressant treatment. </p> </section> <section id="CD011520-sec-0035"> <h5 class="title">Comorbidities</h5> <p>We included studies with people with comorbid psychiatric disorders. We excluded antidepressant trials in people with depression with a serious concomitant physical illness (e.g. myocardial infarction, diabetes, cancer, etc.). </p> </section> <section id="CD011520-sec-0036"> <h5 class="title">Setting</h5> <p>Any setting.</p> </section> <section id="CD011520-sec-0037"> <h5 class="title">Subset data</h5> <p>Based on National Institute for Health and Care Excellence (NICE) guidelines for the treatment of depression in adults (<a href="./references#CD011520-bbs2-0074" title="National Institute for Health and Care Excellence. Depression in Adults. CG90. London (UK): National Institute for Health and Care Excellence, 2009. ">NICE 2009</a>), we included studies in which less than 20% of the included participants had bipolar depression. </p> <p>We included studies with relevant subsets of data (e.g. some participants aged below 18 years) if the data were available for the relevant subset and the randomisation was stratified by the criterion in question. Inclusion of these studies was examined in sensitivity analyses. </p> </section> </section> <section id="CD011520-sec-0038"> <h4 class="title">Types of interventions</h4> <section id="CD011520-sec-0039"> <h5 class="title">Experimental intervention</h5> <p> <ul id="CD011520-list-0001"> <li> <p>Vortioxetine monotherapy. To increase the clinical applicability of the review, we excluded treatment arms employing dosages below the lowest effective dose of 5 mg/day (<a href="./references#CD011520-bbs2-0047" title="European Medicines Agency. Brintellix: EPAR ‐ product information 2014. www.ema.europa.eu/docs/en_GB/document_library/EPAR_‐_Product_Information/human/002717/WC500159449.pdf (accessed 2 February 2015). ">EMA 2014b</a>). We included treatment arms with fixed and flexible dosing schemes. Fixed doses are set a priori and are independent from participant criteria, while in flexible dosing schemes the dose is adapted according predefined criteria, for example, insufficient response. </p> </li> </ul> </p> </section> <section id="CD011520-sec-0040"> <h5 class="title">Comparator intervention</h5> <p> <ul id="CD011520-list-0002"> <li> <p>Placebo.</p> </li> <li> <p>Another antidepressant as monotherapy, including:</p> <ul id="CD011520-list-0003"> <li> <p>conventional TCA or heterocyclic antidepressants (amitriptyline, amoxapine, clomipramine, desipramine, dosulepin/dothiepin, doxepin, imipramine, lofepramine, maprotiline, nortriptyline, protriptyline, trimipramine); </p> </li> <li> <p>SSRIs (fluoxetine, fluvoxamine, citalopram, paroxetine, escitalopram);</p> </li> <li> <p>SNRIs (venlafaxine, duloxetine, milnacipran);</p> </li> <li> <p>MAOIs (phenelzine, isocarboxazide, tranylcypromine, moclobemide, brofaromine);</p> </li> <li> <p>other antidepressant agents (mirtazapine, bupropion, reboxetine, agomelatine) or non‐conventional antidepressive agents (herbal products such as hypericum). </p> </li> </ul> </li> </ul> </p> <p>We applied no restrictions on dosage of the comparators, but we conducted sensitivity analyses and excluded studies with unequal dosing. </p> </section> </section> <section id="CD011520-sec-0041"> <h4 class="title">Types of outcome measures</h4> <p>We included studies that meet the above inclusion criteria regardless of whether they report on the following outcomes. </p> <section id="CD011520-sec-0042"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD011520-list-0004"> <li> <p>Response to treatment: the primary efficacy outcome was the number of participants who responded to acute treatment, as defined by a reduction of at least 50% on the Hamilton Depression Rating Scale (HAM‐D) scale (<a href="./references#CD011520-bbs2-0064" title="HamiltonM . A rating scale for depression. Journal of Neurology, Neurosurgery and Psychiatry1960;23:56‐62. ">Hamilton 1960</a>) or Montgomery‐Åsberg Depression Scale (MADRS; <a href="./references#CD011520-bbs2-0072" title="MontgomerySA , AsbergM . A new depression scale designed to be sensitive to change. British Journal of Psychiatry1979;134:382‐9. ">Montgomery 1979</a>), or any other depression scale, or "much or very much improved" (score 1 or 2) on Clinical Global Impression ‐ Improvement (CGI‐I) (<a href="./references#CD011520-bbs2-0061" title="GuyW , BonatoRR . Manual for the ECDEU Assessment Battery 2. Chevy Chase (MD): National Institute of Mental Health, 1970. ">Guy 1970</a>). We did not consider other definitions of response in this Cochrane Review. </p> </li> </ul> </p> <p>Where more than one scale was provided, we gave preference as listed. We used response rate instead of a continuous symptom score for the primary efficacy analysis to make the interpretation of results easier (<a href="./references#CD011520-bbs2-0062" title="GuyattGH , JuniperEF , WalterSD , GriffithLE , GoldsteinRS . Interpreting treatment effects in randomised trials. BMJ1998;316(7132):690‐3. ">Guyatt 1998</a>). </p> <p> <ul id="CD011520-list-0005"> <li> <p>Total number of dropouts: primary outcome measuring acceptability was the total number of participants dropping out during the trial as a proportion of the total number of randomised participants. </p> </li> </ul> </p> </section> <section id="CD011520-sec-0043"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD011520-list-0006"> <li> <p>Remission: number of participants who achieved remission. We defined remission a priori as: </p> </li> </ul> <ul class="plain" id="CD011520-list-0007"> <li> <ul id="CD011520-list-0008"> <li> <p>7 points or less on the 17‐item HAM‐D and as 8 points or less for all the other longer versions of HAM‐D; </p> </li> <li> <p>10 or less points on the MADRS;</p> </li> <li> <p>"not ill or borderline mentally ill" (score 1 or 2) on Clinical Global Impression ‐ Severity (CGI‐S) (<a href="./references#CD011520-bbs2-0061" title="GuyW , BonatoRR . Manual for the ECDEU Assessment Battery 2. Chevy Chase (MD): National Institute of Mental Health, 1970. ">Guy 1970</a>) at endpoint. </p> </li> </ul> </li> </ul> </p> <p>We did not consider other definitions of remissions in this Cochrane Review.</p> <p> <ul id="CD011520-list-0009"> <li> <p>Depressive symptoms: endpoint mean scores, or mean change scores at endpoint on HAM‐D, MADRS, or any other depression rating scale score. </p> </li> </ul> <ul id="CD011520-list-0010"> <li> <p>Dropouts due to adverse events: number of participants who dropped out due to adverse events during the trial as a proportion of the total number of randomised participants. </p> </li> </ul> <ul id="CD011520-list-0011"> <li> <p>Dropouts due to inefficacy: number of participants who dropped out due to inefficacy during the trial as a proportion of the total number of randomised participants. </p> </li> </ul> <ul id="CD011520-list-0012"> <li> <p>Tolerability: evaluated using the total number of participants experiencing at least one adverse event. </p> </li> </ul> </p> <p>We collected any data on specific adverse effects and reported these data in tables. However, due to the poor reporting in RCTs (<a href="./references#CD011520-bbs2-0090" title="ZorzelaL , GolderS , LiuY , PilkingtonK , HartlingL , JoffeA , et al. Quality of reporting in systematic reviews of adverse events: systematic review. BMJ (Clinical Research Ed.)2014;348:f7668. ">Zorzela 2014</a>), we did not summarise these data in meta‐analyses. </p> <p>Although the effect on cognition is a relevant outcome for people treated with psychopharmacological treatments, we decided to exclude cognition as an outcome. According to the EMA, cognition was not systematically assessed (<a href="./references#CD011520-bbs2-0046" title="European Medicines Agency. Brintellix EPAR ‐ public assessment report 2014. www.ema.europa.eu/docs/en_GB/document_library/EPAR_‐_Public_assessment_report/human/002717/WC500159447.pdf (accessed 2 February 2015). ">EMA 2014a</a>). The EMA report on vortioxetine indicated that only three studies reported this outcome and that a meta‐analysis by the manufacturer of these studies had outcome reporting bias (<a href="./references#CD011520-bbs2-0046" title="European Medicines Agency. Brintellix EPAR ‐ public assessment report 2014. www.ema.europa.eu/docs/en_GB/document_library/EPAR_‐_Public_assessment_report/human/002717/WC500159447.pdf (accessed 2 February 2015). ">EMA 2014a</a>). Furthermore, the EMA report pointed out that it was not possible to distinguish between an effect on cognition and a relief of depressive symptoms, because no active comparator was included. </p> <section id="CD011520-sec-0044"> <h6 class="title">Timing of outcome assessment</h6> <p>Our primary outcomes were the acute phase treatment response (between four and 12 weeks). When studies reported efficacy data at different time points, we gave preference to the time point closest to eight weeks. </p> </section> <section id="CD011520-sec-0045"> <h6 class="title">Hierarchy of outcome measures</h6> <p>We included efficacy data measured by HAM‐D (<a href="./references#CD011520-bbs2-0064" title="HamiltonM . A rating scale for depression. Journal of Neurology, Neurosurgery and Psychiatry1960;23:56‐62. ">Hamilton 1960</a>), MADRS (<a href="./references#CD011520-bbs2-0072" title="MontgomerySA , AsbergM . A new depression scale designed to be sensitive to change. British Journal of Psychiatry1979;134:382‐9. ">Montgomery 1979</a>), or any other depression scale. Response or remission rates may also be based on CGI‐I scores (<a href="./references#CD011520-bbs2-0061" title="GuyW , BonatoRR . Manual for the ECDEU Assessment Battery 2. Chevy Chase (MD): National Institute of Mental Health, 1970. ">Guy 1970</a>) or a combination of these outcomes. Where more than one criterion was provided, we planned to use the data according to the following hierarchy: HAM‐D, MADRS, other depression scales and CGI and combination of these in cases of remission and response rates. However, due to the reporting of the MADRS (see <a href="#CD011520-sec-0072">Description of studies</a>) we gave preference to MADRS outcomes (see <a href="#CD011520-sec-0153">Differences between protocol and review</a>). We did not include CGI scores as a continuous outcome. The HAM‐D scale is available in various versions which differ in the number of included items. The versions with 17, 21 or 24 items are the most common and we gave preference to these in this order. Studies may also use different criteria for response or remission. We gave preference according to the list described in the corresponding outcome section (see <a href="#CD011520-sec-0042">Primary outcomes</a>; <a href="#CD011520-sec-0043">Secondary outcomes</a>). </p> </section> </section> </section> </section> <section id="CD011520-sec-0046"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD011520-sec-0047"> <h4 class="title">Cochrane Collaboration Depression, Anxiety and Neurosis Review Group's Specialized Register (CCDANCTR) </h4> <p>The Cochrane Collaboration Depression, Anxiety and Neurosis Group (CCDAN) maintain two clinical trials registers at their editorial base in Bristol, UK: a References Register and a Studies Register. The CCDANCTR‐References Register contains over 37,000 reports of RCTs in depression, anxiety and neurosis. Approximately 60% of these references have been tagged to individual, coded trials. The coded trials are held in the CCDANCTR‐Studies Register and records are linked between the two registers using unique Study ID tags. Coding of trials is based on the EU‐PSI coding manual, using a controlled vocabulary (see <a href="http://cmd.cochrane.org/specialised-register" target="_blank">Cochrane Collaboration Depression, Anxiety &amp; Neurosis Group</a> for further details). Reports of trials for inclusion in the Group's registers are collated from routine (weekly), generic searches of MEDLINE (from 1950), Embase (from 1974) and PsycINFO (from 1967); quarterly searches of the Cochrane Central Register of Controlled Trials (CENTRAL) and review‐specific searches of additional databases. Reports of trials are also sourced from international trials registers via the WHO trials portal (the International Clinical Trials Registry Platform (<a href="http://apps.who.int/trialsearch/" target="_blank">ICTRP</a>)), pharmaceutical companies, handsearching of key journals, conference proceedings, and other (non‐Cochrane) systematic reviews and meta‐analyses. </p> <p>Details of <a href="http://ccdan.cochrane.org/search-strategies-identification-studies" target="_blank">CCDAN's generic search strategies</a> (used to identify RCTs) can be found on the Group's website. </p> </section> <section id="CD011520-sec-0048"> <h4 class="title">Electronic searches</h4> <p>We performed the following electronic searches with no restrictions on date, language or publication status. </p> <p> <ul id="CD011520-list-0013"> <li> <p><b>CCDANCTR‐Studies Register</b> using the following controlled search terms: </p> </li> </ul> </p> <p>Condition = depress*<br/> AND<br/> Intervention = Vortioxetine or "Lu AA21004" </p> <p> <ul id="CD011520-list-0014"> <li> <p><b>CCDANCTR‐References Register</b> using a more sensitive set of free‐text terms to identify additional untagged/uncoded reports of RCTs: </p> </li> </ul> </p> <p>Free‐text = (depress* or dysthymi* or "mood disorder*" or "affective disorder*" or "affective symptom*") and (Vortioxetine or "Lu AA21004" or LuAA21004 or Brintellix) </p> <p> <ul id="CD011520-list-0015"> <li> <p>International trial registries via the WHO trials portal (<a href="http://apps.who.int/trialsearch/" target="_blank">ICTRP</a>) and <a href="http://www.clinicaltrials.gov/" target="_blank">ClinicalTrials.gov</a> to identify unpublished or ongoing studies, together with the trial registries of relevant pharmaceutical companies: </p> </li> </ul> <ul class="plain" id="CD011520-list-0016"> <li> <ul id="CD011520-list-0017"> <li> <p><a href="http://www.lundbeck.com/trials" target="_blank">Lundbeck Clinical Trials Registry</a>; </p> </li> <li> <p><a href="https://www.takeda.com/research/ct/policy/" target="_blank">Takeda Clinical Study Protocols and Results</a>. </p> </li> </ul> </li> </ul> <ul id="CD011520-list-0018"> <li> <p>Regulatory databases including those of the FDA in the US (<a href="http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm" target="_blank">Drugs@FDA</a>) and the EMA (<a href="http://www.ema.europa.eu/" target="_blank">EMA</a>). </p> </li> </ul> </p> </section> <section id="CD011520-sec-0049"> <h4 class="title">Searching other resources</h4> <section id="CD011520-sec-0050"> <h5 class="title">Reference lists</h5> <p>We checked the reference lists of all included studies and relevant systematic reviews to identify additional studies missed from the original electronic searches (e.g. unpublished or in‐press citations). Also, we conducted a cited reference search on the Web of Science. </p> </section> <section id="CD011520-sec-0051"> <h5 class="title">Correspondence</h5> <p>We contacted trialists and subject experts for information on unpublished or ongoing studies or to request additional trial data. </p> </section> </section> </section> <section id="CD011520-sec-0052"> <h3 class="title" id="CD011520-sec-0052">Data collection and analysis</h3> <section id="CD011520-sec-0053"> <h4 class="title">Selection of studies</h4> <p>Two review authors (GO, MK) independently screened titles and abstracts for inclusion of all studies identified by the search and coded them as 'potentially eligible.' We retrieved the full‐texts of study reports/publications rated as 'potentially eligible' by one or both review authors. Two review authors (GO, MK) independently screened the full‐text articles and identified studies for inclusion, and identified and recorded reasons for exclusion of the ineligible studies (see <a href="./references#CD011520-sec-0156" title="">Characteristics of excluded studies</a> table). We resolved any disagreements through discussion or, if required, by consulting a third review author (CB). We collated multiple reports of the same study and included them a single study. </p> </section> <section id="CD011520-sec-0054"> <h4 class="title">Data extraction and management</h4> <p>We used a data collection form which had been piloted on at least one study in the review to extract study characteristics and outcome data. Two review authors (CB, MK) independently extracted study characteristics and outcome data from included studies. We extracted the following study characteristics. </p> <p> <ul id="CD011520-list-0019"> <li> <p>Methods: blinding, total duration of study, details of 'run in' periods, number of study centres and location, study setting, withdrawals and date of study. </p> </li> <li> <p>Participants: sample size, mean age, age range, gender, severity of condition, diagnostic criteria, inclusion criteria and exclusion criteria. </p> </li> <li> <p>Interventions: intervention, comparison, concomitant medications, excluded medications, dose and dosing scheme (fixed versus flexible). </p> </li> <li> <p>Outcomes: primary and secondary outcomes specified and collected, and time points reported. </p> </li> <li> <p>Notes: funding for trial and notable conflicts of interest of trial authors.</p> </li> </ul> </p> <p>We noted in the <a href="./references#CD011520-sec-0155" title="">Characteristics of included studies</a> table if outcome data were not reported in a usable way. We resolved disagreements by consensus or by involving a third review author (CB). One review author (MK) transferred data into Review Manager 5 (<a href="./references#CD011520-bbs2-0077" title="The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">RevMan 2014</a>). Two review authors (GO, JB) double checked the data entered for correctness by comparing the data presented in the systematic review with the study reports. A third review author (CB) spot‐checked study characteristics for accuracy against the trial report. </p> <section id="CD011520-sec-0055"> <h5 class="title">Main planned comparisons</h5> <p>We combined the comparators (see <a href="#CD011520-sec-0038">Types of interventions</a>) into classes in the meta‐analyses. Therefore, the main planned comparisons were: </p> <p> <ul id="CD011520-list-0020"> <li> <p>vortioxetine versus placebo;</p> </li> <li> <p>vortioxetine versus TCAs/heterocyclics;</p> </li> <li> <p>vortioxetine versus SSRIs;</p> </li> <li> <p>vortioxetine versus SNRIs;</p> </li> <li> <p>vortioxetine versus MAOIs;</p> </li> <li> <p>vortioxetine versus other antidepressant agents.</p> </li> </ul> </p> <p>Wherever suitable, we presented data with substances as subgroups within each class.</p> </section> </section> <section id="CD011520-sec-0056"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two review authors (MK, GO) independently assessed risk of bias for each study using the criteria outlined in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD011520-bbs2-0065" title="HigginsJPT , GreenS , editor(s) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011</a>). We resolved any disagreements by discussion or by involving a third review author (CB). We assessed the risk of bias in the included studies according to the following domains. </p> <p> <ul id="CD011520-list-0021"> <li> <p>Random sequence generation.</p> </li> <li> <p>Allocation concealment.</p> </li> <li> <p>Blinding of participants and personnel.</p> </li> <li> <p>Blinding of outcome assessment.</p> </li> <li> <p>Incomplete outcome data.</p> </li> <li> <p>Selective outcome reporting.</p> </li> <li> <p>Other bias.</p> </li> </ul> </p> <p>We judged potential sources of bias as 'high,' 'low' or 'unclear' and provided supporting quotation a from the study report together with a justification for our judgement in the 'Risk of bias' table. The risk of bias judgements were summarised across different studies for each of the domains listed. We considered blinding separately for different key outcomes where necessary (e.g. for unblinded outcome assessment, risk of bias for treatment discontinuation may be different than for a participant‐reported scale). Where information on risk of bias relates to unpublished data or correspondence with a trial author, we noted this in the 'Risk of bias' table. </p> <p>When considering treatment effects, we took into account the risk of bias for the studies that contributed to that outcome. </p> </section> <section id="CD011520-sec-0057"> <h4 class="title">Measures of treatment effect</h4> <section id="CD011520-sec-0058"> <h5 class="title">Dichotomous data</h5> <p>We analysed dichotomous data as risk ratios (RRs), because RRs are more intuitive in their interpretation than odds ratios (<a href="./references#CD011520-bbs2-0058" title="GrantRL . Converting an odds ratio to a range of plausible relative risks for better communication of research findings. BMJ (Clinical Research Ed.)2014;348:f7450. ">Grant 2014</a>), with 95% confidence intervals (CI). Where reported intention‐to‐treat (ITT) analysis was based on a 'modified' ITT not including all dropouts (e.g. leaving out dropouts without postbaseline assessment), we applied a conservative approach and considered these dropouts as non‐responders or non‐remitters (i.e. assumed they would have experienced the negative outcome by the end of the trial, e.g. failure to respond to treatment). </p> </section> <section id="CD011520-sec-0059"> <h5 class="title">Continuous data</h5> <p>We analysed continuous data as mean difference (MD) with 95% CI, if all studies reported the necessary data from HAM‐D‐scales as an outcome. In cases that data from different scales were combined, we used standardised mean difference (SMD) with 95% CI. We entered and presented data with a consistent direction of effect. Data were analysed as endpoint data. We combined endpoint and change scores only if data were analysed as MD. Analyses were conducted with ITT data as reported (e.g. data from last observation carried forward (LOCF) or mixed model for repeated measurements (MMRM) methods). </p> <p>We conducted meta‐analyses only where this was meaningful (i.e. if the treatments, participants and underlying clinical question were similar enough for pooling to make sense). </p> </section> </section> <section id="CD011520-sec-0060"> <h4 class="title">Unit of analysis issues</h4> <section id="CD011520-sec-0061"> <h5 class="title">Cluster‐randomised controlled trials</h5> <p>Cluster‐RCTs were eligible for inclusion if sufficient information was available to account for the clustering (see <a href="#CD011520-sec-0153">Differences between protocol and review</a>). </p> </section> <section id="CD011520-sec-0062"> <h5 class="title">Cross‐over trials</h5> <p>For trials with a cross‐over design, we considered only the results from a first randomisation period (see <a href="#CD011520-sec-0153">Differences between protocol and review</a>). </p> </section> <section id="CD011520-sec-0063"> <h5 class="title">Studies with multiple treatment groups</h5> <p>If more than one treatment arm was reported in a single trial, we only included the relevant treatment arms. In case of multiple relevant treatment arms (e.g. different dosages), we combined these treatment arms into a single group. For dichotomous outcomes, we summarised data across groups; while for continuous outcomes, we combined means and standard deviations according to Chapter 7 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (Section 7.7.3.8, <a href="./references#CD011520-bbs2-0065" title="HigginsJPT , GreenS , editor(s) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011</a>). </p> <p>In case of relevant treatment arms that could not be combined (e.g. different SSRIs as comparators), we divided the sample size of the shared group so that the two arms were treated as independent comparisons. </p> </section> </section> <section id="CD011520-sec-0064"> <h4 class="title">Dealing with missing data</h4> <p>We contacted study authors or study sponsors to verify key study characteristics and missing outcome data. Attempts to contact authors and sponsors were documented, as well as additional data we received in these correspondences. </p> <p>In the absence of supplemental data from the authors, we planned to calculate the SDs of the HAM‐D (or any other depression scale) and response/remission rates according to validated imputation methods (<a href="./references#CD011520-bbs2-0053" title="FurukawaTA , CiprianiA , BarbuiC , BrambillaP , WatanabeN . Imputing response rates from means and standard deviations in meta‐analyses. International Clinical Psychopharmacology2005;20(1):49‐52. ">Furukawa 2005</a>; <a href="./references#CD011520-bbs2-0054" title="FurukawaTA , BarbuiC , CiprianiA , BrambillaP , WatanabeN . Imputing missing standard deviations in meta‐analyses can provide accurate results. Journal of Clinical Epidemiology2006;59(1):7‐10. ">Furukawa 2006</a>). We planned to examine the validity of these imputations in sensitivity analyses. </p> </section> <section id="CD011520-sec-0065"> <h4 class="title">Assessment of heterogeneity</h4> <p>Variations in participants and interventions lead to clinical heterogeneity. We extracted basic study characteristics (see <a href="#CD011520-sec-0052">Data collection and analysis</a>) from the studies and described these in the <a href="./references#CD011520-sec-0155" title="">Characteristics of included studies</a> tables. A decision was then made as to whether studies were similar enough to combine in meta‐analyses. </p> <p>We quantified statistical heterogeneity of the studies using the I<sup>2</sup> statistic and Chi<sup>2</sup> test. As the Chi<sup>2</sup> test is known to have low power, we used P = 0.10 as a threshold for statistical significance. Our interpretation of the I<sup>2</sup> statistic followed the recommendation of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> and we considered the I<sup>2</sup> statistic as: </p> <p> <ul id="CD011520-list-0022"> <li> <p>0% to 40%: might not be important;</p> </li> <li> <p>30% to 60%: may represent moderate heterogeneity;</p> </li> <li> <p>50% to 90%: may represent substantial heterogeneity;</p> </li> <li> <p>75% to 100%: considerable heterogeneity.</p> </li> </ul> </p> <p>We also assessed heterogeneity by visual inspection of forest plots.</p> </section> <section id="CD011520-sec-0066"> <h4 class="title">Assessment of reporting biases</h4> <p>Publication bias was scrutinised by visual inspection of funnel plots if we include more than 10 studies in the analysis of the outcome in question. </p> </section> <section id="CD011520-sec-0067"> <h4 class="title">Data synthesis</h4> <p>We used a random‐effects model in our primary analysis. We expected some heterogeneity in the studies included and the random‐effects model incorporates the variance between studies in the model. As a result, CIs are wider. The random‐effects model has the highest generalisability in an empirical examination of summary effect measures for meta‐analyses (<a href="./references#CD011520-bbs2-0052" title="FurukawaTA , GuyattGH , GriffithLE . Can we individualize the 'number needed to treat'? An empirical study of summary effect measures in meta‐analyses. International Journal of Epidemiology2002;31(1):72‐6. ">Furukawa 2002</a>). We routinely examined the robustness of this summary measure by checking the results under a fixed‐effect model. Material differences between the models were reported. </p> </section> <section id="CD011520-sec-0068"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We only conducted subgroup and sensitivity analysis for the primary outcomes.</p> <p>A priori, we planned to perform the following subgroup analyses.</p> <p> <ul id="CD011520-list-0023"> <li> <p>Vortioxetine dosing: fixed versus flexible dosing schemes.</p> </li> <li> <p>Treatment setting: primary care versus inpatient care versus outpatient care.</p> </li> <li> <p>Older people (aged more than 65 years): included versus excluded.</p> </li> </ul> </p> </section> <section id="CD011520-sec-0069"> <h4 class="title">Sensitivity analysis</h4> <p>We planned to perform the following sensitivity analyses to examine the robustness of the effect size. </p> <p> <ul id="CD011520-list-0024"> <li> <p>Exclusion of trials with unequal dosing. We defined comparability of doses by comparing the percentage of the maximum licensed daily dose in both groups (e.g. vortioxetine 10 mg/day (50% of 20 mg/day) equals fluoxetine 40 mg/day (50% of 80 mg/day)). </p> </li> <li> <p>Exclusion of studies that did not employ a double‐blind approach.</p> </li> <li> <p>Exclusion of studies with subsets of people with bipolar disorders.</p> </li> <li> <p>Exclusion of trials with dropout rates of more than 20% in one of the treatment arms included. </p> </li> <li> <p>Exclusion of studies with imputed data.</p> </li> <li> <p>Exclusion of studied sponsored by the manufacturer of vortioxetine.</p> </li> </ul> </p> <section id="CD011520-sec-0070"> <h5 class="title">'Summary of findings' table</h5> <p>We employed the GRADE approach to interpret findings (<a href="./references#CD011520-bbs2-0068" title="LangendamMW , AklEA , DahmP , GlasziouP , GuyattG , SchünemannHJ . Assessing and presenting summaries of evidence in Cochrane Reviews. Systematic Reviews2013;2:81. ">Langendam 2013</a>) and used <a href="./references#CD011520-bbs2-0057" title="GRADE Working Group, McMaster University. GRADEpro. Hamilton (ON): GRADE Working Group, McMaster University, 2014. ">GRADEpro</a> to import data from Review Manager 5 (<a href="./references#CD011520-bbs2-0077" title="The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">RevMan 2014</a>) to create 'Summary of findings' tables. These tables provide outcome‐specific information concerning the overall quality of evidence from each included study in the comparison, the magnitude of effect of the interventions examined and the sum of available data on the outcomes. </p> <p>For each comparison, we reported the primary outcomes (response and total number of dropouts) and secondary outcomes (remission, depressive symptoms, dropouts due to adverse events, dropouts due to inefficacy and participants experience at least one adverse event). </p> </section> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD011520-sec-0071" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD011520-sec-0071"></div> <section id="CD011520-sec-0072"> <h3 class="title">Description of studies</h3> <section id="CD011520-sec-0073"> <h4 class="title">Results of the search</h4> <p>The literature search identified 113 records including eight duplicates. We excluded 45 of the remaining 105 records based on the abstracts. We retrieved 60 full‐text articles for detailed examination, which led to the exclusion of 45 records. The majority (35 trials) were secondary publications of already included or excluded trials. Two studies did not meet our inclusion criterion for acute treatment (<a href="./references#CD011520-bbs2-0018" title="JacobsenPL , MahableshwarkarAR , ChenY , ChronesL , ClaytonAH . Effect of vortioxetine vs. escitalopram on sexual functioning in adults with well‐treated major depressive disorder experiencing SSRI‐induced sexual dysfunction. Journal of Sexual Medicine2015;12(10):2036‐48. ">Jacobsen 2015a</a>; <a href="./references#CD011520-bbs2-0019" title="JacobsenPL , HarperL , ChronesL , ChanS , MahableshwarkarAR . Safety and tolerability of vortioxetine (15 and 20 mg) in patients with major depressive disorder: results of an open‐label, flexible‐dose, 52‐week extension study. International Clinical Psychopharmacology2015;30(5):255‐64. ">Jacobsen 2015b</a>); two were relapse prevention studies (<a href="./references#CD011520-bbs2-0016" title="BoulengerJ‐P , LoftH , FloreaI . A randomized clinical study of Lu AA21004 in the prevention of relapse in patients with major depressive disorder. Journal of Psychopharmacology (Oxford, England)2012;26(11):1408‐16. NCT00596817 . Efficacy of Lu AA21004 in the prevention of relapse of major depressive episodes. clinicaltrials.gov/ct2/show/NCT00596817 Date first received: January 8, 2008. ">Boulenger 2012</a>; <a href="./references#CD011520-bbs2-0021" title="NCT02371980 . A randomized, double‐blind, placebo‐controlled, phase 4, relapse prevention study evaluating the efficacy and safety of vortioxetine (5, 10 and 20 mg) in adults with major depressive disorder. clinicaltrials.gov/show/NCT02371980 Date first received: 20 February 2015. ">NCT02371980</a>); one trial did not meet our criterion for depression because it randomised remitted participants and healthy controls only (<a href="./references#CD011520-bbs2-0017" title="BrowningM , SmithJ , ConenS , SmallmanR , BuchbjergJ , LarsenKg , et al. Vortioxetine reduces BOLD signal during performance of the N‐back task in subjects remitted from depression and healthy control participants. 28th European College of Neuropsychopharmacology, ECNP Congress; 2015 Aug 29 to Sep 1; Amsterdam, Netherlands. 2015:S314‐5. BrowningM , SmithJ , ConenS , SmallmanR , BuchbjergJ , LarsenKg , et al. Vortioxetine reduces bold signal during performance of the N‐Back task in subjects remitted from depression and healthy control participants [abstract]. 53rd Annual Meeting of the American College of Neuropsychopharmacology, ACNP; 2014 Dec 7‐11; Phoenix (AZ). 2014:S480. ConenS , McKieS , SmallmanRP , DuttaA , DawsonGr , SmithJ , et al. Effects of vortioxetine on resting‐state activity in subjects remitted from depression and healthy controls. 28th European College of Neuropsychopharmacology, ECNP Congress; 2015 Aug 29 to Sep 1; Amsterdam, Netherlands. 2015:S442. DawsonG , ConenS , McKieS , SmallmanR , SmithJ , BrowningM , et al. Effects of vortioxetine on resting‐state activity in subjects remitted from depression and healthy controls. 53rd Annual Meeting of the American College of Neuropsychopharmacology, ACNP; 2014 Dec 7‐11; Phoenix (AZ). 2014:S214‐5. ">Browning 2014</a>); and one study randomised participants to vortioxetine or agomelatine after an inadequate response to at least six weeks of SSRI or SNRI treatment (<a href="./references#CD011520-bbs2-0020" title="HaggstromL , NielsenRZ , DanchenkoN , PoulsenL . A randomised, double‐blind, study of vortioxetine versus agomelatine in adults with major depressive disorder (MDD) with inadequate response to SSRI/SNRI treatment. 26th European College of Neuropsychopharmacology, ECNP Congress; 2013 Oct 5‐9; Barcelona, Spain. 2013:S412. HaggstromL , NielsenRZ , DragheimM . Randomized, double‐blind, study of vortioxetine versus agomelatine in adults with MDD after inadequate response to SSRI or SNRI treatment. European Psychiatry2013;28(Suppl 1):3009. MontgomerySA , NielsenRZ , PoulsenLH , HaggstromL . A randomised, double‐blind study in adults with major depressive disorder with an inadequate response to a single course of selective serotonin reuptake inhibitor or serotonin‐noradrenaline reuptake inhibitor treatment switched to vortioxetine or agomelatine. Human Psychopharmacology2014;29(5):470‐82. [EUCTR2011‐002362‐21; NCT01488071] NCT01488071 . A randomised, double‐blind, parallel‐group, active‐controlled, flexible dose study evaluating the effects of Lu AA21004 versus agomelatine in adult patients suffering from major depressive disorder with inadequate response to antidepressant treatment. clinicaltrials.gov/show/NCT01488071 Date first received: 29 November 2011. PapakostasG , DragheimM , NielsenRZ . Efficacy and tolerability of vortioxetine is independent of previous treatment in MDD patients switched after an inadequate response. European Neuropsychopharmacology2014;24:S466. ">Montgomery 2014</a>). We identified two ongoing studies (<a href="./references#CD011520-bbs2-0024" title="NCT02294305 . Vortioxetine versus placebo in major depressive disorder comorbid with social anxiety disorder. clinicaltrials.gov/show/NCT02294305 Date first received: 11 November 2014. ">NCT02294305</a>; <a href="./references#CD011520-bbs2-0025" title="Jprn‐Japiccti‐152831 . A randomized, double‐blind, placebo‐controlled, parallel‐group, phase III study to assess the efficacy and safety of Lu AA21004 in patients with major depressive disorder. www.clinicaltrials.jp/user/showCteDetailE.jsp?japicId=JapicCTI‐152831 Date first received: 4 March 2015. NCT02389816 . A randomized, double‐blind, placebo‐controlled, parallel‐group, phase III study to assess the efficacy and safety of Lu AA21004 in patients with major depressive disorder. clinicaltrials.gov/show/NCT02389816 Date first received: 10 March 2015. ">NCT02389816</a>) which may fulfil the inclusion criteria of this review and two studies are awaiting assessment as there are no published results (<a href="./references#CD011520-bbs2-0022" title="NCT02272517 . An interventional, randomised, double‐blind, parallel‐group, active‐comparator, flexible‐dose study on the efficacy of vortioxetine versus escitalopram on cognitive dysfunction in patients with inadequate response to current antidepressant treatment of major depressive disorder. clinicaltrials.gov/show/NCT02272517 Date first received: 21 October 2014. ">NCT02272517</a>; <a href="./references#CD011520-bbs2-0023" title="NCT02279966 . An interventional, randomised, double‐blind, parallel‐group, placebo‐controlled, active‐referenced (paroxetine), fixed‐dose study on the efficacy of vortioxetine on cognitive dysfunction in working patients with major depressive disorder. clinicaltrials.gov/show/NCT02279966 Date first received: 21 October 2014. ">NCT02279966</a>). Request of additional information by the manufactures or the authors was not necessary. The literature search was last updated in May 2016 (see <a href="#CD011520-fig-0001">Figure 1</a>; <a href="./references#CD011520-sec-0156" title="">Characteristics of excluded studies</a> table). </p> <div class="figure" id="CD011520-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD011520-fig-0001" src="/cdsr/doi/10.1002/14651858.CD011520.pub2/media/CDSR/CD011520/image_n/nCD011520-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> </section> <section id="CD011520-sec-0074"> <h4 class="title">Included studies</h4> <p>Fifteen studies were included in this systematic review (<a href="./references#CD011520-bbs2-0001" title="AlvarezE , PerezV , DragheimM , LoftH , ArtigasF . A double‐blind, randomized, placebo‐controlled, active reference study of Lu AA21004 in patients with major depressive disorder. International Journal of Neuropsychopharmacology2012;15(5):589‐600. [Lundbeck 11492A; NCT00839423] NCT00839423 . Randomised placebo‐controlled venlafaxine‐referenced study of efficacy and safety of 5 and 10 mg of vortioxetine (Lu AA21004) in acute treatment of major depressive disorder in adults. clinicaltrials.gov/ct2/show/NCT00839423 Date first received: 6 February 2009. ">Alvarez 2012</a>; <a href="./references#CD011520-bbs2-0002" title="BaldwinD , LoftH , DragheimM . A randomised, double‐blind, placebo controlled, duloxetine‐referenced, fixed‐dose study of three dosages of Lu AA21004 in MDD treatment. European Neuropsychopharmacology2011;21(Suppl 3):S390. BaldwinDS , LoftH , DragheimM . A randomised, double‐blind, placebo controlled, duloxetine‐referenced, fixed‐dose study of three dosages of Lu AA21004 in acute treatment of major depressive disorder (MDD). European Neuropsychopharmacology2012;22(7):482‐91. [Lundbeck 11984A; NCT00635219] NCT00635219 . Randomised placebo‐controlled duloxetine‐referenced efficacy and safety study of 2.5, 5 and 10 mg of vortioxetine (Lu AA21004) in acute treatment of major depressive disorder. clinicaltrials.gov/ct2/show/NCT00635219 Date first received: 3 March 2008. ">Baldwin 2012</a>; <a href="./references#CD011520-bbs2-0003" title="BoulengerJ‐P , LoftH , OlsenCK . Efficacy and safety of vortioxetine (Lu AA21004), 15 and 20 mg/day: a randomized, double‐blind, placebo‐controlled, duloxetine‐referenced study in the acute treatment of adult patients with major depressive disorder. International Clinical Psychopharmacology2014;29(3):138‐49. [NCT01140906] NCT01140906 . A randomised, double‐blind, parallel‐group, placebo‐controlled, duloxetine‐referenced, fixed‐dose study evaluating the efficacy and safety of Lu AA21004 (15 and 20 mg/day) in the acute treatment of adult patients with major depressive disorder. clinicaltrials.gov/show/NCT01140906 Date first received: 9 June 2010. ">Boulenger 2014</a>; <a href="./references#CD011520-bbs2-0004" title="HenigsbergN , MahableshwarkarA , JacobsenP , ChenY , ThaseME . Efficacy and tolerability of multiple doses of LU AA21004 in an 8‐week trial of adults with major depressive disorder. European Neuropsychopharmacology2011;21(Suppl 3):S393. HenigsbergN , MahableshwarkarAR , JacobsenP , ChenY , ThaseME . A randomized, double‐blind, placebo‐controlled 8‐week trial of the efficacy and tolerability of multiple doses of Lu AA21004 in adults with major depressive disorder. Journal of Clinical Psychology2012;73(7):953‐9. NCT00707980 . A long‐term, open‐label, flexible‐dose, extension study evaluating the safety and tolerability of Lu AA21004 in subjects with major depressive disorder. clinicaltrials.gov/ct2/show/NCT00707980 Date first received: 27 June 2008. NCT00735709 . A randomized, double‐blind, parallel‐group, placebo‐controlled, fixed‐dose study comparing the efficacy and safety of 3 doses of Lu AA21004 in acute treatment of adults with major depressive disorder. clinicaltrials.gov/show/NCT00735709 Date first received: 14 August 2008. ">Henigsberg 2012</a>; <a href="./references#CD011520-bbs2-0005" title="JacobsenPL , MahableshwarkarAR , SerenkoM , ChanS , TrivediMH . A randomized, double‐blind, placebo‐controlled study of the efficacy and safety of vortioxetine 10 mg and 20 mg in adults with major depressive disorder. Journal of Clinical Psychiatry2015;76(5):575‐82. NCT01163266 . A phase 3, randomized, double‐blind, parallel‐group, placebo‐controlled, fixed‐dose study comparing the efficacy and safety of 2 doses (10 and 20 mg) of Lu AA21004 in acute treatment of adults with major depressive disorder. clinicaltrials.gov/show/NCT01163266 Date first received: 14 July 2010. ">Jacobsen 2015</a>; <a href="./references#CD011520-bbs2-0006" title="JainR , MahableshwarkarAR , JacobsenPL , ChenY , ThaseME . A randomized, double‐blind, placebo‐controlled 6‐wk trial of the efficacy and tolerability of 5 mg vortioxetine in adults with major depressive disorder. International Journal of Neuropsychopharmacology2013;16(2):313‐21. NCT00672958 . A randomized, double‐blind, parallel‐group, placebo‐controlled, fixed‐dose study comparing the efficacy and safety of Lu AA21004 versus placebo in acute treatment of adults with major depressive disorder. clinicaltrials.gov/show/NCT00672958 Date first received: 2 May 2008. ">Jain 2013</a>; <a href="./references#CD011520-bbs2-0007" title="KatonaC , HansenT , OlsenCK . A randomised, double‐blind, placebo controlled, active‐referenced study of the multimodal antidepressant Lu AA21004 in the treatment of elderly depressed patients. European Neuropsychopharmacology2012;22:S258‐9. KatonaC , HansenT , OlsenCK . A randomized, double‐blind, placebo‐controlled, duloxetine‐referenced, fixed‐dose study comparing the efficacy and safety of Lu AA21004 in elderly patients with major depressive disorder. International Clinical Psychopharmacology2012;27(4):215‐23. [Lundbeck 12541A; NCT00811252] NCT00811252 . Randomised placebo‐controlled duloxetine‐referenced study of efficacy and safety of 5 mg of vortioxetine (Lu AA21004) in acute treatment of major depressive disorder in elderly patients. clinicaltrials.gov/ct2/show/NCT00811252 Date first received: 17 December 2008. ">Katona 2012</a>; <a href="./references#CD011520-bbs2-0008" title="MahableshwarkarAR , JacobsenPL , ChenY . A randomized, double‐blind trial of 2.5mg and 5mg vortioxetine (Lu AA21004) versus placebo for 8 weeks in adults with major depressive disorder. Current Medical Research and Opinion2013;29(3):217‐26. [NCT00672620] NCT00672620 . A randomized, double‐blind, parallel‐group, placebo‐controlled, active‐referenced, fixed‐dose study comparing the efficacy and safety of 2 doses of Lu AA21004 in acute treatment of adults with major depressive disorder. clinicaltrials.gov/show/NCT00672620 Date first received: 2 May 2008. NCT00707980 . A long‐term, open‐label, flexible‐dose, extension study evaluating the safety and tolerability of Lu AA21004 in subjects with major depressive disorder. clinicaltrials.gov/ct2/show/NCT00707980 Date first received: 27 June 2008. ">Mahableshwarkar 2013</a>; <a href="./references#CD011520-bbs2-0009" title="MahableshwarkarAR , JacobsenPL , ChenY , SerenkoM , TrivediMH . A randomized, double‐blind, duloxetine‐referenced study comparing efficacy and tolerability of 2 fixed doses of vortioxetine in the acute treatment of adults with MDD. Psychopharmacology2015;232(12):2061‐70. NCT01153009 . A phase 3, randomized, double‐blind, parallel‐group, placebo‐controlled, duloxetine‐referenced, fixed‐dose study comparing the efficacy and safety of 2 doses (15 and 20 mg) of Lu AA21004 in acute treatment of adults with major depressive disorder. clinicaltrials.gov/show/NCT01153009 Date first received: 28 June 2010. ">Mahableshwarkar 2015a</a>; <a href="./references#CD011520-bbs2-0010" title="JacobsonW , HarveyP , MerikleE , ZhongW , NomikosG , OlsenCK , et al. Impact of vortioxetine on functional capacity in MDD patients with subjective cognitive dysfunction: performance on the University of California San Diego performance‐based skills assessment (UPSA). 54th Annual Meeting of the American College of Neuropsychopharmacology, ACNP; 2015 Dec 6‐10; Hollywood (FL). 2015:S150‐1. JacobsonW , OlsenC , MahableshwarkarA , YinzhongC , KeefeR . Effect of vortioxetine on functional capacity in patients with major depressive disorder with self‐reported cognitive dysfunction. 28th European College of Neuropsychopharmacology, ECNP Congress; 2015 29 Aug ‐ 1 Sept; Amsterdam Netherlands. 2015:S460. KeefeR , MahableshwarkarA , ZajeckaJ , JacobsonW , ChenY . Efficacy of vortioxetine on cognitive function in patients with major depressive disorder: cognitive test performance results: from a randomized, double‐blind, duloxetine‐referenced, placebo‐controlled. Neuropsychopharmacology2014;39:S389‐90. MahableshwarkarAR , ZajeckaJ , JacobsonW , ChenY , KeefeRS . A randomized, placebo‐controlled, active‐reference, double‐blind, flexible‐dose study of the efficacy of vortioxetine on cognitive function in major depressive disorder. Neuropsychopharmacology2015;40(8):2025‐37. NCT01564862 . A randomized, double‐blind, parallel‐group, placebo‐controlled, active‐referenced, flexible dose study on the efficacy of Lu AA21004 on cognitive dysfunction in adult subjects with major depressive disorder (MDD). clinicaltrials.gov/show/NCT01564862 Date first received: 26 March 2012. ">Mahableshwarkar 2015b</a>; <a href="./references#CD011520-bbs2-0011" title="MahableshwarkarAR , JacobsenPL , SerenkoM , ChenY , TrivediMH . A randomized, double‐blind, placebo‐controlled study of the efficacy and safety of 2 doses of vortioxetine in adults with major depressive disorder. Journal of Clinical Psychiatry2015;76(5):583‐91. NCT01179516 . A phase 3, randomized, double‐blind, parallel‐group, placebo‐controlled, fixed‐dose study comparing the efficacy and safety of 2 doses (10 and 15 mg) of Lu AA21004 in acute treatment of adults with major depressive disorder. clinicaltrials.gov/show/NCT01179516 Date first received: 9 August 2010. ">Mahableshwarkar 2015c</a>; <a href="./references#CD011520-bbs2-0012" title="HarrisonJ . Assessment of cognitive dysfunction in patients with depression ‐ which test is best?. 28th European College of Neuropsychopharmacology, ECNP Congress; 2015 29 Aug ‐ 1 Sept; Amsterdam Netherlands. 2015:S669. McIntyreRS , LophavenS , OlsenCK . A randomized, double‐blind, placebo‐controlled study of vortioxetine on cognitive function in depressed adults. International Journal of Neuropsychopharmacology2014;17(10):1557‐67. [NCT01422213] McIntyreRS , LophavenS , OlsenCK . Randomized, double‐blind, placebo‐controlled study of the efficacy of vortioxetine on cognitive dysfunction in adult patients with major depressive disorder (MDD). 52nd Annual Meeting of the American College of Neuropsychopharmacology, ACNP; 2013 Dec 8‐12; Hollywood (FL). 2013:S380‐1. NCT01422213 . Randomised, double‐blind, parallel‐group, placebo‐controlled, fixed dose study on the efficacy of [vortioxetine] Lu AA21004 on cognitive dysfunction in adult patients with major depressive disorder (MDD). clinicaltrials.gov/show/NCT01422213 Date first received: 22 August 2011. ">McIntyre 2014</a>; <a href="./references#CD011520-bbs2-0013" title="Euctr2010‐022257‐41‐Lv . A multinational, randomized, double‐blind, placebo‐controlled, dose ranging study to assess the efficacy and safety of Lu AA21004 in patients with major depressive disorder ‐ efficacy and safety of Lu AA21004 for treatment of major depressive disorder. www.clinicaltrialsregister.eu/ctr‐search/search?query=eudract_number:2010‐022257‐412010. NCT01255787 . A multinational, randomized, double‐blind, placebo‐controlled, dose ranging study to assess the efficacy and safety of Lu AA21004 in patients with major depressive disorder. clinicaltrials.gov/show/NCT01255787 Date first received: 6 December 2010. ">NCT01255787</a>; <a href="./references#CD011520-bbs2-0014" title="Jprn‐Japiccti‐111492 . A randomized, double‐blind, placebo‐controlled, phase III study to assess the efficacy and safety of LuAA21004 in patients with major depressive disorder. www.clinicaltrials.jp/user/showCteDetailE.jsp?japicId=JapicCTI‐111492 Date first received: 9 May 2011. NCT01355081 . A randomized, double‐blind, placebo‐controlled, parallel‐group, phase III study to assess the efficacy and safety of Lu AA21004 in patients with major depressive disorder. clinicaltrials.gov/show/NCT01355081 Date first received: 16 May 2011. ">Takeda 2011</a>; <a href="./references#CD011520-bbs2-0015" title="Kct0000432 . Randomised, double‐blind, parallel‐group, active‐comparator (venlafaxine extended release), fixed‐dose study of LuAA21004 in major depressive disorder in Asian countries. cris.nih.go.kr/cris/en/search/search_result_st01.jsp?seq=2532 Date first approved: 16 August 2011. NCT01571453 . Randomised, double‐blind, parallel‐group, active‐comparator (venlafaxine extended release), fixed‐dose study of [vortioxetine] Lu AA21004 in major depressive disorder in Asian countries. clinicaltrials.gov/show/NCT01571453 Date first received: 28 March 2012. WangG , GislumM , FilippovG , MontgomeryS . Comparison of vortioxetine versus venlafaxine XR in adults in Asia with major depressive disorder: a randomized, double‐blind study. Current Medical Research and Opinion2015;31(4):785‐94. ">Wang 2015</a>). Two of these were unpublished trials carried out by a pharmaceutical company (Takeda) (<a href="./references#CD011520-bbs2-0013" title="Euctr2010‐022257‐41‐Lv . A multinational, randomized, double‐blind, placebo‐controlled, dose ranging study to assess the efficacy and safety of Lu AA21004 in patients with major depressive disorder ‐ efficacy and safety of Lu AA21004 for treatment of major depressive disorder. www.clinicaltrialsregister.eu/ctr‐search/search?query=eudract_number:2010‐022257‐412010. NCT01255787 . A multinational, randomized, double‐blind, placebo‐controlled, dose ranging study to assess the efficacy and safety of Lu AA21004 in patients with major depressive disorder. clinicaltrials.gov/show/NCT01255787 Date first received: 6 December 2010. ">NCT01255787</a>; <a href="./references#CD011520-bbs2-0014" title="Jprn‐Japiccti‐111492 . A randomized, double‐blind, placebo‐controlled, phase III study to assess the efficacy and safety of LuAA21004 in patients with major depressive disorder. www.clinicaltrials.jp/user/showCteDetailE.jsp?japicId=JapicCTI‐111492 Date first received: 9 May 2011. NCT01355081 . A randomized, double‐blind, placebo‐controlled, parallel‐group, phase III study to assess the efficacy and safety of Lu AA21004 in patients with major depressive disorder. clinicaltrials.gov/show/NCT01355081 Date first received: 16 May 2011. ">Takeda 2011</a>). (See <a href="./references#CD011520-sec-0155" title="">Characteristics of included studies</a> table). </p> <section id="CD011520-sec-0075"> <h5 class="title">Design</h5> <p>All included studies were randomised trials and applied double‐blind methodology. Seven studies were three‐armed with vortioxetine, an active comparator and placebo (<a href="./references#CD011520-bbs2-0001" title="AlvarezE , PerezV , DragheimM , LoftH , ArtigasF . A double‐blind, randomized, placebo‐controlled, active reference study of Lu AA21004 in patients with major depressive disorder. International Journal of Neuropsychopharmacology2012;15(5):589‐600. [Lundbeck 11492A; NCT00839423] NCT00839423 . Randomised placebo‐controlled venlafaxine‐referenced study of efficacy and safety of 5 and 10 mg of vortioxetine (Lu AA21004) in acute treatment of major depressive disorder in adults. clinicaltrials.gov/ct2/show/NCT00839423 Date first received: 6 February 2009. ">Alvarez 2012</a>; <a href="./references#CD011520-bbs2-0002" title="BaldwinD , LoftH , DragheimM . A randomised, double‐blind, placebo controlled, duloxetine‐referenced, fixed‐dose study of three dosages of Lu AA21004 in MDD treatment. European Neuropsychopharmacology2011;21(Suppl 3):S390. BaldwinDS , LoftH , DragheimM . A randomised, double‐blind, placebo controlled, duloxetine‐referenced, fixed‐dose study of three dosages of Lu AA21004 in acute treatment of major depressive disorder (MDD). European Neuropsychopharmacology2012;22(7):482‐91. [Lundbeck 11984A; NCT00635219] NCT00635219 . Randomised placebo‐controlled duloxetine‐referenced efficacy and safety study of 2.5, 5 and 10 mg of vortioxetine (Lu AA21004) in acute treatment of major depressive disorder. clinicaltrials.gov/ct2/show/NCT00635219 Date first received: 3 March 2008. ">Baldwin 2012</a>; <a href="./references#CD011520-bbs2-0003" title="BoulengerJ‐P , LoftH , OlsenCK . Efficacy and safety of vortioxetine (Lu AA21004), 15 and 20 mg/day: a randomized, double‐blind, placebo‐controlled, duloxetine‐referenced study in the acute treatment of adult patients with major depressive disorder. International Clinical Psychopharmacology2014;29(3):138‐49. [NCT01140906] NCT01140906 . A randomised, double‐blind, parallel‐group, placebo‐controlled, duloxetine‐referenced, fixed‐dose study evaluating the efficacy and safety of Lu AA21004 (15 and 20 mg/day) in the acute treatment of adult patients with major depressive disorder. clinicaltrials.gov/show/NCT01140906 Date first received: 9 June 2010. ">Boulenger 2014</a>; <a href="./references#CD011520-bbs2-0007" title="KatonaC , HansenT , OlsenCK . A randomised, double‐blind, placebo controlled, active‐referenced study of the multimodal antidepressant Lu AA21004 in the treatment of elderly depressed patients. European Neuropsychopharmacology2012;22:S258‐9. KatonaC , HansenT , OlsenCK . A randomized, double‐blind, placebo‐controlled, duloxetine‐referenced, fixed‐dose study comparing the efficacy and safety of Lu AA21004 in elderly patients with major depressive disorder. International Clinical Psychopharmacology2012;27(4):215‐23. [Lundbeck 12541A; NCT00811252] NCT00811252 . Randomised placebo‐controlled duloxetine‐referenced study of efficacy and safety of 5 mg of vortioxetine (Lu AA21004) in acute treatment of major depressive disorder in elderly patients. clinicaltrials.gov/ct2/show/NCT00811252 Date first received: 17 December 2008. ">Katona 2012</a>; <a href="./references#CD011520-bbs2-0008" title="MahableshwarkarAR , JacobsenPL , ChenY . A randomized, double‐blind trial of 2.5mg and 5mg vortioxetine (Lu AA21004) versus placebo for 8 weeks in adults with major depressive disorder. Current Medical Research and Opinion2013;29(3):217‐26. [NCT00672620] NCT00672620 . A randomized, double‐blind, parallel‐group, placebo‐controlled, active‐referenced, fixed‐dose study comparing the efficacy and safety of 2 doses of Lu AA21004 in acute treatment of adults with major depressive disorder. clinicaltrials.gov/show/NCT00672620 Date first received: 2 May 2008. NCT00707980 . A long‐term, open‐label, flexible‐dose, extension study evaluating the safety and tolerability of Lu AA21004 in subjects with major depressive disorder. clinicaltrials.gov/ct2/show/NCT00707980 Date first received: 27 June 2008. ">Mahableshwarkar 2013</a>; <a href="./references#CD011520-bbs2-0009" title="MahableshwarkarAR , JacobsenPL , ChenY , SerenkoM , TrivediMH . A randomized, double‐blind, duloxetine‐referenced study comparing efficacy and tolerability of 2 fixed doses of vortioxetine in the acute treatment of adults with MDD. Psychopharmacology2015;232(12):2061‐70. NCT01153009 . A phase 3, randomized, double‐blind, parallel‐group, placebo‐controlled, duloxetine‐referenced, fixed‐dose study comparing the efficacy and safety of 2 doses (15 and 20 mg) of Lu AA21004 in acute treatment of adults with major depressive disorder. clinicaltrials.gov/show/NCT01153009 Date first received: 28 June 2010. ">Mahableshwarkar 2015a</a>; <a href="./references#CD011520-bbs2-0010" title="JacobsonW , HarveyP , MerikleE , ZhongW , NomikosG , OlsenCK , et al. Impact of vortioxetine on functional capacity in MDD patients with subjective cognitive dysfunction: performance on the University of California San Diego performance‐based skills assessment (UPSA). 54th Annual Meeting of the American College of Neuropsychopharmacology, ACNP; 2015 Dec 6‐10; Hollywood (FL). 2015:S150‐1. JacobsonW , OlsenC , MahableshwarkarA , YinzhongC , KeefeR . Effect of vortioxetine on functional capacity in patients with major depressive disorder with self‐reported cognitive dysfunction. 28th European College of Neuropsychopharmacology, ECNP Congress; 2015 29 Aug ‐ 1 Sept; Amsterdam Netherlands. 2015:S460. KeefeR , MahableshwarkarA , ZajeckaJ , JacobsonW , ChenY . Efficacy of vortioxetine on cognitive function in patients with major depressive disorder: cognitive test performance results: from a randomized, double‐blind, duloxetine‐referenced, placebo‐controlled. Neuropsychopharmacology2014;39:S389‐90. MahableshwarkarAR , ZajeckaJ , JacobsonW , ChenY , KeefeRS . A randomized, placebo‐controlled, active‐reference, double‐blind, flexible‐dose study of the efficacy of vortioxetine on cognitive function in major depressive disorder. Neuropsychopharmacology2015;40(8):2025‐37. NCT01564862 . A randomized, double‐blind, parallel‐group, placebo‐controlled, active‐referenced, flexible dose study on the efficacy of Lu AA21004 on cognitive dysfunction in adult subjects with major depressive disorder (MDD). clinicaltrials.gov/show/NCT01564862 Date first received: 26 March 2012. ">Mahableshwarkar 2015b</a>). Eight studies were two‐armed, among these seven studies were placebo‐controlled (<a href="./references#CD011520-bbs2-0004" title="HenigsbergN , MahableshwarkarA , JacobsenP , ChenY , ThaseME . Efficacy and tolerability of multiple doses of LU AA21004 in an 8‐week trial of adults with major depressive disorder. European Neuropsychopharmacology2011;21(Suppl 3):S393. HenigsbergN , MahableshwarkarAR , JacobsenP , ChenY , ThaseME . A randomized, double‐blind, placebo‐controlled 8‐week trial of the efficacy and tolerability of multiple doses of Lu AA21004 in adults with major depressive disorder. Journal of Clinical Psychology2012;73(7):953‐9. NCT00707980 . A long‐term, open‐label, flexible‐dose, extension study evaluating the safety and tolerability of Lu AA21004 in subjects with major depressive disorder. clinicaltrials.gov/ct2/show/NCT00707980 Date first received: 27 June 2008. NCT00735709 . A randomized, double‐blind, parallel‐group, placebo‐controlled, fixed‐dose study comparing the efficacy and safety of 3 doses of Lu AA21004 in acute treatment of adults with major depressive disorder. clinicaltrials.gov/show/NCT00735709 Date first received: 14 August 2008. ">Henigsberg 2012</a>; <a href="./references#CD011520-bbs2-0005" title="JacobsenPL , MahableshwarkarAR , SerenkoM , ChanS , TrivediMH . A randomized, double‐blind, placebo‐controlled study of the efficacy and safety of vortioxetine 10 mg and 20 mg in adults with major depressive disorder. Journal of Clinical Psychiatry2015;76(5):575‐82. NCT01163266 . A phase 3, randomized, double‐blind, parallel‐group, placebo‐controlled, fixed‐dose study comparing the efficacy and safety of 2 doses (10 and 20 mg) of Lu AA21004 in acute treatment of adults with major depressive disorder. clinicaltrials.gov/show/NCT01163266 Date first received: 14 July 2010. ">Jacobsen 2015</a>; <a href="./references#CD011520-bbs2-0006" title="JainR , MahableshwarkarAR , JacobsenPL , ChenY , ThaseME . A randomized, double‐blind, placebo‐controlled 6‐wk trial of the efficacy and tolerability of 5 mg vortioxetine in adults with major depressive disorder. International Journal of Neuropsychopharmacology2013;16(2):313‐21. NCT00672958 . A randomized, double‐blind, parallel‐group, placebo‐controlled, fixed‐dose study comparing the efficacy and safety of Lu AA21004 versus placebo in acute treatment of adults with major depressive disorder. clinicaltrials.gov/show/NCT00672958 Date first received: 2 May 2008. ">Jain 2013</a>; <a href="./references#CD011520-bbs2-0011" title="MahableshwarkarAR , JacobsenPL , SerenkoM , ChenY , TrivediMH . A randomized, double‐blind, placebo‐controlled study of the efficacy and safety of 2 doses of vortioxetine in adults with major depressive disorder. Journal of Clinical Psychiatry2015;76(5):583‐91. NCT01179516 . A phase 3, randomized, double‐blind, parallel‐group, placebo‐controlled, fixed‐dose study comparing the efficacy and safety of 2 doses (10 and 15 mg) of Lu AA21004 in acute treatment of adults with major depressive disorder. clinicaltrials.gov/show/NCT01179516 Date first received: 9 August 2010. ">Mahableshwarkar 2015c</a>; <a href="./references#CD011520-bbs2-0012" title="HarrisonJ . Assessment of cognitive dysfunction in patients with depression ‐ which test is best?. 28th European College of Neuropsychopharmacology, ECNP Congress; 2015 29 Aug ‐ 1 Sept; Amsterdam Netherlands. 2015:S669. McIntyreRS , LophavenS , OlsenCK . A randomized, double‐blind, placebo‐controlled study of vortioxetine on cognitive function in depressed adults. International Journal of Neuropsychopharmacology2014;17(10):1557‐67. [NCT01422213] McIntyreRS , LophavenS , OlsenCK . Randomized, double‐blind, placebo‐controlled study of the efficacy of vortioxetine on cognitive dysfunction in adult patients with major depressive disorder (MDD). 52nd Annual Meeting of the American College of Neuropsychopharmacology, ACNP; 2013 Dec 8‐12; Hollywood (FL). 2013:S380‐1. NCT01422213 . Randomised, double‐blind, parallel‐group, placebo‐controlled, fixed dose study on the efficacy of [vortioxetine] Lu AA21004 on cognitive dysfunction in adult patients with major depressive disorder (MDD). clinicaltrials.gov/show/NCT01422213 Date first received: 22 August 2011. ">McIntyre 2014</a>; <a href="./references#CD011520-bbs2-0013" title="Euctr2010‐022257‐41‐Lv . A multinational, randomized, double‐blind, placebo‐controlled, dose ranging study to assess the efficacy and safety of Lu AA21004 in patients with major depressive disorder ‐ efficacy and safety of Lu AA21004 for treatment of major depressive disorder. www.clinicaltrialsregister.eu/ctr‐search/search?query=eudract_number:2010‐022257‐412010. NCT01255787 . A multinational, randomized, double‐blind, placebo‐controlled, dose ranging study to assess the efficacy and safety of Lu AA21004 in patients with major depressive disorder. clinicaltrials.gov/show/NCT01255787 Date first received: 6 December 2010. ">NCT01255787</a>; <a href="./references#CD011520-bbs2-0014" title="Jprn‐Japiccti‐111492 . A randomized, double‐blind, placebo‐controlled, phase III study to assess the efficacy and safety of LuAA21004 in patients with major depressive disorder. www.clinicaltrials.jp/user/showCteDetailE.jsp?japicId=JapicCTI‐111492 Date first received: 9 May 2011. NCT01355081 . A randomized, double‐blind, placebo‐controlled, parallel‐group, phase III study to assess the efficacy and safety of Lu AA21004 in patients with major depressive disorder. clinicaltrials.gov/show/NCT01355081 Date first received: 16 May 2011. ">Takeda 2011</a>), and one study was active controlled only (<a href="./references#CD011520-bbs2-0015" title="Kct0000432 . Randomised, double‐blind, parallel‐group, active‐comparator (venlafaxine extended release), fixed‐dose study of LuAA21004 in major depressive disorder in Asian countries. cris.nih.go.kr/cris/en/search/search_result_st01.jsp?seq=2532 Date first approved: 16 August 2011. NCT01571453 . Randomised, double‐blind, parallel‐group, active‐comparator (venlafaxine extended release), fixed‐dose study of [vortioxetine] Lu AA21004 in major depressive disorder in Asian countries. clinicaltrials.gov/show/NCT01571453 Date first received: 28 March 2012. WangG , GislumM , FilippovG , MontgomeryS . Comparison of vortioxetine versus venlafaxine XR in adults in Asia with major depressive disorder: a randomized, double‐blind study. Current Medical Research and Opinion2015;31(4):785‐94. ">Wang 2015</a>). </p> </section> <section id="CD011520-sec-0076"> <h5 class="title">Trial duration</h5> <p>Two studies lasted six weeks (<a href="./references#CD011520-bbs2-0001" title="AlvarezE , PerezV , DragheimM , LoftH , ArtigasF . A double‐blind, randomized, placebo‐controlled, active reference study of Lu AA21004 in patients with major depressive disorder. International Journal of Neuropsychopharmacology2012;15(5):589‐600. [Lundbeck 11492A; NCT00839423] NCT00839423 . Randomised placebo‐controlled venlafaxine‐referenced study of efficacy and safety of 5 and 10 mg of vortioxetine (Lu AA21004) in acute treatment of major depressive disorder in adults. clinicaltrials.gov/ct2/show/NCT00839423 Date first received: 6 February 2009. ">Alvarez 2012</a>; <a href="./references#CD011520-bbs2-0006" title="JainR , MahableshwarkarAR , JacobsenPL , ChenY , ThaseME . A randomized, double‐blind, placebo‐controlled 6‐wk trial of the efficacy and tolerability of 5 mg vortioxetine in adults with major depressive disorder. International Journal of Neuropsychopharmacology2013;16(2):313‐21. NCT00672958 . A randomized, double‐blind, parallel‐group, placebo‐controlled, fixed‐dose study comparing the efficacy and safety of Lu AA21004 versus placebo in acute treatment of adults with major depressive disorder. clinicaltrials.gov/show/NCT00672958 Date first received: 2 May 2008. ">Jain 2013</a>), and 13 studies lasted eight weeks (<a href="./references#CD011520-bbs2-0002" title="BaldwinD , LoftH , DragheimM . A randomised, double‐blind, placebo controlled, duloxetine‐referenced, fixed‐dose study of three dosages of Lu AA21004 in MDD treatment. European Neuropsychopharmacology2011;21(Suppl 3):S390. BaldwinDS , LoftH , DragheimM . A randomised, double‐blind, placebo controlled, duloxetine‐referenced, fixed‐dose study of three dosages of Lu AA21004 in acute treatment of major depressive disorder (MDD). European Neuropsychopharmacology2012;22(7):482‐91. [Lundbeck 11984A; NCT00635219] NCT00635219 . Randomised placebo‐controlled duloxetine‐referenced efficacy and safety study of 2.5, 5 and 10 mg of vortioxetine (Lu AA21004) in acute treatment of major depressive disorder. clinicaltrials.gov/ct2/show/NCT00635219 Date first received: 3 March 2008. ">Baldwin 2012</a>; <a href="./references#CD011520-bbs2-0003" title="BoulengerJ‐P , LoftH , OlsenCK . Efficacy and safety of vortioxetine (Lu AA21004), 15 and 20 mg/day: a randomized, double‐blind, placebo‐controlled, duloxetine‐referenced study in the acute treatment of adult patients with major depressive disorder. International Clinical Psychopharmacology2014;29(3):138‐49. [NCT01140906] NCT01140906 . A randomised, double‐blind, parallel‐group, placebo‐controlled, duloxetine‐referenced, fixed‐dose study evaluating the efficacy and safety of Lu AA21004 (15 and 20 mg/day) in the acute treatment of adult patients with major depressive disorder. clinicaltrials.gov/show/NCT01140906 Date first received: 9 June 2010. ">Boulenger 2014</a>; <a href="./references#CD011520-bbs2-0004" title="HenigsbergN , MahableshwarkarA , JacobsenP , ChenY , ThaseME . Efficacy and tolerability of multiple doses of LU AA21004 in an 8‐week trial of adults with major depressive disorder. European Neuropsychopharmacology2011;21(Suppl 3):S393. HenigsbergN , MahableshwarkarAR , JacobsenP , ChenY , ThaseME . A randomized, double‐blind, placebo‐controlled 8‐week trial of the efficacy and tolerability of multiple doses of Lu AA21004 in adults with major depressive disorder. Journal of Clinical Psychology2012;73(7):953‐9. NCT00707980 . A long‐term, open‐label, flexible‐dose, extension study evaluating the safety and tolerability of Lu AA21004 in subjects with major depressive disorder. clinicaltrials.gov/ct2/show/NCT00707980 Date first received: 27 June 2008. NCT00735709 . A randomized, double‐blind, parallel‐group, placebo‐controlled, fixed‐dose study comparing the efficacy and safety of 3 doses of Lu AA21004 in acute treatment of adults with major depressive disorder. clinicaltrials.gov/show/NCT00735709 Date first received: 14 August 2008. ">Henigsberg 2012</a>; <a href="./references#CD011520-bbs2-0005" title="JacobsenPL , MahableshwarkarAR , SerenkoM , ChanS , TrivediMH . A randomized, double‐blind, placebo‐controlled study of the efficacy and safety of vortioxetine 10 mg and 20 mg in adults with major depressive disorder. Journal of Clinical Psychiatry2015;76(5):575‐82. NCT01163266 . A phase 3, randomized, double‐blind, parallel‐group, placebo‐controlled, fixed‐dose study comparing the efficacy and safety of 2 doses (10 and 20 mg) of Lu AA21004 in acute treatment of adults with major depressive disorder. clinicaltrials.gov/show/NCT01163266 Date first received: 14 July 2010. ">Jacobsen 2015</a>; <a href="./references#CD011520-bbs2-0007" title="KatonaC , HansenT , OlsenCK . A randomised, double‐blind, placebo controlled, active‐referenced study of the multimodal antidepressant Lu AA21004 in the treatment of elderly depressed patients. European Neuropsychopharmacology2012;22:S258‐9. KatonaC , HansenT , OlsenCK . A randomized, double‐blind, placebo‐controlled, duloxetine‐referenced, fixed‐dose study comparing the efficacy and safety of Lu AA21004 in elderly patients with major depressive disorder. International Clinical Psychopharmacology2012;27(4):215‐23. [Lundbeck 12541A; NCT00811252] NCT00811252 . Randomised placebo‐controlled duloxetine‐referenced study of efficacy and safety of 5 mg of vortioxetine (Lu AA21004) in acute treatment of major depressive disorder in elderly patients. clinicaltrials.gov/ct2/show/NCT00811252 Date first received: 17 December 2008. ">Katona 2012</a>; <a href="./references#CD011520-bbs2-0008" title="MahableshwarkarAR , JacobsenPL , ChenY . A randomized, double‐blind trial of 2.5mg and 5mg vortioxetine (Lu AA21004) versus placebo for 8 weeks in adults with major depressive disorder. Current Medical Research and Opinion2013;29(3):217‐26. [NCT00672620] NCT00672620 . A randomized, double‐blind, parallel‐group, placebo‐controlled, active‐referenced, fixed‐dose study comparing the efficacy and safety of 2 doses of Lu AA21004 in acute treatment of adults with major depressive disorder. clinicaltrials.gov/show/NCT00672620 Date first received: 2 May 2008. NCT00707980 . A long‐term, open‐label, flexible‐dose, extension study evaluating the safety and tolerability of Lu AA21004 in subjects with major depressive disorder. clinicaltrials.gov/ct2/show/NCT00707980 Date first received: 27 June 2008. ">Mahableshwarkar 2013</a>; <a href="./references#CD011520-bbs2-0009" title="MahableshwarkarAR , JacobsenPL , ChenY , SerenkoM , TrivediMH . A randomized, double‐blind, duloxetine‐referenced study comparing efficacy and tolerability of 2 fixed doses of vortioxetine in the acute treatment of adults with MDD. Psychopharmacology2015;232(12):2061‐70. NCT01153009 . A phase 3, randomized, double‐blind, parallel‐group, placebo‐controlled, duloxetine‐referenced, fixed‐dose study comparing the efficacy and safety of 2 doses (15 and 20 mg) of Lu AA21004 in acute treatment of adults with major depressive disorder. clinicaltrials.gov/show/NCT01153009 Date first received: 28 June 2010. ">Mahableshwarkar 2015a</a>; <a href="./references#CD011520-bbs2-0010" title="JacobsonW , HarveyP , MerikleE , ZhongW , NomikosG , OlsenCK , et al. Impact of vortioxetine on functional capacity in MDD patients with subjective cognitive dysfunction: performance on the University of California San Diego performance‐based skills assessment (UPSA). 54th Annual Meeting of the American College of Neuropsychopharmacology, ACNP; 2015 Dec 6‐10; Hollywood (FL). 2015:S150‐1. JacobsonW , OlsenC , MahableshwarkarA , YinzhongC , KeefeR . Effect of vortioxetine on functional capacity in patients with major depressive disorder with self‐reported cognitive dysfunction. 28th European College of Neuropsychopharmacology, ECNP Congress; 2015 29 Aug ‐ 1 Sept; Amsterdam Netherlands. 2015:S460. KeefeR , MahableshwarkarA , ZajeckaJ , JacobsonW , ChenY . Efficacy of vortioxetine on cognitive function in patients with major depressive disorder: cognitive test performance results: from a randomized, double‐blind, duloxetine‐referenced, placebo‐controlled. Neuropsychopharmacology2014;39:S389‐90. MahableshwarkarAR , ZajeckaJ , JacobsonW , ChenY , KeefeRS . A randomized, placebo‐controlled, active‐reference, double‐blind, flexible‐dose study of the efficacy of vortioxetine on cognitive function in major depressive disorder. Neuropsychopharmacology2015;40(8):2025‐37. NCT01564862 . A randomized, double‐blind, parallel‐group, placebo‐controlled, active‐referenced, flexible dose study on the efficacy of Lu AA21004 on cognitive dysfunction in adult subjects with major depressive disorder (MDD). clinicaltrials.gov/show/NCT01564862 Date first received: 26 March 2012. ">Mahableshwarkar 2015b</a>; <a href="./references#CD011520-bbs2-0011" title="MahableshwarkarAR , JacobsenPL , SerenkoM , ChenY , TrivediMH . A randomized, double‐blind, placebo‐controlled study of the efficacy and safety of 2 doses of vortioxetine in adults with major depressive disorder. Journal of Clinical Psychiatry2015;76(5):583‐91. NCT01179516 . A phase 3, randomized, double‐blind, parallel‐group, placebo‐controlled, fixed‐dose study comparing the efficacy and safety of 2 doses (10 and 15 mg) of Lu AA21004 in acute treatment of adults with major depressive disorder. clinicaltrials.gov/show/NCT01179516 Date first received: 9 August 2010. ">Mahableshwarkar 2015c</a>; <a href="./references#CD011520-bbs2-0012" title="HarrisonJ . Assessment of cognitive dysfunction in patients with depression ‐ which test is best?. 28th European College of Neuropsychopharmacology, ECNP Congress; 2015 29 Aug ‐ 1 Sept; Amsterdam Netherlands. 2015:S669. McIntyreRS , LophavenS , OlsenCK . A randomized, double‐blind, placebo‐controlled study of vortioxetine on cognitive function in depressed adults. International Journal of Neuropsychopharmacology2014;17(10):1557‐67. [NCT01422213] McIntyreRS , LophavenS , OlsenCK . Randomized, double‐blind, placebo‐controlled study of the efficacy of vortioxetine on cognitive dysfunction in adult patients with major depressive disorder (MDD). 52nd Annual Meeting of the American College of Neuropsychopharmacology, ACNP; 2013 Dec 8‐12; Hollywood (FL). 2013:S380‐1. NCT01422213 . Randomised, double‐blind, parallel‐group, placebo‐controlled, fixed dose study on the efficacy of [vortioxetine] Lu AA21004 on cognitive dysfunction in adult patients with major depressive disorder (MDD). clinicaltrials.gov/show/NCT01422213 Date first received: 22 August 2011. ">McIntyre 2014</a>; <a href="./references#CD011520-bbs2-0013" title="Euctr2010‐022257‐41‐Lv . A multinational, randomized, double‐blind, placebo‐controlled, dose ranging study to assess the efficacy and safety of Lu AA21004 in patients with major depressive disorder ‐ efficacy and safety of Lu AA21004 for treatment of major depressive disorder. www.clinicaltrialsregister.eu/ctr‐search/search?query=eudract_number:2010‐022257‐412010. NCT01255787 . A multinational, randomized, double‐blind, placebo‐controlled, dose ranging study to assess the efficacy and safety of Lu AA21004 in patients with major depressive disorder. clinicaltrials.gov/show/NCT01255787 Date first received: 6 December 2010. ">NCT01255787</a>; <a href="./references#CD011520-bbs2-0014" title="Jprn‐Japiccti‐111492 . A randomized, double‐blind, placebo‐controlled, phase III study to assess the efficacy and safety of LuAA21004 in patients with major depressive disorder. www.clinicaltrials.jp/user/showCteDetailE.jsp?japicId=JapicCTI‐111492 Date first received: 9 May 2011. NCT01355081 . A randomized, double‐blind, placebo‐controlled, parallel‐group, phase III study to assess the efficacy and safety of Lu AA21004 in patients with major depressive disorder. clinicaltrials.gov/show/NCT01355081 Date first received: 16 May 2011. ">Takeda 2011</a>; <a href="./references#CD011520-bbs2-0015" title="Kct0000432 . Randomised, double‐blind, parallel‐group, active‐comparator (venlafaxine extended release), fixed‐dose study of LuAA21004 in major depressive disorder in Asian countries. cris.nih.go.kr/cris/en/search/search_result_st01.jsp?seq=2532 Date first approved: 16 August 2011. NCT01571453 . Randomised, double‐blind, parallel‐group, active‐comparator (venlafaxine extended release), fixed‐dose study of [vortioxetine] Lu AA21004 in major depressive disorder in Asian countries. clinicaltrials.gov/show/NCT01571453 Date first received: 28 March 2012. WangG , GislumM , FilippovG , MontgomeryS . Comparison of vortioxetine versus venlafaxine XR in adults in Asia with major depressive disorder: a randomized, double‐blind study. Current Medical Research and Opinion2015;31(4):785‐94. ">Wang 2015</a>). </p> </section> <section id="CD011520-sec-0077"> <h5 class="title">Sample sizes</h5> <p>Overall, the studies included 7746 participants. Of these, 4134 were randomised to vortioxetine. Of the remaining 3612 participants, 2299 were randomised to placebo, 1313 to SNRIs (344 to venlafaxine and 969 to duloxetine). The mean sample size per arm was 209 participants (range 105 to 448). </p> </section> <section id="CD011520-sec-0078"> <h5 class="title">Setting</h5> <p>All studies were multicentre trials. Six studies were conducted in a single nation: the USA (<a href="./references#CD011520-bbs2-0005" title="JacobsenPL , MahableshwarkarAR , SerenkoM , ChanS , TrivediMH . A randomized, double‐blind, placebo‐controlled study of the efficacy and safety of vortioxetine 10 mg and 20 mg in adults with major depressive disorder. Journal of Clinical Psychiatry2015;76(5):575‐82. NCT01163266 . A phase 3, randomized, double‐blind, parallel‐group, placebo‐controlled, fixed‐dose study comparing the efficacy and safety of 2 doses (10 and 20 mg) of Lu AA21004 in acute treatment of adults with major depressive disorder. clinicaltrials.gov/show/NCT01163266 Date first received: 14 July 2010. ">Jacobsen 2015</a>; <a href="./references#CD011520-bbs2-0006" title="JainR , MahableshwarkarAR , JacobsenPL , ChenY , ThaseME . A randomized, double‐blind, placebo‐controlled 6‐wk trial of the efficacy and tolerability of 5 mg vortioxetine in adults with major depressive disorder. International Journal of Neuropsychopharmacology2013;16(2):313‐21. NCT00672958 . A randomized, double‐blind, parallel‐group, placebo‐controlled, fixed‐dose study comparing the efficacy and safety of Lu AA21004 versus placebo in acute treatment of adults with major depressive disorder. clinicaltrials.gov/show/NCT00672958 Date first received: 2 May 2008. ">Jain 2013</a>; <a href="./references#CD011520-bbs2-0008" title="MahableshwarkarAR , JacobsenPL , ChenY . A randomized, double‐blind trial of 2.5mg and 5mg vortioxetine (Lu AA21004) versus placebo for 8 weeks in adults with major depressive disorder. Current Medical Research and Opinion2013;29(3):217‐26. [NCT00672620] NCT00672620 . A randomized, double‐blind, parallel‐group, placebo‐controlled, active‐referenced, fixed‐dose study comparing the efficacy and safety of 2 doses of Lu AA21004 in acute treatment of adults with major depressive disorder. clinicaltrials.gov/show/NCT00672620 Date first received: 2 May 2008. NCT00707980 . A long‐term, open‐label, flexible‐dose, extension study evaluating the safety and tolerability of Lu AA21004 in subjects with major depressive disorder. clinicaltrials.gov/ct2/show/NCT00707980 Date first received: 27 June 2008. ">Mahableshwarkar 2013</a>; <a href="./references#CD011520-bbs2-0009" title="MahableshwarkarAR , JacobsenPL , ChenY , SerenkoM , TrivediMH . A randomized, double‐blind, duloxetine‐referenced study comparing efficacy and tolerability of 2 fixed doses of vortioxetine in the acute treatment of adults with MDD. Psychopharmacology2015;232(12):2061‐70. NCT01153009 . A phase 3, randomized, double‐blind, parallel‐group, placebo‐controlled, duloxetine‐referenced, fixed‐dose study comparing the efficacy and safety of 2 doses (15 and 20 mg) of Lu AA21004 in acute treatment of adults with major depressive disorder. clinicaltrials.gov/show/NCT01153009 Date first received: 28 June 2010. ">Mahableshwarkar 2015a</a>; <a href="./references#CD011520-bbs2-0011" title="MahableshwarkarAR , JacobsenPL , SerenkoM , ChenY , TrivediMH . A randomized, double‐blind, placebo‐controlled study of the efficacy and safety of 2 doses of vortioxetine in adults with major depressive disorder. Journal of Clinical Psychiatry2015;76(5):583‐91. NCT01179516 . A phase 3, randomized, double‐blind, parallel‐group, placebo‐controlled, fixed‐dose study comparing the efficacy and safety of 2 doses (10 and 15 mg) of Lu AA21004 in acute treatment of adults with major depressive disorder. clinicaltrials.gov/show/NCT01179516 Date first received: 9 August 2010. ">Mahableshwarkar 2015c</a>) and Japan (<a href="./references#CD011520-bbs2-0014" title="Jprn‐Japiccti‐111492 . A randomized, double‐blind, placebo‐controlled, phase III study to assess the efficacy and safety of LuAA21004 in patients with major depressive disorder. www.clinicaltrials.jp/user/showCteDetailE.jsp?japicId=JapicCTI‐111492 Date first received: 9 May 2011. NCT01355081 . A randomized, double‐blind, placebo‐controlled, parallel‐group, phase III study to assess the efficacy and safety of Lu AA21004 in patients with major depressive disorder. clinicaltrials.gov/show/NCT01355081 Date first received: 16 May 2011. ">Takeda 2011</a>). One multinational study recruited Asian participants only (<a href="./references#CD011520-bbs2-0015" title="Kct0000432 . Randomised, double‐blind, parallel‐group, active‐comparator (venlafaxine extended release), fixed‐dose study of LuAA21004 in major depressive disorder in Asian countries. cris.nih.go.kr/cris/en/search/search_result_st01.jsp?seq=2532 Date first approved: 16 August 2011. NCT01571453 . Randomised, double‐blind, parallel‐group, active‐comparator (venlafaxine extended release), fixed‐dose study of [vortioxetine] Lu AA21004 in major depressive disorder in Asian countries. clinicaltrials.gov/show/NCT01571453 Date first received: 28 March 2012. WangG , GislumM , FilippovG , MontgomeryS . Comparison of vortioxetine versus venlafaxine XR in adults in Asia with major depressive disorder: a randomized, double‐blind study. Current Medical Research and Opinion2015;31(4):785‐94. ">Wang 2015</a>). The other studies were multinational across continents. An overview of countries where participants were recruited is given in <a href="#CD011520-fig-0002">Figure 2</a>. </p> <div class="figure" id="CD011520-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Countries participating in trials. The categories represent the number of studies randomising participants within a country." data-id="CD011520-fig-0002" src="/cdsr/doi/10.1002/14651858.CD011520.pub2/media/CDSR/CD011520/image_n/nCD011520-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Countries participating in trials. The categories represent the number of studies randomising participants within a country. </p> </div> </div> </div> <p>Four studies enrolled both inpatients and outpatients (<a href="./references#CD011520-bbs2-0002" title="BaldwinD , LoftH , DragheimM . A randomised, double‐blind, placebo controlled, duloxetine‐referenced, fixed‐dose study of three dosages of Lu AA21004 in MDD treatment. European Neuropsychopharmacology2011;21(Suppl 3):S390. BaldwinDS , LoftH , DragheimM . A randomised, double‐blind, placebo controlled, duloxetine‐referenced, fixed‐dose study of three dosages of Lu AA21004 in acute treatment of major depressive disorder (MDD). European Neuropsychopharmacology2012;22(7):482‐91. [Lundbeck 11984A; NCT00635219] NCT00635219 . Randomised placebo‐controlled duloxetine‐referenced efficacy and safety study of 2.5, 5 and 10 mg of vortioxetine (Lu AA21004) in acute treatment of major depressive disorder. clinicaltrials.gov/ct2/show/NCT00635219 Date first received: 3 March 2008. ">Baldwin 2012</a>; <a href="./references#CD011520-bbs2-0003" title="BoulengerJ‐P , LoftH , OlsenCK . Efficacy and safety of vortioxetine (Lu AA21004), 15 and 20 mg/day: a randomized, double‐blind, placebo‐controlled, duloxetine‐referenced study in the acute treatment of adult patients with major depressive disorder. International Clinical Psychopharmacology2014;29(3):138‐49. [NCT01140906] NCT01140906 . A randomised, double‐blind, parallel‐group, placebo‐controlled, duloxetine‐referenced, fixed‐dose study evaluating the efficacy and safety of Lu AA21004 (15 and 20 mg/day) in the acute treatment of adult patients with major depressive disorder. clinicaltrials.gov/show/NCT01140906 Date first received: 9 June 2010. ">Boulenger 2014</a>; <a href="./references#CD011520-bbs2-0012" title="HarrisonJ . Assessment of cognitive dysfunction in patients with depression ‐ which test is best?. 28th European College of Neuropsychopharmacology, ECNP Congress; 2015 29 Aug ‐ 1 Sept; Amsterdam Netherlands. 2015:S669. McIntyreRS , LophavenS , OlsenCK . A randomized, double‐blind, placebo‐controlled study of vortioxetine on cognitive function in depressed adults. International Journal of Neuropsychopharmacology2014;17(10):1557‐67. [NCT01422213] McIntyreRS , LophavenS , OlsenCK . Randomized, double‐blind, placebo‐controlled study of the efficacy of vortioxetine on cognitive dysfunction in adult patients with major depressive disorder (MDD). 52nd Annual Meeting of the American College of Neuropsychopharmacology, ACNP; 2013 Dec 8‐12; Hollywood (FL). 2013:S380‐1. NCT01422213 . Randomised, double‐blind, parallel‐group, placebo‐controlled, fixed dose study on the efficacy of [vortioxetine] Lu AA21004 on cognitive dysfunction in adult patients with major depressive disorder (MDD). clinicaltrials.gov/show/NCT01422213 Date first received: 22 August 2011. ">McIntyre 2014</a>; <a href="./references#CD011520-bbs2-0015" title="Kct0000432 . Randomised, double‐blind, parallel‐group, active‐comparator (venlafaxine extended release), fixed‐dose study of LuAA21004 in major depressive disorder in Asian countries. cris.nih.go.kr/cris/en/search/search_result_st01.jsp?seq=2532 Date first approved: 16 August 2011. NCT01571453 . Randomised, double‐blind, parallel‐group, active‐comparator (venlafaxine extended release), fixed‐dose study of [vortioxetine] Lu AA21004 in major depressive disorder in Asian countries. clinicaltrials.gov/show/NCT01571453 Date first received: 28 March 2012. WangG , GislumM , FilippovG , MontgomeryS . Comparison of vortioxetine versus venlafaxine XR in adults in Asia with major depressive disorder: a randomized, double‐blind study. Current Medical Research and Opinion2015;31(4):785‐94. ">Wang 2015</a>). Three studies recruited exclusively outpatients (<a href="./references#CD011520-bbs2-0001" title="AlvarezE , PerezV , DragheimM , LoftH , ArtigasF . A double‐blind, randomized, placebo‐controlled, active reference study of Lu AA21004 in patients with major depressive disorder. International Journal of Neuropsychopharmacology2012;15(5):589‐600. [Lundbeck 11492A; NCT00839423] NCT00839423 . Randomised placebo‐controlled venlafaxine‐referenced study of efficacy and safety of 5 and 10 mg of vortioxetine (Lu AA21004) in acute treatment of major depressive disorder in adults. clinicaltrials.gov/ct2/show/NCT00839423 Date first received: 6 February 2009. ">Alvarez 2012</a>; <a href="./references#CD011520-bbs2-0005" title="JacobsenPL , MahableshwarkarAR , SerenkoM , ChanS , TrivediMH . A randomized, double‐blind, placebo‐controlled study of the efficacy and safety of vortioxetine 10 mg and 20 mg in adults with major depressive disorder. Journal of Clinical Psychiatry2015;76(5):575‐82. NCT01163266 . A phase 3, randomized, double‐blind, parallel‐group, placebo‐controlled, fixed‐dose study comparing the efficacy and safety of 2 doses (10 and 20 mg) of Lu AA21004 in acute treatment of adults with major depressive disorder. clinicaltrials.gov/show/NCT01163266 Date first received: 14 July 2010. ">Jacobsen 2015</a>; <a href="./references#CD011520-bbs2-0006" title="JainR , MahableshwarkarAR , JacobsenPL , ChenY , ThaseME . A randomized, double‐blind, placebo‐controlled 6‐wk trial of the efficacy and tolerability of 5 mg vortioxetine in adults with major depressive disorder. International Journal of Neuropsychopharmacology2013;16(2):313‐21. NCT00672958 . A randomized, double‐blind, parallel‐group, placebo‐controlled, fixed‐dose study comparing the efficacy and safety of Lu AA21004 versus placebo in acute treatment of adults with major depressive disorder. clinicaltrials.gov/show/NCT00672958 Date first received: 2 May 2008. ">Jain 2013</a>). Eight studies did not explicitly report the setting (<a href="./references#CD011520-bbs2-0004" title="HenigsbergN , MahableshwarkarA , JacobsenP , ChenY , ThaseME . Efficacy and tolerability of multiple doses of LU AA21004 in an 8‐week trial of adults with major depressive disorder. European Neuropsychopharmacology2011;21(Suppl 3):S393. HenigsbergN , MahableshwarkarAR , JacobsenP , ChenY , ThaseME . A randomized, double‐blind, placebo‐controlled 8‐week trial of the efficacy and tolerability of multiple doses of Lu AA21004 in adults with major depressive disorder. Journal of Clinical Psychology2012;73(7):953‐9. NCT00707980 . A long‐term, open‐label, flexible‐dose, extension study evaluating the safety and tolerability of Lu AA21004 in subjects with major depressive disorder. clinicaltrials.gov/ct2/show/NCT00707980 Date first received: 27 June 2008. NCT00735709 . A randomized, double‐blind, parallel‐group, placebo‐controlled, fixed‐dose study comparing the efficacy and safety of 3 doses of Lu AA21004 in acute treatment of adults with major depressive disorder. clinicaltrials.gov/show/NCT00735709 Date first received: 14 August 2008. ">Henigsberg 2012</a>; <a href="./references#CD011520-bbs2-0007" title="KatonaC , HansenT , OlsenCK . A randomised, double‐blind, placebo controlled, active‐referenced study of the multimodal antidepressant Lu AA21004 in the treatment of elderly depressed patients. European Neuropsychopharmacology2012;22:S258‐9. KatonaC , HansenT , OlsenCK . A randomized, double‐blind, placebo‐controlled, duloxetine‐referenced, fixed‐dose study comparing the efficacy and safety of Lu AA21004 in elderly patients with major depressive disorder. International Clinical Psychopharmacology2012;27(4):215‐23. [Lundbeck 12541A; NCT00811252] NCT00811252 . Randomised placebo‐controlled duloxetine‐referenced study of efficacy and safety of 5 mg of vortioxetine (Lu AA21004) in acute treatment of major depressive disorder in elderly patients. clinicaltrials.gov/ct2/show/NCT00811252 Date first received: 17 December 2008. ">Katona 2012</a>; <a href="./references#CD011520-bbs2-0008" title="MahableshwarkarAR , JacobsenPL , ChenY . A randomized, double‐blind trial of 2.5mg and 5mg vortioxetine (Lu AA21004) versus placebo for 8 weeks in adults with major depressive disorder. Current Medical Research and Opinion2013;29(3):217‐26. [NCT00672620] NCT00672620 . A randomized, double‐blind, parallel‐group, placebo‐controlled, active‐referenced, fixed‐dose study comparing the efficacy and safety of 2 doses of Lu AA21004 in acute treatment of adults with major depressive disorder. clinicaltrials.gov/show/NCT00672620 Date first received: 2 May 2008. NCT00707980 . A long‐term, open‐label, flexible‐dose, extension study evaluating the safety and tolerability of Lu AA21004 in subjects with major depressive disorder. clinicaltrials.gov/ct2/show/NCT00707980 Date first received: 27 June 2008. ">Mahableshwarkar 2013</a>; <a href="./references#CD011520-bbs2-0009" title="MahableshwarkarAR , JacobsenPL , ChenY , SerenkoM , TrivediMH . A randomized, double‐blind, duloxetine‐referenced study comparing efficacy and tolerability of 2 fixed doses of vortioxetine in the acute treatment of adults with MDD. Psychopharmacology2015;232(12):2061‐70. NCT01153009 . A phase 3, randomized, double‐blind, parallel‐group, placebo‐controlled, duloxetine‐referenced, fixed‐dose study comparing the efficacy and safety of 2 doses (15 and 20 mg) of Lu AA21004 in acute treatment of adults with major depressive disorder. clinicaltrials.gov/show/NCT01153009 Date first received: 28 June 2010. ">Mahableshwarkar 2015a</a>; <a href="./references#CD011520-bbs2-0010" title="JacobsonW , HarveyP , MerikleE , ZhongW , NomikosG , OlsenCK , et al. Impact of vortioxetine on functional capacity in MDD patients with subjective cognitive dysfunction: performance on the University of California San Diego performance‐based skills assessment (UPSA). 54th Annual Meeting of the American College of Neuropsychopharmacology, ACNP; 2015 Dec 6‐10; Hollywood (FL). 2015:S150‐1. JacobsonW , OlsenC , MahableshwarkarA , YinzhongC , KeefeR . Effect of vortioxetine on functional capacity in patients with major depressive disorder with self‐reported cognitive dysfunction. 28th European College of Neuropsychopharmacology, ECNP Congress; 2015 29 Aug ‐ 1 Sept; Amsterdam Netherlands. 2015:S460. KeefeR , MahableshwarkarA , ZajeckaJ , JacobsonW , ChenY . Efficacy of vortioxetine on cognitive function in patients with major depressive disorder: cognitive test performance results: from a randomized, double‐blind, duloxetine‐referenced, placebo‐controlled. Neuropsychopharmacology2014;39:S389‐90. MahableshwarkarAR , ZajeckaJ , JacobsonW , ChenY , KeefeRS . A randomized, placebo‐controlled, active‐reference, double‐blind, flexible‐dose study of the efficacy of vortioxetine on cognitive function in major depressive disorder. Neuropsychopharmacology2015;40(8):2025‐37. NCT01564862 . A randomized, double‐blind, parallel‐group, placebo‐controlled, active‐referenced, flexible dose study on the efficacy of Lu AA21004 on cognitive dysfunction in adult subjects with major depressive disorder (MDD). clinicaltrials.gov/show/NCT01564862 Date first received: 26 March 2012. ">Mahableshwarkar 2015b</a>; <a href="./references#CD011520-bbs2-0011" title="MahableshwarkarAR , JacobsenPL , SerenkoM , ChenY , TrivediMH . A randomized, double‐blind, placebo‐controlled study of the efficacy and safety of 2 doses of vortioxetine in adults with major depressive disorder. Journal of Clinical Psychiatry2015;76(5):583‐91. NCT01179516 . A phase 3, randomized, double‐blind, parallel‐group, placebo‐controlled, fixed‐dose study comparing the efficacy and safety of 2 doses (10 and 15 mg) of Lu AA21004 in acute treatment of adults with major depressive disorder. clinicaltrials.gov/show/NCT01179516 Date first received: 9 August 2010. ">Mahableshwarkar 2015c</a>; <a href="./references#CD011520-bbs2-0013" title="Euctr2010‐022257‐41‐Lv . A multinational, randomized, double‐blind, placebo‐controlled, dose ranging study to assess the efficacy and safety of Lu AA21004 in patients with major depressive disorder ‐ efficacy and safety of Lu AA21004 for treatment of major depressive disorder. www.clinicaltrialsregister.eu/ctr‐search/search?query=eudract_number:2010‐022257‐412010. NCT01255787 . A multinational, randomized, double‐blind, placebo‐controlled, dose ranging study to assess the efficacy and safety of Lu AA21004 in patients with major depressive disorder. clinicaltrials.gov/show/NCT01255787 Date first received: 6 December 2010. ">NCT01255787</a>; <a href="./references#CD011520-bbs2-0014" title="Jprn‐Japiccti‐111492 . A randomized, double‐blind, placebo‐controlled, phase III study to assess the efficacy and safety of LuAA21004 in patients with major depressive disorder. www.clinicaltrials.jp/user/showCteDetailE.jsp?japicId=JapicCTI‐111492 Date first received: 9 May 2011. NCT01355081 . A randomized, double‐blind, placebo‐controlled, parallel‐group, phase III study to assess the efficacy and safety of Lu AA21004 in patients with major depressive disorder. clinicaltrials.gov/show/NCT01355081 Date first received: 16 May 2011. ">Takeda 2011</a>). </p> </section> <section id="CD011520-sec-0079"> <h5 class="title">Participants</h5> <p>All studies included participants with a diagnosis of MDD. No trial enrolled people with comorbid psychiatric disorders. </p> <p>Thirteen studies randomised participants from 18 years of age: eight studies recruited participants aged between 18 and 75 years (<a href="./references#CD011520-bbs2-0002" title="BaldwinD , LoftH , DragheimM . A randomised, double‐blind, placebo controlled, duloxetine‐referenced, fixed‐dose study of three dosages of Lu AA21004 in MDD treatment. European Neuropsychopharmacology2011;21(Suppl 3):S390. BaldwinDS , LoftH , DragheimM . A randomised, double‐blind, placebo controlled, duloxetine‐referenced, fixed‐dose study of three dosages of Lu AA21004 in acute treatment of major depressive disorder (MDD). European Neuropsychopharmacology2012;22(7):482‐91. [Lundbeck 11984A; NCT00635219] NCT00635219 . Randomised placebo‐controlled duloxetine‐referenced efficacy and safety study of 2.5, 5 and 10 mg of vortioxetine (Lu AA21004) in acute treatment of major depressive disorder. clinicaltrials.gov/ct2/show/NCT00635219 Date first received: 3 March 2008. ">Baldwin 2012</a>; <a href="./references#CD011520-bbs2-0003" title="BoulengerJ‐P , LoftH , OlsenCK . Efficacy and safety of vortioxetine (Lu AA21004), 15 and 20 mg/day: a randomized, double‐blind, placebo‐controlled, duloxetine‐referenced study in the acute treatment of adult patients with major depressive disorder. International Clinical Psychopharmacology2014;29(3):138‐49. [NCT01140906] NCT01140906 . A randomised, double‐blind, parallel‐group, placebo‐controlled, duloxetine‐referenced, fixed‐dose study evaluating the efficacy and safety of Lu AA21004 (15 and 20 mg/day) in the acute treatment of adult patients with major depressive disorder. clinicaltrials.gov/show/NCT01140906 Date first received: 9 June 2010. ">Boulenger 2014</a>; <a href="./references#CD011520-bbs2-0004" title="HenigsbergN , MahableshwarkarA , JacobsenP , ChenY , ThaseME . Efficacy and tolerability of multiple doses of LU AA21004 in an 8‐week trial of adults with major depressive disorder. European Neuropsychopharmacology2011;21(Suppl 3):S393. HenigsbergN , MahableshwarkarAR , JacobsenP , ChenY , ThaseME . A randomized, double‐blind, placebo‐controlled 8‐week trial of the efficacy and tolerability of multiple doses of Lu AA21004 in adults with major depressive disorder. Journal of Clinical Psychology2012;73(7):953‐9. NCT00707980 . A long‐term, open‐label, flexible‐dose, extension study evaluating the safety and tolerability of Lu AA21004 in subjects with major depressive disorder. clinicaltrials.gov/ct2/show/NCT00707980 Date first received: 27 June 2008. NCT00735709 . A randomized, double‐blind, parallel‐group, placebo‐controlled, fixed‐dose study comparing the efficacy and safety of 3 doses of Lu AA21004 in acute treatment of adults with major depressive disorder. clinicaltrials.gov/show/NCT00735709 Date first received: 14 August 2008. ">Henigsberg 2012</a>; <a href="./references#CD011520-bbs2-0005" title="JacobsenPL , MahableshwarkarAR , SerenkoM , ChanS , TrivediMH . A randomized, double‐blind, placebo‐controlled study of the efficacy and safety of vortioxetine 10 mg and 20 mg in adults with major depressive disorder. Journal of Clinical Psychiatry2015;76(5):575‐82. NCT01163266 . A phase 3, randomized, double‐blind, parallel‐group, placebo‐controlled, fixed‐dose study comparing the efficacy and safety of 2 doses (10 and 20 mg) of Lu AA21004 in acute treatment of adults with major depressive disorder. clinicaltrials.gov/show/NCT01163266 Date first received: 14 July 2010. ">Jacobsen 2015</a>; <a href="./references#CD011520-bbs2-0006" title="JainR , MahableshwarkarAR , JacobsenPL , ChenY , ThaseME . A randomized, double‐blind, placebo‐controlled 6‐wk trial of the efficacy and tolerability of 5 mg vortioxetine in adults with major depressive disorder. International Journal of Neuropsychopharmacology2013;16(2):313‐21. NCT00672958 . A randomized, double‐blind, parallel‐group, placebo‐controlled, fixed‐dose study comparing the efficacy and safety of Lu AA21004 versus placebo in acute treatment of adults with major depressive disorder. clinicaltrials.gov/show/NCT00672958 Date first received: 2 May 2008. ">Jain 2013</a>; <a href="./references#CD011520-bbs2-0008" title="MahableshwarkarAR , JacobsenPL , ChenY . A randomized, double‐blind trial of 2.5mg and 5mg vortioxetine (Lu AA21004) versus placebo for 8 weeks in adults with major depressive disorder. Current Medical Research and Opinion2013;29(3):217‐26. [NCT00672620] NCT00672620 . A randomized, double‐blind, parallel‐group, placebo‐controlled, active‐referenced, fixed‐dose study comparing the efficacy and safety of 2 doses of Lu AA21004 in acute treatment of adults with major depressive disorder. clinicaltrials.gov/show/NCT00672620 Date first received: 2 May 2008. NCT00707980 . A long‐term, open‐label, flexible‐dose, extension study evaluating the safety and tolerability of Lu AA21004 in subjects with major depressive disorder. clinicaltrials.gov/ct2/show/NCT00707980 Date first received: 27 June 2008. ">Mahableshwarkar 2013</a>; <a href="./references#CD011520-bbs2-0009" title="MahableshwarkarAR , JacobsenPL , ChenY , SerenkoM , TrivediMH . A randomized, double‐blind, duloxetine‐referenced study comparing efficacy and tolerability of 2 fixed doses of vortioxetine in the acute treatment of adults with MDD. Psychopharmacology2015;232(12):2061‐70. NCT01153009 . A phase 3, randomized, double‐blind, parallel‐group, placebo‐controlled, duloxetine‐referenced, fixed‐dose study comparing the efficacy and safety of 2 doses (15 and 20 mg) of Lu AA21004 in acute treatment of adults with major depressive disorder. clinicaltrials.gov/show/NCT01153009 Date first received: 28 June 2010. ">Mahableshwarkar 2015a</a>; <a href="./references#CD011520-bbs2-0011" title="MahableshwarkarAR , JacobsenPL , SerenkoM , ChenY , TrivediMH . A randomized, double‐blind, placebo‐controlled study of the efficacy and safety of 2 doses of vortioxetine in adults with major depressive disorder. Journal of Clinical Psychiatry2015;76(5):583‐91. NCT01179516 . A phase 3, randomized, double‐blind, parallel‐group, placebo‐controlled, fixed‐dose study comparing the efficacy and safety of 2 doses (10 and 15 mg) of Lu AA21004 in acute treatment of adults with major depressive disorder. clinicaltrials.gov/show/NCT01179516 Date first received: 9 August 2010. ">Mahableshwarkar 2015c</a>), and four studies recruited between the ages of 18 and 65 years (<a href="./references#CD011520-bbs2-0001" title="AlvarezE , PerezV , DragheimM , LoftH , ArtigasF . A double‐blind, randomized, placebo‐controlled, active reference study of Lu AA21004 in patients with major depressive disorder. International Journal of Neuropsychopharmacology2012;15(5):589‐600. [Lundbeck 11492A; NCT00839423] NCT00839423 . Randomised placebo‐controlled venlafaxine‐referenced study of efficacy and safety of 5 and 10 mg of vortioxetine (Lu AA21004) in acute treatment of major depressive disorder in adults. clinicaltrials.gov/ct2/show/NCT00839423 Date first received: 6 February 2009. ">Alvarez 2012</a>; <a href="./references#CD011520-bbs2-0010" title="JacobsonW , HarveyP , MerikleE , ZhongW , NomikosG , OlsenCK , et al. Impact of vortioxetine on functional capacity in MDD patients with subjective cognitive dysfunction: performance on the University of California San Diego performance‐based skills assessment (UPSA). 54th Annual Meeting of the American College of Neuropsychopharmacology, ACNP; 2015 Dec 6‐10; Hollywood (FL). 2015:S150‐1. JacobsonW , OlsenC , MahableshwarkarA , YinzhongC , KeefeR . Effect of vortioxetine on functional capacity in patients with major depressive disorder with self‐reported cognitive dysfunction. 28th European College of Neuropsychopharmacology, ECNP Congress; 2015 29 Aug ‐ 1 Sept; Amsterdam Netherlands. 2015:S460. KeefeR , MahableshwarkarA , ZajeckaJ , JacobsonW , ChenY . Efficacy of vortioxetine on cognitive function in patients with major depressive disorder: cognitive test performance results: from a randomized, double‐blind, duloxetine‐referenced, placebo‐controlled. Neuropsychopharmacology2014;39:S389‐90. MahableshwarkarAR , ZajeckaJ , JacobsonW , ChenY , KeefeRS . A randomized, placebo‐controlled, active‐reference, double‐blind, flexible‐dose study of the efficacy of vortioxetine on cognitive function in major depressive disorder. Neuropsychopharmacology2015;40(8):2025‐37. NCT01564862 . A randomized, double‐blind, parallel‐group, placebo‐controlled, active‐referenced, flexible dose study on the efficacy of Lu AA21004 on cognitive dysfunction in adult subjects with major depressive disorder (MDD). clinicaltrials.gov/show/NCT01564862 Date first received: 26 March 2012. ">Mahableshwarkar 2015b</a>; <a href="./references#CD011520-bbs2-0012" title="HarrisonJ . Assessment of cognitive dysfunction in patients with depression ‐ which test is best?. 28th European College of Neuropsychopharmacology, ECNP Congress; 2015 29 Aug ‐ 1 Sept; Amsterdam Netherlands. 2015:S669. McIntyreRS , LophavenS , OlsenCK . A randomized, double‐blind, placebo‐controlled study of vortioxetine on cognitive function in depressed adults. International Journal of Neuropsychopharmacology2014;17(10):1557‐67. [NCT01422213] McIntyreRS , LophavenS , OlsenCK . Randomized, double‐blind, placebo‐controlled study of the efficacy of vortioxetine on cognitive dysfunction in adult patients with major depressive disorder (MDD). 52nd Annual Meeting of the American College of Neuropsychopharmacology, ACNP; 2013 Dec 8‐12; Hollywood (FL). 2013:S380‐1. NCT01422213 . Randomised, double‐blind, parallel‐group, placebo‐controlled, fixed dose study on the efficacy of [vortioxetine] Lu AA21004 on cognitive dysfunction in adult patients with major depressive disorder (MDD). clinicaltrials.gov/show/NCT01422213 Date first received: 22 August 2011. ">McIntyre 2014</a>; <a href="./references#CD011520-bbs2-0015" title="Kct0000432 . Randomised, double‐blind, parallel‐group, active‐comparator (venlafaxine extended release), fixed‐dose study of LuAA21004 in major depressive disorder in Asian countries. cris.nih.go.kr/cris/en/search/search_result_st01.jsp?seq=2532 Date first approved: 16 August 2011. NCT01571453 . Randomised, double‐blind, parallel‐group, active‐comparator (venlafaxine extended release), fixed‐dose study of [vortioxetine] Lu AA21004 in major depressive disorder in Asian countries. clinicaltrials.gov/show/NCT01571453 Date first received: 28 March 2012. WangG , GislumM , FilippovG , MontgomeryS . Comparison of vortioxetine versus venlafaxine XR in adults in Asia with major depressive disorder: a randomized, double‐blind study. Current Medical Research and Opinion2015;31(4):785‐94. ">Wang 2015</a>). Two studies recruited participants from 20 years of age: one study between the ages of 20 and 64 years (<a href="./references#CD011520-bbs2-0013" title="Euctr2010‐022257‐41‐Lv . A multinational, randomized, double‐blind, placebo‐controlled, dose ranging study to assess the efficacy and safety of Lu AA21004 in patients with major depressive disorder ‐ efficacy and safety of Lu AA21004 for treatment of major depressive disorder. www.clinicaltrialsregister.eu/ctr‐search/search?query=eudract_number:2010‐022257‐412010. NCT01255787 . A multinational, randomized, double‐blind, placebo‐controlled, dose ranging study to assess the efficacy and safety of Lu AA21004 in patients with major depressive disorder. clinicaltrials.gov/show/NCT01255787 Date first received: 6 December 2010. ">NCT01255787</a>), and one study between the ages of 20 and 75 years (<a href="./references#CD011520-bbs2-0014" title="Jprn‐Japiccti‐111492 . A randomized, double‐blind, placebo‐controlled, phase III study to assess the efficacy and safety of LuAA21004 in patients with major depressive disorder. www.clinicaltrials.jp/user/showCteDetailE.jsp?japicId=JapicCTI‐111492 Date first received: 9 May 2011. NCT01355081 . A randomized, double‐blind, placebo‐controlled, parallel‐group, phase III study to assess the efficacy and safety of Lu AA21004 in patients with major depressive disorder. clinicaltrials.gov/show/NCT01355081 Date first received: 16 May 2011. ">Takeda 2011</a>). One study included only older participants (<a href="./references#CD011520-bbs2-0007" title="KatonaC , HansenT , OlsenCK . A randomised, double‐blind, placebo controlled, active‐referenced study of the multimodal antidepressant Lu AA21004 in the treatment of elderly depressed patients. European Neuropsychopharmacology2012;22:S258‐9. KatonaC , HansenT , OlsenCK . A randomized, double‐blind, placebo‐controlled, duloxetine‐referenced, fixed‐dose study comparing the efficacy and safety of Lu AA21004 in elderly patients with major depressive disorder. International Clinical Psychopharmacology2012;27(4):215‐23. [Lundbeck 12541A; NCT00811252] NCT00811252 . Randomised placebo‐controlled duloxetine‐referenced study of efficacy and safety of 5 mg of vortioxetine (Lu AA21004) in acute treatment of major depressive disorder in elderly patients. clinicaltrials.gov/ct2/show/NCT00811252 Date first received: 17 December 2008. ">Katona 2012</a>; aged 65 to 88 years). </p> </section> <section id="CD011520-sec-0080"> <h5 class="title">Interventions and comparators</h5> <p>Eight studies compared vortioxetine to SNRIs: two compared vortioxetine to venlafaxine (<a href="./references#CD011520-bbs2-0001" title="AlvarezE , PerezV , DragheimM , LoftH , ArtigasF . A double‐blind, randomized, placebo‐controlled, active reference study of Lu AA21004 in patients with major depressive disorder. International Journal of Neuropsychopharmacology2012;15(5):589‐600. [Lundbeck 11492A; NCT00839423] NCT00839423 . Randomised placebo‐controlled venlafaxine‐referenced study of efficacy and safety of 5 and 10 mg of vortioxetine (Lu AA21004) in acute treatment of major depressive disorder in adults. clinicaltrials.gov/ct2/show/NCT00839423 Date first received: 6 February 2009. ">Alvarez 2012</a>; <a href="./references#CD011520-bbs2-0015" title="Kct0000432 . Randomised, double‐blind, parallel‐group, active‐comparator (venlafaxine extended release), fixed‐dose study of LuAA21004 in major depressive disorder in Asian countries. cris.nih.go.kr/cris/en/search/search_result_st01.jsp?seq=2532 Date first approved: 16 August 2011. NCT01571453 . Randomised, double‐blind, parallel‐group, active‐comparator (venlafaxine extended release), fixed‐dose study of [vortioxetine] Lu AA21004 in major depressive disorder in Asian countries. clinicaltrials.gov/show/NCT01571453 Date first received: 28 March 2012. WangG , GislumM , FilippovG , MontgomeryS . Comparison of vortioxetine versus venlafaxine XR in adults in Asia with major depressive disorder: a randomized, double‐blind study. Current Medical Research and Opinion2015;31(4):785‐94. ">Wang 2015</a>), and six compared vortioxetine to duloxetine (<a href="./references#CD011520-bbs2-0002" title="BaldwinD , LoftH , DragheimM . A randomised, double‐blind, placebo controlled, duloxetine‐referenced, fixed‐dose study of three dosages of Lu AA21004 in MDD treatment. European Neuropsychopharmacology2011;21(Suppl 3):S390. BaldwinDS , LoftH , DragheimM . A randomised, double‐blind, placebo controlled, duloxetine‐referenced, fixed‐dose study of three dosages of Lu AA21004 in acute treatment of major depressive disorder (MDD). European Neuropsychopharmacology2012;22(7):482‐91. [Lundbeck 11984A; NCT00635219] NCT00635219 . Randomised placebo‐controlled duloxetine‐referenced efficacy and safety study of 2.5, 5 and 10 mg of vortioxetine (Lu AA21004) in acute treatment of major depressive disorder. clinicaltrials.gov/ct2/show/NCT00635219 Date first received: 3 March 2008. ">Baldwin 2012</a>; <a href="./references#CD011520-bbs2-0003" title="BoulengerJ‐P , LoftH , OlsenCK . Efficacy and safety of vortioxetine (Lu AA21004), 15 and 20 mg/day: a randomized, double‐blind, placebo‐controlled, duloxetine‐referenced study in the acute treatment of adult patients with major depressive disorder. International Clinical Psychopharmacology2014;29(3):138‐49. [NCT01140906] NCT01140906 . A randomised, double‐blind, parallel‐group, placebo‐controlled, duloxetine‐referenced, fixed‐dose study evaluating the efficacy and safety of Lu AA21004 (15 and 20 mg/day) in the acute treatment of adult patients with major depressive disorder. clinicaltrials.gov/show/NCT01140906 Date first received: 9 June 2010. ">Boulenger 2014</a>; <a href="./references#CD011520-bbs2-0007" title="KatonaC , HansenT , OlsenCK . A randomised, double‐blind, placebo controlled, active‐referenced study of the multimodal antidepressant Lu AA21004 in the treatment of elderly depressed patients. European Neuropsychopharmacology2012;22:S258‐9. KatonaC , HansenT , OlsenCK . A randomized, double‐blind, placebo‐controlled, duloxetine‐referenced, fixed‐dose study comparing the efficacy and safety of Lu AA21004 in elderly patients with major depressive disorder. International Clinical Psychopharmacology2012;27(4):215‐23. [Lundbeck 12541A; NCT00811252] NCT00811252 . Randomised placebo‐controlled duloxetine‐referenced study of efficacy and safety of 5 mg of vortioxetine (Lu AA21004) in acute treatment of major depressive disorder in elderly patients. clinicaltrials.gov/ct2/show/NCT00811252 Date first received: 17 December 2008. ">Katona 2012</a>; <a href="./references#CD011520-bbs2-0008" title="MahableshwarkarAR , JacobsenPL , ChenY . A randomized, double‐blind trial of 2.5mg and 5mg vortioxetine (Lu AA21004) versus placebo for 8 weeks in adults with major depressive disorder. Current Medical Research and Opinion2013;29(3):217‐26. [NCT00672620] NCT00672620 . A randomized, double‐blind, parallel‐group, placebo‐controlled, active‐referenced, fixed‐dose study comparing the efficacy and safety of 2 doses of Lu AA21004 in acute treatment of adults with major depressive disorder. clinicaltrials.gov/show/NCT00672620 Date first received: 2 May 2008. NCT00707980 . A long‐term, open‐label, flexible‐dose, extension study evaluating the safety and tolerability of Lu AA21004 in subjects with major depressive disorder. clinicaltrials.gov/ct2/show/NCT00707980 Date first received: 27 June 2008. ">Mahableshwarkar 2013</a>; <a href="./references#CD011520-bbs2-0009" title="MahableshwarkarAR , JacobsenPL , ChenY , SerenkoM , TrivediMH . A randomized, double‐blind, duloxetine‐referenced study comparing efficacy and tolerability of 2 fixed doses of vortioxetine in the acute treatment of adults with MDD. Psychopharmacology2015;232(12):2061‐70. NCT01153009 . A phase 3, randomized, double‐blind, parallel‐group, placebo‐controlled, duloxetine‐referenced, fixed‐dose study comparing the efficacy and safety of 2 doses (15 and 20 mg) of Lu AA21004 in acute treatment of adults with major depressive disorder. clinicaltrials.gov/show/NCT01153009 Date first received: 28 June 2010. ">Mahableshwarkar 2015a</a>; <a href="./references#CD011520-bbs2-0010" title="JacobsonW , HarveyP , MerikleE , ZhongW , NomikosG , OlsenCK , et al. Impact of vortioxetine on functional capacity in MDD patients with subjective cognitive dysfunction: performance on the University of California San Diego performance‐based skills assessment (UPSA). 54th Annual Meeting of the American College of Neuropsychopharmacology, ACNP; 2015 Dec 6‐10; Hollywood (FL). 2015:S150‐1. JacobsonW , OlsenC , MahableshwarkarA , YinzhongC , KeefeR . Effect of vortioxetine on functional capacity in patients with major depressive disorder with self‐reported cognitive dysfunction. 28th European College of Neuropsychopharmacology, ECNP Congress; 2015 29 Aug ‐ 1 Sept; Amsterdam Netherlands. 2015:S460. KeefeR , MahableshwarkarA , ZajeckaJ , JacobsonW , ChenY . Efficacy of vortioxetine on cognitive function in patients with major depressive disorder: cognitive test performance results: from a randomized, double‐blind, duloxetine‐referenced, placebo‐controlled. Neuropsychopharmacology2014;39:S389‐90. MahableshwarkarAR , ZajeckaJ , JacobsonW , ChenY , KeefeRS . A randomized, placebo‐controlled, active‐reference, double‐blind, flexible‐dose study of the efficacy of vortioxetine on cognitive function in major depressive disorder. Neuropsychopharmacology2015;40(8):2025‐37. NCT01564862 . A randomized, double‐blind, parallel‐group, placebo‐controlled, active‐referenced, flexible dose study on the efficacy of Lu AA21004 on cognitive dysfunction in adult subjects with major depressive disorder (MDD). clinicaltrials.gov/show/NCT01564862 Date first received: 26 March 2012. ">Mahableshwarkar 2015b</a>). Seven studies compared vortioxetine to placebo only (<a href="./references#CD011520-bbs2-0004" title="HenigsbergN , MahableshwarkarA , JacobsenP , ChenY , ThaseME . Efficacy and tolerability of multiple doses of LU AA21004 in an 8‐week trial of adults with major depressive disorder. European Neuropsychopharmacology2011;21(Suppl 3):S393. HenigsbergN , MahableshwarkarAR , JacobsenP , ChenY , ThaseME . A randomized, double‐blind, placebo‐controlled 8‐week trial of the efficacy and tolerability of multiple doses of Lu AA21004 in adults with major depressive disorder. Journal of Clinical Psychology2012;73(7):953‐9. NCT00707980 . A long‐term, open‐label, flexible‐dose, extension study evaluating the safety and tolerability of Lu AA21004 in subjects with major depressive disorder. clinicaltrials.gov/ct2/show/NCT00707980 Date first received: 27 June 2008. NCT00735709 . A randomized, double‐blind, parallel‐group, placebo‐controlled, fixed‐dose study comparing the efficacy and safety of 3 doses of Lu AA21004 in acute treatment of adults with major depressive disorder. clinicaltrials.gov/show/NCT00735709 Date first received: 14 August 2008. ">Henigsberg 2012</a>; <a href="./references#CD011520-bbs2-0005" title="JacobsenPL , MahableshwarkarAR , SerenkoM , ChanS , TrivediMH . A randomized, double‐blind, placebo‐controlled study of the efficacy and safety of vortioxetine 10 mg and 20 mg in adults with major depressive disorder. Journal of Clinical Psychiatry2015;76(5):575‐82. NCT01163266 . A phase 3, randomized, double‐blind, parallel‐group, placebo‐controlled, fixed‐dose study comparing the efficacy and safety of 2 doses (10 and 20 mg) of Lu AA21004 in acute treatment of adults with major depressive disorder. clinicaltrials.gov/show/NCT01163266 Date first received: 14 July 2010. ">Jacobsen 2015</a>; <a href="./references#CD011520-bbs2-0006" title="JainR , MahableshwarkarAR , JacobsenPL , ChenY , ThaseME . A randomized, double‐blind, placebo‐controlled 6‐wk trial of the efficacy and tolerability of 5 mg vortioxetine in adults with major depressive disorder. International Journal of Neuropsychopharmacology2013;16(2):313‐21. NCT00672958 . A randomized, double‐blind, parallel‐group, placebo‐controlled, fixed‐dose study comparing the efficacy and safety of Lu AA21004 versus placebo in acute treatment of adults with major depressive disorder. clinicaltrials.gov/show/NCT00672958 Date first received: 2 May 2008. ">Jain 2013</a>; <a href="./references#CD011520-bbs2-0012" title="HarrisonJ . Assessment of cognitive dysfunction in patients with depression ‐ which test is best?. 28th European College of Neuropsychopharmacology, ECNP Congress; 2015 29 Aug ‐ 1 Sept; Amsterdam Netherlands. 2015:S669. McIntyreRS , LophavenS , OlsenCK . A randomized, double‐blind, placebo‐controlled study of vortioxetine on cognitive function in depressed adults. International Journal of Neuropsychopharmacology2014;17(10):1557‐67. [NCT01422213] McIntyreRS , LophavenS , OlsenCK . Randomized, double‐blind, placebo‐controlled study of the efficacy of vortioxetine on cognitive dysfunction in adult patients with major depressive disorder (MDD). 52nd Annual Meeting of the American College of Neuropsychopharmacology, ACNP; 2013 Dec 8‐12; Hollywood (FL). 2013:S380‐1. NCT01422213 . Randomised, double‐blind, parallel‐group, placebo‐controlled, fixed dose study on the efficacy of [vortioxetine] Lu AA21004 on cognitive dysfunction in adult patients with major depressive disorder (MDD). clinicaltrials.gov/show/NCT01422213 Date first received: 22 August 2011. ">McIntyre 2014</a>; <a href="./references#CD011520-bbs2-0011" title="MahableshwarkarAR , JacobsenPL , SerenkoM , ChenY , TrivediMH . A randomized, double‐blind, placebo‐controlled study of the efficacy and safety of 2 doses of vortioxetine in adults with major depressive disorder. Journal of Clinical Psychiatry2015;76(5):583‐91. NCT01179516 . A phase 3, randomized, double‐blind, parallel‐group, placebo‐controlled, fixed‐dose study comparing the efficacy and safety of 2 doses (10 and 15 mg) of Lu AA21004 in acute treatment of adults with major depressive disorder. clinicaltrials.gov/show/NCT01179516 Date first received: 9 August 2010. ">Mahableshwarkar 2015c</a>; <a href="./references#CD011520-bbs2-0013" title="Euctr2010‐022257‐41‐Lv . A multinational, randomized, double‐blind, placebo‐controlled, dose ranging study to assess the efficacy and safety of Lu AA21004 in patients with major depressive disorder ‐ efficacy and safety of Lu AA21004 for treatment of major depressive disorder. www.clinicaltrialsregister.eu/ctr‐search/search?query=eudract_number:2010‐022257‐412010. NCT01255787 . A multinational, randomized, double‐blind, placebo‐controlled, dose ranging study to assess the efficacy and safety of Lu AA21004 in patients with major depressive disorder. clinicaltrials.gov/show/NCT01255787 Date first received: 6 December 2010. ">NCT01255787</a>; <a href="./references#CD011520-bbs2-0014" title="Jprn‐Japiccti‐111492 . A randomized, double‐blind, placebo‐controlled, phase III study to assess the efficacy and safety of LuAA21004 in patients with major depressive disorder. www.clinicaltrials.jp/user/showCteDetailE.jsp?japicId=JapicCTI‐111492 Date first received: 9 May 2011. NCT01355081 . A randomized, double‐blind, placebo‐controlled, parallel‐group, phase III study to assess the efficacy and safety of Lu AA21004 in patients with major depressive disorder. clinicaltrials.gov/show/NCT01355081 Date first received: 16 May 2011. ">Takeda 2011</a>). We found no studies comparing vortioxetine to TCAs/heterocyclics, SSRIs, MAOIs or other antidepressant agents. </p> <p>One study used a flexible vortioxetine dose scheme (range from 10 mg/day to 20 mg/day) (<a href="./references#CD011520-bbs2-0010" title="JacobsonW , HarveyP , MerikleE , ZhongW , NomikosG , OlsenCK , et al. Impact of vortioxetine on functional capacity in MDD patients with subjective cognitive dysfunction: performance on the University of California San Diego performance‐based skills assessment (UPSA). 54th Annual Meeting of the American College of Neuropsychopharmacology, ACNP; 2015 Dec 6‐10; Hollywood (FL). 2015:S150‐1. JacobsonW , OlsenC , MahableshwarkarA , YinzhongC , KeefeR . Effect of vortioxetine on functional capacity in patients with major depressive disorder with self‐reported cognitive dysfunction. 28th European College of Neuropsychopharmacology, ECNP Congress; 2015 29 Aug ‐ 1 Sept; Amsterdam Netherlands. 2015:S460. KeefeR , MahableshwarkarA , ZajeckaJ , JacobsonW , ChenY . Efficacy of vortioxetine on cognitive function in patients with major depressive disorder: cognitive test performance results: from a randomized, double‐blind, duloxetine‐referenced, placebo‐controlled. Neuropsychopharmacology2014;39:S389‐90. MahableshwarkarAR , ZajeckaJ , JacobsonW , ChenY , KeefeRS . A randomized, placebo‐controlled, active‐reference, double‐blind, flexible‐dose study of the efficacy of vortioxetine on cognitive function in major depressive disorder. Neuropsychopharmacology2015;40(8):2025‐37. NCT01564862 . A randomized, double‐blind, parallel‐group, placebo‐controlled, active‐referenced, flexible dose study on the efficacy of Lu AA21004 on cognitive dysfunction in adult subjects with major depressive disorder (MDD). clinicaltrials.gov/show/NCT01564862 Date first received: 26 March 2012. ">Mahableshwarkar 2015b</a>). The other 14 trials used a fixed vortioxetine doses scheme (5 mg/day, 10 mg/day, 15 mg/day or 20 mg/day). Two studies applied subtherapeutic dosages of vortioxetine below 5 mg/day (1 mg/day (<a href="./references#CD011520-bbs2-0004" title="HenigsbergN , MahableshwarkarA , JacobsenP , ChenY , ThaseME . Efficacy and tolerability of multiple doses of LU AA21004 in an 8‐week trial of adults with major depressive disorder. European Neuropsychopharmacology2011;21(Suppl 3):S393. HenigsbergN , MahableshwarkarAR , JacobsenP , ChenY , ThaseME . A randomized, double‐blind, placebo‐controlled 8‐week trial of the efficacy and tolerability of multiple doses of Lu AA21004 in adults with major depressive disorder. Journal of Clinical Psychology2012;73(7):953‐9. NCT00707980 . A long‐term, open‐label, flexible‐dose, extension study evaluating the safety and tolerability of Lu AA21004 in subjects with major depressive disorder. clinicaltrials.gov/ct2/show/NCT00707980 Date first received: 27 June 2008. NCT00735709 . A randomized, double‐blind, parallel‐group, placebo‐controlled, fixed‐dose study comparing the efficacy and safety of 3 doses of Lu AA21004 in acute treatment of adults with major depressive disorder. clinicaltrials.gov/show/NCT00735709 Date first received: 14 August 2008. ">Henigsberg 2012</a>); 2.5 mg/day (<a href="./references#CD011520-bbs2-0008" title="MahableshwarkarAR , JacobsenPL , ChenY . A randomized, double‐blind trial of 2.5mg and 5mg vortioxetine (Lu AA21004) versus placebo for 8 weeks in adults with major depressive disorder. Current Medical Research and Opinion2013;29(3):217‐26. [NCT00672620] NCT00672620 . A randomized, double‐blind, parallel‐group, placebo‐controlled, active‐referenced, fixed‐dose study comparing the efficacy and safety of 2 doses of Lu AA21004 in acute treatment of adults with major depressive disorder. clinicaltrials.gov/show/NCT00672620 Date first received: 2 May 2008. NCT00707980 . A long‐term, open‐label, flexible‐dose, extension study evaluating the safety and tolerability of Lu AA21004 in subjects with major depressive disorder. clinicaltrials.gov/ct2/show/NCT00707980 Date first received: 27 June 2008. ">Mahableshwarkar 2013</a>)). These treatment arms were excluded. </p> </section> <section id="CD011520-sec-0081"> <h5 class="title">Outcomes</h5> <p>All 15 studies provided efficacy data (either as dichotomous or as continuous outcome) and tolerability/acceptability data and could be entered into a meta‐analysis. </p> <p>Nine studies used the MADRS for their primary outcome measures (<a href="./references#CD011520-bbs2-0001" title="AlvarezE , PerezV , DragheimM , LoftH , ArtigasF . A double‐blind, randomized, placebo‐controlled, active reference study of Lu AA21004 in patients with major depressive disorder. International Journal of Neuropsychopharmacology2012;15(5):589‐600. [Lundbeck 11492A; NCT00839423] NCT00839423 . Randomised placebo‐controlled venlafaxine‐referenced study of efficacy and safety of 5 and 10 mg of vortioxetine (Lu AA21004) in acute treatment of major depressive disorder in adults. clinicaltrials.gov/ct2/show/NCT00839423 Date first received: 6 February 2009. ">Alvarez 2012</a>; <a href="./references#CD011520-bbs2-0002" title="BaldwinD , LoftH , DragheimM . A randomised, double‐blind, placebo controlled, duloxetine‐referenced, fixed‐dose study of three dosages of Lu AA21004 in MDD treatment. European Neuropsychopharmacology2011;21(Suppl 3):S390. BaldwinDS , LoftH , DragheimM . A randomised, double‐blind, placebo controlled, duloxetine‐referenced, fixed‐dose study of three dosages of Lu AA21004 in acute treatment of major depressive disorder (MDD). European Neuropsychopharmacology2012;22(7):482‐91. [Lundbeck 11984A; NCT00635219] NCT00635219 . Randomised placebo‐controlled duloxetine‐referenced efficacy and safety study of 2.5, 5 and 10 mg of vortioxetine (Lu AA21004) in acute treatment of major depressive disorder. clinicaltrials.gov/ct2/show/NCT00635219 Date first received: 3 March 2008. ">Baldwin 2012</a>; <a href="./references#CD011520-bbs2-0003" title="BoulengerJ‐P , LoftH , OlsenCK . Efficacy and safety of vortioxetine (Lu AA21004), 15 and 20 mg/day: a randomized, double‐blind, placebo‐controlled, duloxetine‐referenced study in the acute treatment of adult patients with major depressive disorder. International Clinical Psychopharmacology2014;29(3):138‐49. [NCT01140906] NCT01140906 . A randomised, double‐blind, parallel‐group, placebo‐controlled, duloxetine‐referenced, fixed‐dose study evaluating the efficacy and safety of Lu AA21004 (15 and 20 mg/day) in the acute treatment of adult patients with major depressive disorder. clinicaltrials.gov/show/NCT01140906 Date first received: 9 June 2010. ">Boulenger 2014</a>; <a href="./references#CD011520-bbs2-0005" title="JacobsenPL , MahableshwarkarAR , SerenkoM , ChanS , TrivediMH . A randomized, double‐blind, placebo‐controlled study of the efficacy and safety of vortioxetine 10 mg and 20 mg in adults with major depressive disorder. Journal of Clinical Psychiatry2015;76(5):575‐82. NCT01163266 . A phase 3, randomized, double‐blind, parallel‐group, placebo‐controlled, fixed‐dose study comparing the efficacy and safety of 2 doses (10 and 20 mg) of Lu AA21004 in acute treatment of adults with major depressive disorder. clinicaltrials.gov/show/NCT01163266 Date first received: 14 July 2010. ">Jacobsen 2015</a>; <a href="./references#CD011520-bbs2-0009" title="MahableshwarkarAR , JacobsenPL , ChenY , SerenkoM , TrivediMH . A randomized, double‐blind, duloxetine‐referenced study comparing efficacy and tolerability of 2 fixed doses of vortioxetine in the acute treatment of adults with MDD. Psychopharmacology2015;232(12):2061‐70. NCT01153009 . A phase 3, randomized, double‐blind, parallel‐group, placebo‐controlled, duloxetine‐referenced, fixed‐dose study comparing the efficacy and safety of 2 doses (15 and 20 mg) of Lu AA21004 in acute treatment of adults with major depressive disorder. clinicaltrials.gov/show/NCT01153009 Date first received: 28 June 2010. ">Mahableshwarkar 2015a</a>; <a href="./references#CD011520-bbs2-0011" title="MahableshwarkarAR , JacobsenPL , SerenkoM , ChenY , TrivediMH . A randomized, double‐blind, placebo‐controlled study of the efficacy and safety of 2 doses of vortioxetine in adults with major depressive disorder. Journal of Clinical Psychiatry2015;76(5):583‐91. NCT01179516 . A phase 3, randomized, double‐blind, parallel‐group, placebo‐controlled, fixed‐dose study comparing the efficacy and safety of 2 doses (10 and 15 mg) of Lu AA21004 in acute treatment of adults with major depressive disorder. clinicaltrials.gov/show/NCT01179516 Date first received: 9 August 2010. ">Mahableshwarkar 2015c</a>; <a href="./references#CD011520-bbs2-0013" title="Euctr2010‐022257‐41‐Lv . A multinational, randomized, double‐blind, placebo‐controlled, dose ranging study to assess the efficacy and safety of Lu AA21004 in patients with major depressive disorder ‐ efficacy and safety of Lu AA21004 for treatment of major depressive disorder. www.clinicaltrialsregister.eu/ctr‐search/search?query=eudract_number:2010‐022257‐412010. NCT01255787 . A multinational, randomized, double‐blind, placebo‐controlled, dose ranging study to assess the efficacy and safety of Lu AA21004 in patients with major depressive disorder. clinicaltrials.gov/show/NCT01255787 Date first received: 6 December 2010. ">NCT01255787</a>; <a href="./references#CD011520-bbs2-0014" title="Jprn‐Japiccti‐111492 . A randomized, double‐blind, placebo‐controlled, phase III study to assess the efficacy and safety of LuAA21004 in patients with major depressive disorder. www.clinicaltrials.jp/user/showCteDetailE.jsp?japicId=JapicCTI‐111492 Date first received: 9 May 2011. NCT01355081 . A randomized, double‐blind, placebo‐controlled, parallel‐group, phase III study to assess the efficacy and safety of Lu AA21004 in patients with major depressive disorder. clinicaltrials.gov/show/NCT01355081 Date first received: 16 May 2011. ">Takeda 2011</a>; <a href="./references#CD011520-bbs2-0015" title="Kct0000432 . Randomised, double‐blind, parallel‐group, active‐comparator (venlafaxine extended release), fixed‐dose study of LuAA21004 in major depressive disorder in Asian countries. cris.nih.go.kr/cris/en/search/search_result_st01.jsp?seq=2532 Date first approved: 16 August 2011. NCT01571453 . Randomised, double‐blind, parallel‐group, active‐comparator (venlafaxine extended release), fixed‐dose study of [vortioxetine] Lu AA21004 in major depressive disorder in Asian countries. clinicaltrials.gov/show/NCT01571453 Date first received: 28 March 2012. WangG , GislumM , FilippovG , MontgomeryS . Comparison of vortioxetine versus venlafaxine XR in adults in Asia with major depressive disorder: a randomized, double‐blind study. Current Medical Research and Opinion2015;31(4):785‐94. ">Wang 2015</a>). Four studies used the HAM‐D‐24 (<a href="./references#CD011520-bbs2-0004" title="HenigsbergN , MahableshwarkarA , JacobsenP , ChenY , ThaseME . Efficacy and tolerability of multiple doses of LU AA21004 in an 8‐week trial of adults with major depressive disorder. European Neuropsychopharmacology2011;21(Suppl 3):S393. HenigsbergN , MahableshwarkarAR , JacobsenP , ChenY , ThaseME . A randomized, double‐blind, placebo‐controlled 8‐week trial of the efficacy and tolerability of multiple doses of Lu AA21004 in adults with major depressive disorder. Journal of Clinical Psychology2012;73(7):953‐9. NCT00707980 . A long‐term, open‐label, flexible‐dose, extension study evaluating the safety and tolerability of Lu AA21004 in subjects with major depressive disorder. clinicaltrials.gov/ct2/show/NCT00707980 Date first received: 27 June 2008. NCT00735709 . A randomized, double‐blind, parallel‐group, placebo‐controlled, fixed‐dose study comparing the efficacy and safety of 3 doses of Lu AA21004 in acute treatment of adults with major depressive disorder. clinicaltrials.gov/show/NCT00735709 Date first received: 14 August 2008. ">Henigsberg 2012</a>; <a href="./references#CD011520-bbs2-0006" title="JainR , MahableshwarkarAR , JacobsenPL , ChenY , ThaseME . A randomized, double‐blind, placebo‐controlled 6‐wk trial of the efficacy and tolerability of 5 mg vortioxetine in adults with major depressive disorder. International Journal of Neuropsychopharmacology2013;16(2):313‐21. NCT00672958 . A randomized, double‐blind, parallel‐group, placebo‐controlled, fixed‐dose study comparing the efficacy and safety of Lu AA21004 versus placebo in acute treatment of adults with major depressive disorder. clinicaltrials.gov/show/NCT00672958 Date first received: 2 May 2008. ">Jain 2013</a>; <a href="./references#CD011520-bbs2-0007" title="KatonaC , HansenT , OlsenCK . A randomised, double‐blind, placebo controlled, active‐referenced study of the multimodal antidepressant Lu AA21004 in the treatment of elderly depressed patients. European Neuropsychopharmacology2012;22:S258‐9. KatonaC , HansenT , OlsenCK . A randomized, double‐blind, placebo‐controlled, duloxetine‐referenced, fixed‐dose study comparing the efficacy and safety of Lu AA21004 in elderly patients with major depressive disorder. International Clinical Psychopharmacology2012;27(4):215‐23. [Lundbeck 12541A; NCT00811252] NCT00811252 . Randomised placebo‐controlled duloxetine‐referenced study of efficacy and safety of 5 mg of vortioxetine (Lu AA21004) in acute treatment of major depressive disorder in elderly patients. clinicaltrials.gov/ct2/show/NCT00811252 Date first received: 17 December 2008. ">Katona 2012</a>; <a href="./references#CD011520-bbs2-0008" title="MahableshwarkarAR , JacobsenPL , ChenY . A randomized, double‐blind trial of 2.5mg and 5mg vortioxetine (Lu AA21004) versus placebo for 8 weeks in adults with major depressive disorder. Current Medical Research and Opinion2013;29(3):217‐26. [NCT00672620] NCT00672620 . A randomized, double‐blind, parallel‐group, placebo‐controlled, active‐referenced, fixed‐dose study comparing the efficacy and safety of 2 doses of Lu AA21004 in acute treatment of adults with major depressive disorder. clinicaltrials.gov/show/NCT00672620 Date first received: 2 May 2008. NCT00707980 . A long‐term, open‐label, flexible‐dose, extension study evaluating the safety and tolerability of Lu AA21004 in subjects with major depressive disorder. clinicaltrials.gov/ct2/show/NCT00707980 Date first received: 27 June 2008. ">Mahableshwarkar 2013</a>), two studies used the Digit Symbol Substitution Test (DSST) (<a href="./references#CD011520-bbs2-0010" title="JacobsonW , HarveyP , MerikleE , ZhongW , NomikosG , OlsenCK , et al. Impact of vortioxetine on functional capacity in MDD patients with subjective cognitive dysfunction: performance on the University of California San Diego performance‐based skills assessment (UPSA). 54th Annual Meeting of the American College of Neuropsychopharmacology, ACNP; 2015 Dec 6‐10; Hollywood (FL). 2015:S150‐1. JacobsonW , OlsenC , MahableshwarkarA , YinzhongC , KeefeR . Effect of vortioxetine on functional capacity in patients with major depressive disorder with self‐reported cognitive dysfunction. 28th European College of Neuropsychopharmacology, ECNP Congress; 2015 29 Aug ‐ 1 Sept; Amsterdam Netherlands. 2015:S460. KeefeR , MahableshwarkarA , ZajeckaJ , JacobsonW , ChenY . Efficacy of vortioxetine on cognitive function in patients with major depressive disorder: cognitive test performance results: from a randomized, double‐blind, duloxetine‐referenced, placebo‐controlled. Neuropsychopharmacology2014;39:S389‐90. MahableshwarkarAR , ZajeckaJ , JacobsonW , ChenY , KeefeRS . A randomized, placebo‐controlled, active‐reference, double‐blind, flexible‐dose study of the efficacy of vortioxetine on cognitive function in major depressive disorder. Neuropsychopharmacology2015;40(8):2025‐37. NCT01564862 . A randomized, double‐blind, parallel‐group, placebo‐controlled, active‐referenced, flexible dose study on the efficacy of Lu AA21004 on cognitive dysfunction in adult subjects with major depressive disorder (MDD). clinicaltrials.gov/show/NCT01564862 Date first received: 26 March 2012. ">Mahableshwarkar 2015b</a>; <a href="./references#CD011520-bbs2-0012" title="HarrisonJ . Assessment of cognitive dysfunction in patients with depression ‐ which test is best?. 28th European College of Neuropsychopharmacology, ECNP Congress; 2015 29 Aug ‐ 1 Sept; Amsterdam Netherlands. 2015:S669. McIntyreRS , LophavenS , OlsenCK . A randomized, double‐blind, placebo‐controlled study of vortioxetine on cognitive function in depressed adults. International Journal of Neuropsychopharmacology2014;17(10):1557‐67. [NCT01422213] McIntyreRS , LophavenS , OlsenCK . Randomized, double‐blind, placebo‐controlled study of the efficacy of vortioxetine on cognitive dysfunction in adult patients with major depressive disorder (MDD). 52nd Annual Meeting of the American College of Neuropsychopharmacology, ACNP; 2013 Dec 8‐12; Hollywood (FL). 2013:S380‐1. NCT01422213 . Randomised, double‐blind, parallel‐group, placebo‐controlled, fixed dose study on the efficacy of [vortioxetine] Lu AA21004 on cognitive dysfunction in adult patients with major depressive disorder (MDD). clinicaltrials.gov/show/NCT01422213 Date first received: 22 August 2011. ">McIntyre 2014</a>), and one study additionally the Rey Auditory Verbal Learning Test (RAVLT) (<a href="./references#CD011520-bbs2-0012" title="HarrisonJ . Assessment of cognitive dysfunction in patients with depression ‐ which test is best?. 28th European College of Neuropsychopharmacology, ECNP Congress; 2015 29 Aug ‐ 1 Sept; Amsterdam Netherlands. 2015:S669. McIntyreRS , LophavenS , OlsenCK . A randomized, double‐blind, placebo‐controlled study of vortioxetine on cognitive function in depressed adults. International Journal of Neuropsychopharmacology2014;17(10):1557‐67. [NCT01422213] McIntyreRS , LophavenS , OlsenCK . Randomized, double‐blind, placebo‐controlled study of the efficacy of vortioxetine on cognitive dysfunction in adult patients with major depressive disorder (MDD). 52nd Annual Meeting of the American College of Neuropsychopharmacology, ACNP; 2013 Dec 8‐12; Hollywood (FL). 2013:S380‐1. NCT01422213 . Randomised, double‐blind, parallel‐group, placebo‐controlled, fixed dose study on the efficacy of [vortioxetine] Lu AA21004 on cognitive dysfunction in adult patients with major depressive disorder (MDD). clinicaltrials.gov/show/NCT01422213 Date first received: 22 August 2011. ">McIntyre 2014</a>) for primary outcome measures. For secondary outcomes, the studies used mainly MADRS, CGI‐I, Sheehan Disability Scale (SDS), CGI‐S, HAM‐D‐24, and Hamilton Anxiety Rating Scale (HAM‐A). Two studies also used the HAM‐D‐17 (<a href="./references#CD011520-bbs2-0004" title="HenigsbergN , MahableshwarkarA , JacobsenP , ChenY , ThaseME . Efficacy and tolerability of multiple doses of LU AA21004 in an 8‐week trial of adults with major depressive disorder. European Neuropsychopharmacology2011;21(Suppl 3):S393. HenigsbergN , MahableshwarkarAR , JacobsenP , ChenY , ThaseME . A randomized, double‐blind, placebo‐controlled 8‐week trial of the efficacy and tolerability of multiple doses of Lu AA21004 in adults with major depressive disorder. Journal of Clinical Psychology2012;73(7):953‐9. NCT00707980 . A long‐term, open‐label, flexible‐dose, extension study evaluating the safety and tolerability of Lu AA21004 in subjects with major depressive disorder. clinicaltrials.gov/ct2/show/NCT00707980 Date first received: 27 June 2008. NCT00735709 . A randomized, double‐blind, parallel‐group, placebo‐controlled, fixed‐dose study comparing the efficacy and safety of 3 doses of Lu AA21004 in acute treatment of adults with major depressive disorder. clinicaltrials.gov/show/NCT00735709 Date first received: 14 August 2008. ">Henigsberg 2012</a>; <a href="./references#CD011520-bbs2-0014" title="Jprn‐Japiccti‐111492 . A randomized, double‐blind, placebo‐controlled, phase III study to assess the efficacy and safety of LuAA21004 in patients with major depressive disorder. www.clinicaltrials.jp/user/showCteDetailE.jsp?japicId=JapicCTI‐111492 Date first received: 9 May 2011. NCT01355081 . A randomized, double‐blind, placebo‐controlled, parallel‐group, phase III study to assess the efficacy and safety of Lu AA21004 in patients with major depressive disorder. clinicaltrials.gov/show/NCT01355081 Date first received: 16 May 2011. ">Takeda 2011</a>), and two studies used additional cognitive tests (DSST, RAVLT, Trail Making Test ‐ A (TMT‐A), Trail Making Test ‐ B (TMT‐B), Stroop, Perceived Deficits Questionnaire (PDQ), Simple Reaction Time (SRT), Cognitive Reflection Test (CRT), Groton Maze Learning Test (GMLT), Detection Task (DT), Identification Task (IT), and One‐Back Task (<a href="./references#CD011520-bbs2-0010" title="JacobsonW , HarveyP , MerikleE , ZhongW , NomikosG , OlsenCK , et al. Impact of vortioxetine on functional capacity in MDD patients with subjective cognitive dysfunction: performance on the University of California San Diego performance‐based skills assessment (UPSA). 54th Annual Meeting of the American College of Neuropsychopharmacology, ACNP; 2015 Dec 6‐10; Hollywood (FL). 2015:S150‐1. JacobsonW , OlsenC , MahableshwarkarA , YinzhongC , KeefeR . Effect of vortioxetine on functional capacity in patients with major depressive disorder with self‐reported cognitive dysfunction. 28th European College of Neuropsychopharmacology, ECNP Congress; 2015 29 Aug ‐ 1 Sept; Amsterdam Netherlands. 2015:S460. KeefeR , MahableshwarkarA , ZajeckaJ , JacobsonW , ChenY . Efficacy of vortioxetine on cognitive function in patients with major depressive disorder: cognitive test performance results: from a randomized, double‐blind, duloxetine‐referenced, placebo‐controlled. Neuropsychopharmacology2014;39:S389‐90. MahableshwarkarAR , ZajeckaJ , JacobsonW , ChenY , KeefeRS . A randomized, placebo‐controlled, active‐reference, double‐blind, flexible‐dose study of the efficacy of vortioxetine on cognitive function in major depressive disorder. Neuropsychopharmacology2015;40(8):2025‐37. NCT01564862 . A randomized, double‐blind, parallel‐group, placebo‐controlled, active‐referenced, flexible dose study on the efficacy of Lu AA21004 on cognitive dysfunction in adult subjects with major depressive disorder (MDD). clinicaltrials.gov/show/NCT01564862 Date first received: 26 March 2012. ">Mahableshwarkar 2015b</a>; <a href="./references#CD011520-bbs2-0012" title="HarrisonJ . Assessment of cognitive dysfunction in patients with depression ‐ which test is best?. 28th European College of Neuropsychopharmacology, ECNP Congress; 2015 29 Aug ‐ 1 Sept; Amsterdam Netherlands. 2015:S669. McIntyreRS , LophavenS , OlsenCK . A randomized, double‐blind, placebo‐controlled study of vortioxetine on cognitive function in depressed adults. International Journal of Neuropsychopharmacology2014;17(10):1557‐67. [NCT01422213] McIntyreRS , LophavenS , OlsenCK . Randomized, double‐blind, placebo‐controlled study of the efficacy of vortioxetine on cognitive dysfunction in adult patients with major depressive disorder (MDD). 52nd Annual Meeting of the American College of Neuropsychopharmacology, ACNP; 2013 Dec 8‐12; Hollywood (FL). 2013:S380‐1. NCT01422213 . Randomised, double‐blind, parallel‐group, placebo‐controlled, fixed dose study on the efficacy of [vortioxetine] Lu AA21004 on cognitive dysfunction in adult patients with major depressive disorder (MDD). clinicaltrials.gov/show/NCT01422213 Date first received: 22 August 2011. ">McIntyre 2014</a>)). All studies reported response rates and remission rates. Thirteen studies defined the response rate as 50% or greater decrease from baseline in MADRS total score and two studies as 50% or greater decrease from baseline in HAM‐D‐24 total score (<a href="./references#CD011520-bbs2-0006" title="JainR , MahableshwarkarAR , JacobsenPL , ChenY , ThaseME . A randomized, double‐blind, placebo‐controlled 6‐wk trial of the efficacy and tolerability of 5 mg vortioxetine in adults with major depressive disorder. International Journal of Neuropsychopharmacology2013;16(2):313‐21. NCT00672958 . A randomized, double‐blind, parallel‐group, placebo‐controlled, fixed‐dose study comparing the efficacy and safety of Lu AA21004 versus placebo in acute treatment of adults with major depressive disorder. clinicaltrials.gov/show/NCT00672958 Date first received: 2 May 2008. ">Jain 2013</a>; <a href="./references#CD011520-bbs2-0008" title="MahableshwarkarAR , JacobsenPL , ChenY . A randomized, double‐blind trial of 2.5mg and 5mg vortioxetine (Lu AA21004) versus placebo for 8 weeks in adults with major depressive disorder. Current Medical Research and Opinion2013;29(3):217‐26. [NCT00672620] NCT00672620 . A randomized, double‐blind, parallel‐group, placebo‐controlled, active‐referenced, fixed‐dose study comparing the efficacy and safety of 2 doses of Lu AA21004 in acute treatment of adults with major depressive disorder. clinicaltrials.gov/show/NCT00672620 Date first received: 2 May 2008. NCT00707980 . A long‐term, open‐label, flexible‐dose, extension study evaluating the safety and tolerability of Lu AA21004 in subjects with major depressive disorder. clinicaltrials.gov/ct2/show/NCT00707980 Date first received: 27 June 2008. ">Mahableshwarkar 2013</a>). All studies defined the remission rate as MADRS total score of 10 or less. </p> <p>All studies reported dropouts due to any reason and dropouts due to adverse effects. All but one study (<a href="./references#CD011520-bbs2-0012" title="HarrisonJ . Assessment of cognitive dysfunction in patients with depression ‐ which test is best?. 28th European College of Neuropsychopharmacology, ECNP Congress; 2015 29 Aug ‐ 1 Sept; Amsterdam Netherlands. 2015:S669. McIntyreRS , LophavenS , OlsenCK . A randomized, double‐blind, placebo‐controlled study of vortioxetine on cognitive function in depressed adults. International Journal of Neuropsychopharmacology2014;17(10):1557‐67. [NCT01422213] McIntyreRS , LophavenS , OlsenCK . Randomized, double‐blind, placebo‐controlled study of the efficacy of vortioxetine on cognitive dysfunction in adult patients with major depressive disorder (MDD). 52nd Annual Meeting of the American College of Neuropsychopharmacology, ACNP; 2013 Dec 8‐12; Hollywood (FL). 2013:S380‐1. NCT01422213 . Randomised, double‐blind, parallel‐group, placebo‐controlled, fixed dose study on the efficacy of [vortioxetine] Lu AA21004 on cognitive dysfunction in adult patients with major depressive disorder (MDD). clinicaltrials.gov/show/NCT01422213 Date first received: 22 August 2011. ">McIntyre 2014</a>) reported dropouts due to inefficacy and the total number of participants who experienced adverse effects. </p> <p>As expected, the reporting of the individual adverse effects varied markedly. Seven studies reported adverse events if the incidence was at least 5% per arm (<a href="./references#CD011520-bbs2-0001" title="AlvarezE , PerezV , DragheimM , LoftH , ArtigasF . A double‐blind, randomized, placebo‐controlled, active reference study of Lu AA21004 in patients with major depressive disorder. International Journal of Neuropsychopharmacology2012;15(5):589‐600. [Lundbeck 11492A; NCT00839423] NCT00839423 . Randomised placebo‐controlled venlafaxine‐referenced study of efficacy and safety of 5 and 10 mg of vortioxetine (Lu AA21004) in acute treatment of major depressive disorder in adults. clinicaltrials.gov/ct2/show/NCT00839423 Date first received: 6 February 2009. ">Alvarez 2012</a>; <a href="./references#CD011520-bbs2-0002" title="BaldwinD , LoftH , DragheimM . A randomised, double‐blind, placebo controlled, duloxetine‐referenced, fixed‐dose study of three dosages of Lu AA21004 in MDD treatment. European Neuropsychopharmacology2011;21(Suppl 3):S390. BaldwinDS , LoftH , DragheimM . A randomised, double‐blind, placebo controlled, duloxetine‐referenced, fixed‐dose study of three dosages of Lu AA21004 in acute treatment of major depressive disorder (MDD). European Neuropsychopharmacology2012;22(7):482‐91. [Lundbeck 11984A; NCT00635219] NCT00635219 . Randomised placebo‐controlled duloxetine‐referenced efficacy and safety study of 2.5, 5 and 10 mg of vortioxetine (Lu AA21004) in acute treatment of major depressive disorder. clinicaltrials.gov/ct2/show/NCT00635219 Date first received: 3 March 2008. ">Baldwin 2012</a>; <a href="./references#CD011520-bbs2-0003" title="BoulengerJ‐P , LoftH , OlsenCK . Efficacy and safety of vortioxetine (Lu AA21004), 15 and 20 mg/day: a randomized, double‐blind, placebo‐controlled, duloxetine‐referenced study in the acute treatment of adult patients with major depressive disorder. International Clinical Psychopharmacology2014;29(3):138‐49. [NCT01140906] NCT01140906 . A randomised, double‐blind, parallel‐group, placebo‐controlled, duloxetine‐referenced, fixed‐dose study evaluating the efficacy and safety of Lu AA21004 (15 and 20 mg/day) in the acute treatment of adult patients with major depressive disorder. clinicaltrials.gov/show/NCT01140906 Date first received: 9 June 2010. ">Boulenger 2014</a>; <a href="./references#CD011520-bbs2-0007" title="KatonaC , HansenT , OlsenCK . A randomised, double‐blind, placebo controlled, active‐referenced study of the multimodal antidepressant Lu AA21004 in the treatment of elderly depressed patients. European Neuropsychopharmacology2012;22:S258‐9. KatonaC , HansenT , OlsenCK . A randomized, double‐blind, placebo‐controlled, duloxetine‐referenced, fixed‐dose study comparing the efficacy and safety of Lu AA21004 in elderly patients with major depressive disorder. International Clinical Psychopharmacology2012;27(4):215‐23. [Lundbeck 12541A; NCT00811252] NCT00811252 . Randomised placebo‐controlled duloxetine‐referenced study of efficacy and safety of 5 mg of vortioxetine (Lu AA21004) in acute treatment of major depressive disorder in elderly patients. clinicaltrials.gov/ct2/show/NCT00811252 Date first received: 17 December 2008. ">Katona 2012</a>; <a href="./references#CD011520-bbs2-0010" title="JacobsonW , HarveyP , MerikleE , ZhongW , NomikosG , OlsenCK , et al. Impact of vortioxetine on functional capacity in MDD patients with subjective cognitive dysfunction: performance on the University of California San Diego performance‐based skills assessment (UPSA). 54th Annual Meeting of the American College of Neuropsychopharmacology, ACNP; 2015 Dec 6‐10; Hollywood (FL). 2015:S150‐1. JacobsonW , OlsenC , MahableshwarkarA , YinzhongC , KeefeR . Effect of vortioxetine on functional capacity in patients with major depressive disorder with self‐reported cognitive dysfunction. 28th European College of Neuropsychopharmacology, ECNP Congress; 2015 29 Aug ‐ 1 Sept; Amsterdam Netherlands. 2015:S460. KeefeR , MahableshwarkarA , ZajeckaJ , JacobsonW , ChenY . Efficacy of vortioxetine on cognitive function in patients with major depressive disorder: cognitive test performance results: from a randomized, double‐blind, duloxetine‐referenced, placebo‐controlled. Neuropsychopharmacology2014;39:S389‐90. MahableshwarkarAR , ZajeckaJ , JacobsonW , ChenY , KeefeRS . A randomized, placebo‐controlled, active‐reference, double‐blind, flexible‐dose study of the efficacy of vortioxetine on cognitive function in major depressive disorder. Neuropsychopharmacology2015;40(8):2025‐37. NCT01564862 . A randomized, double‐blind, parallel‐group, placebo‐controlled, active‐referenced, flexible dose study on the efficacy of Lu AA21004 on cognitive dysfunction in adult subjects with major depressive disorder (MDD). clinicaltrials.gov/show/NCT01564862 Date first received: 26 March 2012. ">Mahableshwarkar 2015b</a>; <a href="./references#CD011520-bbs2-0012" title="HarrisonJ . Assessment of cognitive dysfunction in patients with depression ‐ which test is best?. 28th European College of Neuropsychopharmacology, ECNP Congress; 2015 29 Aug ‐ 1 Sept; Amsterdam Netherlands. 2015:S669. McIntyreRS , LophavenS , OlsenCK . A randomized, double‐blind, placebo‐controlled study of vortioxetine on cognitive function in depressed adults. International Journal of Neuropsychopharmacology2014;17(10):1557‐67. [NCT01422213] McIntyreRS , LophavenS , OlsenCK . Randomized, double‐blind, placebo‐controlled study of the efficacy of vortioxetine on cognitive dysfunction in adult patients with major depressive disorder (MDD). 52nd Annual Meeting of the American College of Neuropsychopharmacology, ACNP; 2013 Dec 8‐12; Hollywood (FL). 2013:S380‐1. NCT01422213 . Randomised, double‐blind, parallel‐group, placebo‐controlled, fixed dose study on the efficacy of [vortioxetine] Lu AA21004 on cognitive dysfunction in adult patients with major depressive disorder (MDD). clinicaltrials.gov/show/NCT01422213 Date first received: 22 August 2011. ">McIntyre 2014</a>; <a href="./references#CD011520-bbs2-0015" title="Kct0000432 . Randomised, double‐blind, parallel‐group, active‐comparator (venlafaxine extended release), fixed‐dose study of LuAA21004 in major depressive disorder in Asian countries. cris.nih.go.kr/cris/en/search/search_result_st01.jsp?seq=2532 Date first approved: 16 August 2011. NCT01571453 . Randomised, double‐blind, parallel‐group, active‐comparator (venlafaxine extended release), fixed‐dose study of [vortioxetine] Lu AA21004 in major depressive disorder in Asian countries. clinicaltrials.gov/show/NCT01571453 Date first received: 28 March 2012. WangG , GislumM , FilippovG , MontgomeryS . Comparison of vortioxetine versus venlafaxine XR in adults in Asia with major depressive disorder: a randomized, double‐blind study. Current Medical Research and Opinion2015;31(4):785‐94. ">Wang 2015</a>). Another seven studies set the threshold at 2% (<a href="./references#CD011520-bbs2-0004" title="HenigsbergN , MahableshwarkarA , JacobsenP , ChenY , ThaseME . Efficacy and tolerability of multiple doses of LU AA21004 in an 8‐week trial of adults with major depressive disorder. European Neuropsychopharmacology2011;21(Suppl 3):S393. HenigsbergN , MahableshwarkarAR , JacobsenP , ChenY , ThaseME . A randomized, double‐blind, placebo‐controlled 8‐week trial of the efficacy and tolerability of multiple doses of Lu AA21004 in adults with major depressive disorder. Journal of Clinical Psychology2012;73(7):953‐9. NCT00707980 . A long‐term, open‐label, flexible‐dose, extension study evaluating the safety and tolerability of Lu AA21004 in subjects with major depressive disorder. clinicaltrials.gov/ct2/show/NCT00707980 Date first received: 27 June 2008. NCT00735709 . A randomized, double‐blind, parallel‐group, placebo‐controlled, fixed‐dose study comparing the efficacy and safety of 3 doses of Lu AA21004 in acute treatment of adults with major depressive disorder. clinicaltrials.gov/show/NCT00735709 Date first received: 14 August 2008. ">Henigsberg 2012</a>; <a href="./references#CD011520-bbs2-0005" title="JacobsenPL , MahableshwarkarAR , SerenkoM , ChanS , TrivediMH . A randomized, double‐blind, placebo‐controlled study of the efficacy and safety of vortioxetine 10 mg and 20 mg in adults with major depressive disorder. Journal of Clinical Psychiatry2015;76(5):575‐82. NCT01163266 . A phase 3, randomized, double‐blind, parallel‐group, placebo‐controlled, fixed‐dose study comparing the efficacy and safety of 2 doses (10 and 20 mg) of Lu AA21004 in acute treatment of adults with major depressive disorder. clinicaltrials.gov/show/NCT01163266 Date first received: 14 July 2010. ">Jacobsen 2015</a>; <a href="./references#CD011520-bbs2-0006" title="JainR , MahableshwarkarAR , JacobsenPL , ChenY , ThaseME . A randomized, double‐blind, placebo‐controlled 6‐wk trial of the efficacy and tolerability of 5 mg vortioxetine in adults with major depressive disorder. International Journal of Neuropsychopharmacology2013;16(2):313‐21. NCT00672958 . A randomized, double‐blind, parallel‐group, placebo‐controlled, fixed‐dose study comparing the efficacy and safety of Lu AA21004 versus placebo in acute treatment of adults with major depressive disorder. clinicaltrials.gov/show/NCT00672958 Date first received: 2 May 2008. ">Jain 2013</a>; <a href="./references#CD011520-bbs2-0008" title="MahableshwarkarAR , JacobsenPL , ChenY . A randomized, double‐blind trial of 2.5mg and 5mg vortioxetine (Lu AA21004) versus placebo for 8 weeks in adults with major depressive disorder. Current Medical Research and Opinion2013;29(3):217‐26. [NCT00672620] NCT00672620 . A randomized, double‐blind, parallel‐group, placebo‐controlled, active‐referenced, fixed‐dose study comparing the efficacy and safety of 2 doses of Lu AA21004 in acute treatment of adults with major depressive disorder. clinicaltrials.gov/show/NCT00672620 Date first received: 2 May 2008. NCT00707980 . A long‐term, open‐label, flexible‐dose, extension study evaluating the safety and tolerability of Lu AA21004 in subjects with major depressive disorder. clinicaltrials.gov/ct2/show/NCT00707980 Date first received: 27 June 2008. ">Mahableshwarkar 2013</a>; <a href="./references#CD011520-bbs2-0009" title="MahableshwarkarAR , JacobsenPL , ChenY , SerenkoM , TrivediMH . A randomized, double‐blind, duloxetine‐referenced study comparing efficacy and tolerability of 2 fixed doses of vortioxetine in the acute treatment of adults with MDD. Psychopharmacology2015;232(12):2061‐70. NCT01153009 . A phase 3, randomized, double‐blind, parallel‐group, placebo‐controlled, duloxetine‐referenced, fixed‐dose study comparing the efficacy and safety of 2 doses (15 and 20 mg) of Lu AA21004 in acute treatment of adults with major depressive disorder. clinicaltrials.gov/show/NCT01153009 Date first received: 28 June 2010. ">Mahableshwarkar 2015a</a>; <a href="./references#CD011520-bbs2-0011" title="MahableshwarkarAR , JacobsenPL , SerenkoM , ChenY , TrivediMH . A randomized, double‐blind, placebo‐controlled study of the efficacy and safety of 2 doses of vortioxetine in adults with major depressive disorder. Journal of Clinical Psychiatry2015;76(5):583‐91. NCT01179516 . A phase 3, randomized, double‐blind, parallel‐group, placebo‐controlled, fixed‐dose study comparing the efficacy and safety of 2 doses (10 and 15 mg) of Lu AA21004 in acute treatment of adults with major depressive disorder. clinicaltrials.gov/show/NCT01179516 Date first received: 9 August 2010. ">Mahableshwarkar 2015c</a>; <a href="./references#CD011520-bbs2-0013" title="Euctr2010‐022257‐41‐Lv . A multinational, randomized, double‐blind, placebo‐controlled, dose ranging study to assess the efficacy and safety of Lu AA21004 in patients with major depressive disorder ‐ efficacy and safety of Lu AA21004 for treatment of major depressive disorder. www.clinicaltrialsregister.eu/ctr‐search/search?query=eudract_number:2010‐022257‐412010. NCT01255787 . A multinational, randomized, double‐blind, placebo‐controlled, dose ranging study to assess the efficacy and safety of Lu AA21004 in patients with major depressive disorder. clinicaltrials.gov/show/NCT01255787 Date first received: 6 December 2010. ">NCT01255787</a>), and one study set the threshold at 0% (<a href="./references#CD011520-bbs2-0014" title="Jprn‐Japiccti‐111492 . A randomized, double‐blind, placebo‐controlled, phase III study to assess the efficacy and safety of LuAA21004 in patients with major depressive disorder. www.clinicaltrials.jp/user/showCteDetailE.jsp?japicId=JapicCTI‐111492 Date first received: 9 May 2011. NCT01355081 . A randomized, double‐blind, placebo‐controlled, parallel‐group, phase III study to assess the efficacy and safety of Lu AA21004 in patients with major depressive disorder. clinicaltrials.gov/show/NCT01355081 Date first received: 16 May 2011. ">Takeda 2011</a>). </p> </section> </section> <section id="CD011520-sec-0082"> <h4 class="title">Excluded studies</h4> <p>Overall, we excluded six studies (14 references) from the systematic review because they did not meet the inclusion criteria. They were designed as relapse prevention studies (<a href="./references#CD011520-bbs2-0016" title="BoulengerJ‐P , LoftH , FloreaI . A randomized clinical study of Lu AA21004 in the prevention of relapse in patients with major depressive disorder. Journal of Psychopharmacology (Oxford, England)2012;26(11):1408‐16. NCT00596817 . Efficacy of Lu AA21004 in the prevention of relapse of major depressive episodes. clinicaltrials.gov/ct2/show/NCT00596817 Date first received: January 8, 2008. ">Boulenger 2012</a>; <a href="./references#CD011520-bbs2-0021" title="NCT02371980 . A randomized, double‐blind, placebo‐controlled, phase 4, relapse prevention study evaluating the efficacy and safety of vortioxetine (5, 10 and 20 mg) in adults with major depressive disorder. clinicaltrials.gov/show/NCT02371980 Date first received: 20 February 2015. ">NCT02371980</a>), were not conducted in acute therapy (<a href="./references#CD011520-bbs2-0018" title="JacobsenPL , MahableshwarkarAR , ChenY , ChronesL , ClaytonAH . Effect of vortioxetine vs. escitalopram on sexual functioning in adults with well‐treated major depressive disorder experiencing SSRI‐induced sexual dysfunction. Journal of Sexual Medicine2015;12(10):2036‐48. ">Jacobsen 2015a</a>; <a href="./references#CD011520-bbs2-0019" title="JacobsenPL , HarperL , ChronesL , ChanS , MahableshwarkarAR . Safety and tolerability of vortioxetine (15 and 20 mg) in patients with major depressive disorder: results of an open‐label, flexible‐dose, 52‐week extension study. International Clinical Psychopharmacology2015;30(5):255‐64. ">Jacobsen 2015b</a>), recruited randomised remitted participants or healthy controls (<a href="./references#CD011520-bbs2-0017" title="BrowningM , SmithJ , ConenS , SmallmanR , BuchbjergJ , LarsenKg , et al. Vortioxetine reduces BOLD signal during performance of the N‐back task in subjects remitted from depression and healthy control participants. 28th European College of Neuropsychopharmacology, ECNP Congress; 2015 Aug 29 to Sep 1; Amsterdam, Netherlands. 2015:S314‐5. BrowningM , SmithJ , ConenS , SmallmanR , BuchbjergJ , LarsenKg , et al. Vortioxetine reduces bold signal during performance of the N‐Back task in subjects remitted from depression and healthy control participants [abstract]. 53rd Annual Meeting of the American College of Neuropsychopharmacology, ACNP; 2014 Dec 7‐11; Phoenix (AZ). 2014:S480. ConenS , McKieS , SmallmanRP , DuttaA , DawsonGr , SmithJ , et al. Effects of vortioxetine on resting‐state activity in subjects remitted from depression and healthy controls. 28th European College of Neuropsychopharmacology, ECNP Congress; 2015 Aug 29 to Sep 1; Amsterdam, Netherlands. 2015:S442. DawsonG , ConenS , McKieS , SmallmanR , SmithJ , BrowningM , et al. Effects of vortioxetine on resting‐state activity in subjects remitted from depression and healthy controls. 53rd Annual Meeting of the American College of Neuropsychopharmacology, ACNP; 2014 Dec 7‐11; Phoenix (AZ). 2014:S214‐5. ">Browning 2014</a>), or included participants with a treatment‐resistant depression (<a href="./references#CD011520-bbs2-0020" title="HaggstromL , NielsenRZ , DanchenkoN , PoulsenL . A randomised, double‐blind, study of vortioxetine versus agomelatine in adults with major depressive disorder (MDD) with inadequate response to SSRI/SNRI treatment. 26th European College of Neuropsychopharmacology, ECNP Congress; 2013 Oct 5‐9; Barcelona, Spain. 2013:S412. HaggstromL , NielsenRZ , DragheimM . Randomized, double‐blind, study of vortioxetine versus agomelatine in adults with MDD after inadequate response to SSRI or SNRI treatment. European Psychiatry2013;28(Suppl 1):3009. MontgomerySA , NielsenRZ , PoulsenLH , HaggstromL . A randomised, double‐blind study in adults with major depressive disorder with an inadequate response to a single course of selective serotonin reuptake inhibitor or serotonin‐noradrenaline reuptake inhibitor treatment switched to vortioxetine or agomelatine. Human Psychopharmacology2014;29(5):470‐82. [EUCTR2011‐002362‐21; NCT01488071] NCT01488071 . A randomised, double‐blind, parallel‐group, active‐controlled, flexible dose study evaluating the effects of Lu AA21004 versus agomelatine in adult patients suffering from major depressive disorder with inadequate response to antidepressant treatment. clinicaltrials.gov/show/NCT01488071 Date first received: 29 November 2011. PapakostasG , DragheimM , NielsenRZ . Efficacy and tolerability of vortioxetine is independent of previous treatment in MDD patients switched after an inadequate response. European Neuropsychopharmacology2014;24:S466. ">Montgomery 2014</a>) (see <a href="#CD011520-fig-0001">Figure 1</a> and <a href="./references#CD011520-sec-0156" title="">Characteristics of excluded studies</a> table). </p> <section id="CD011520-sec-0083"> <h5 class="title">Studies awaiting classification</h5> <p>Two studies have recently been completed, but have not yet published results (<a href="./references#CD011520-bbs2-0022" title="NCT02272517 . An interventional, randomised, double‐blind, parallel‐group, active‐comparator, flexible‐dose study on the efficacy of vortioxetine versus escitalopram on cognitive dysfunction in patients with inadequate response to current antidepressant treatment of major depressive disorder. clinicaltrials.gov/show/NCT02272517 Date first received: 21 October 2014. ">NCT02272517</a>; <a href="./references#CD011520-bbs2-0023" title="NCT02279966 . An interventional, randomised, double‐blind, parallel‐group, placebo‐controlled, active‐referenced (paroxetine), fixed‐dose study on the efficacy of vortioxetine on cognitive dysfunction in working patients with major depressive disorder. clinicaltrials.gov/show/NCT02279966 Date first received: 21 October 2014. ">NCT02279966</a>). Both studies are short‐term randomised, double‐blind trials of eight weeks' duration, which examine the effects of vortioxetine on cognitive functions in people with depression in comparison to an SSRI (see <a href="./references#CD011520-sec-0157" title="">Characteristics of studies awaiting classification</a> table). </p> </section> <section id="CD011520-sec-0084"> <h5 class="title">Ongoing studies</h5> <p>We identified two ongoing studies (see <a href="./references#CD011520-sec-0158" title="">Characteristics of ongoing studies</a> table). The ongoing studies are short‐term randomised, double‐blind trials of eight weeks' duration (<a href="./references#CD011520-bbs2-0025" title="Jprn‐Japiccti‐152831 . A randomized, double‐blind, placebo‐controlled, parallel‐group, phase III study to assess the efficacy and safety of Lu AA21004 in patients with major depressive disorder. www.clinicaltrials.jp/user/showCteDetailE.jsp?japicId=JapicCTI‐152831 Date first received: 4 March 2015. NCT02389816 . A randomized, double‐blind, placebo‐controlled, parallel‐group, phase III study to assess the efficacy and safety of Lu AA21004 in patients with major depressive disorder. clinicaltrials.gov/show/NCT02389816 Date first received: 10 March 2015. ">NCT02389816</a>) or 12 weeks' duration (<a href="./references#CD011520-bbs2-0024" title="NCT02294305 . Vortioxetine versus placebo in major depressive disorder comorbid with social anxiety disorder. clinicaltrials.gov/show/NCT02294305 Date first received: 11 November 2014. ">NCT02294305</a>). One study examines the efficacy of vortioxetine for the treatment of depression in people with comorbid social anxiety disorder (<a href="./references#CD011520-bbs2-0024" title="NCT02294305 . Vortioxetine versus placebo in major depressive disorder comorbid with social anxiety disorder. clinicaltrials.gov/show/NCT02294305 Date first received: 11 November 2014. ">NCT02294305</a>). The other study is comparing the efficacy of vortioxetine for the treatment of depression in Japanese people (<a href="./references#CD011520-bbs2-0025" title="Jprn‐Japiccti‐152831 . A randomized, double‐blind, placebo‐controlled, parallel‐group, phase III study to assess the efficacy and safety of Lu AA21004 in patients with major depressive disorder. www.clinicaltrials.jp/user/showCteDetailE.jsp?japicId=JapicCTI‐152831 Date first received: 4 March 2015. NCT02389816 . A randomized, double‐blind, placebo‐controlled, parallel‐group, phase III study to assess the efficacy and safety of Lu AA21004 in patients with major depressive disorder. clinicaltrials.gov/show/NCT02389816 Date first received: 10 March 2015. ">NCT02389816</a>). One study is ongoing, but not recruiting (<a href="./references#CD011520-bbs2-0024" title="NCT02294305 . Vortioxetine versus placebo in major depressive disorder comorbid with social anxiety disorder. clinicaltrials.gov/show/NCT02294305 Date first received: 11 November 2014. ">NCT02294305</a>), the other is currently recruiting participants (<a href="./references#CD011520-bbs2-0025" title="Jprn‐Japiccti‐152831 . A randomized, double‐blind, placebo‐controlled, parallel‐group, phase III study to assess the efficacy and safety of Lu AA21004 in patients with major depressive disorder. www.clinicaltrials.jp/user/showCteDetailE.jsp?japicId=JapicCTI‐152831 Date first received: 4 March 2015. NCT02389816 . A randomized, double‐blind, placebo‐controlled, parallel‐group, phase III study to assess the efficacy and safety of Lu AA21004 in patients with major depressive disorder. clinicaltrials.gov/show/NCT02389816 Date first received: 10 March 2015. ">NCT02389816</a>). </p> </section> </section> </section> <section id="CD011520-sec-0085"> <h3 class="title">Risk of bias in included studies</h3> <p>For graphical representations of the judgements of risk of bias, refer to <a href="#CD011520-fig-0003">Figure 3</a> and <a href="#CD011520-fig-0004">Figure 4</a>. Full details of judgements for every included study are presented in the 'Risk of bias' tables within the <a href="./references#CD011520-sec-0155" title="">Characteristics of included studies</a> table. </p> <div class="figure" id="CD011520-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD011520-fig-0003" src="/cdsr/doi/10.1002/14651858.CD011520.pub2/media/CDSR/CD011520/image_n/nCD011520-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <div class="figure" id="CD011520-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD011520-fig-0004" src="/cdsr/doi/10.1002/14651858.CD011520.pub2/media/CDSR/CD011520/image_n/nCD011520-AFig-FIG04.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <p>We rated none of the studies as having a high risk of bias in any domain, but we rated all studies at unclear risk of bias in at least two domains (see <a href="#CD011520-fig-0003">Figure 3</a> and <a href="#CD011520-fig-0004">Figure 4</a> for summary graphs). All studies were sponsored by the pharmaceutical companies that manufactures vortioxetine (Lundbeck, Takeda), and two of them were unpublished. </p> <section id="CD011520-sec-0086"> <h4 class="title">Allocation</h4> <p>Eight studies did not report details on sequence generation and were judged at unclear risk of bias (<a href="./references#CD011520-bbs2-0004" title="HenigsbergN , MahableshwarkarA , JacobsenP , ChenY , ThaseME . Efficacy and tolerability of multiple doses of LU AA21004 in an 8‐week trial of adults with major depressive disorder. European Neuropsychopharmacology2011;21(Suppl 3):S393. HenigsbergN , MahableshwarkarAR , JacobsenP , ChenY , ThaseME . A randomized, double‐blind, placebo‐controlled 8‐week trial of the efficacy and tolerability of multiple doses of Lu AA21004 in adults with major depressive disorder. Journal of Clinical Psychology2012;73(7):953‐9. NCT00707980 . A long‐term, open‐label, flexible‐dose, extension study evaluating the safety and tolerability of Lu AA21004 in subjects with major depressive disorder. clinicaltrials.gov/ct2/show/NCT00707980 Date first received: 27 June 2008. NCT00735709 . A randomized, double‐blind, parallel‐group, placebo‐controlled, fixed‐dose study comparing the efficacy and safety of 3 doses of Lu AA21004 in acute treatment of adults with major depressive disorder. clinicaltrials.gov/show/NCT00735709 Date first received: 14 August 2008. ">Henigsberg 2012</a>; <a href="./references#CD011520-bbs2-0005" title="JacobsenPL , MahableshwarkarAR , SerenkoM , ChanS , TrivediMH . A randomized, double‐blind, placebo‐controlled study of the efficacy and safety of vortioxetine 10 mg and 20 mg in adults with major depressive disorder. Journal of Clinical Psychiatry2015;76(5):575‐82. NCT01163266 . A phase 3, randomized, double‐blind, parallel‐group, placebo‐controlled, fixed‐dose study comparing the efficacy and safety of 2 doses (10 and 20 mg) of Lu AA21004 in acute treatment of adults with major depressive disorder. clinicaltrials.gov/show/NCT01163266 Date first received: 14 July 2010. ">Jacobsen 2015</a>; <a href="./references#CD011520-bbs2-0008" title="MahableshwarkarAR , JacobsenPL , ChenY . A randomized, double‐blind trial of 2.5mg and 5mg vortioxetine (Lu AA21004) versus placebo for 8 weeks in adults with major depressive disorder. Current Medical Research and Opinion2013;29(3):217‐26. [NCT00672620] NCT00672620 . A randomized, double‐blind, parallel‐group, placebo‐controlled, active‐referenced, fixed‐dose study comparing the efficacy and safety of 2 doses of Lu AA21004 in acute treatment of adults with major depressive disorder. clinicaltrials.gov/show/NCT00672620 Date first received: 2 May 2008. NCT00707980 . A long‐term, open‐label, flexible‐dose, extension study evaluating the safety and tolerability of Lu AA21004 in subjects with major depressive disorder. clinicaltrials.gov/ct2/show/NCT00707980 Date first received: 27 June 2008. ">Mahableshwarkar 2013</a>; <a href="./references#CD011520-bbs2-0009" title="MahableshwarkarAR , JacobsenPL , ChenY , SerenkoM , TrivediMH . A randomized, double‐blind, duloxetine‐referenced study comparing efficacy and tolerability of 2 fixed doses of vortioxetine in the acute treatment of adults with MDD. Psychopharmacology2015;232(12):2061‐70. NCT01153009 . A phase 3, randomized, double‐blind, parallel‐group, placebo‐controlled, duloxetine‐referenced, fixed‐dose study comparing the efficacy and safety of 2 doses (15 and 20 mg) of Lu AA21004 in acute treatment of adults with major depressive disorder. clinicaltrials.gov/show/NCT01153009 Date first received: 28 June 2010. ">Mahableshwarkar 2015a</a>; <a href="./references#CD011520-bbs2-0010" title="JacobsonW , HarveyP , MerikleE , ZhongW , NomikosG , OlsenCK , et al. Impact of vortioxetine on functional capacity in MDD patients with subjective cognitive dysfunction: performance on the University of California San Diego performance‐based skills assessment (UPSA). 54th Annual Meeting of the American College of Neuropsychopharmacology, ACNP; 2015 Dec 6‐10; Hollywood (FL). 2015:S150‐1. JacobsonW , OlsenC , MahableshwarkarA , YinzhongC , KeefeR . Effect of vortioxetine on functional capacity in patients with major depressive disorder with self‐reported cognitive dysfunction. 28th European College of Neuropsychopharmacology, ECNP Congress; 2015 29 Aug ‐ 1 Sept; Amsterdam Netherlands. 2015:S460. KeefeR , MahableshwarkarA , ZajeckaJ , JacobsonW , ChenY . Efficacy of vortioxetine on cognitive function in patients with major depressive disorder: cognitive test performance results: from a randomized, double‐blind, duloxetine‐referenced, placebo‐controlled. Neuropsychopharmacology2014;39:S389‐90. MahableshwarkarAR , ZajeckaJ , JacobsonW , ChenY , KeefeRS . A randomized, placebo‐controlled, active‐reference, double‐blind, flexible‐dose study of the efficacy of vortioxetine on cognitive function in major depressive disorder. Neuropsychopharmacology2015;40(8):2025‐37. NCT01564862 . A randomized, double‐blind, parallel‐group, placebo‐controlled, active‐referenced, flexible dose study on the efficacy of Lu AA21004 on cognitive dysfunction in adult subjects with major depressive disorder (MDD). clinicaltrials.gov/show/NCT01564862 Date first received: 26 March 2012. ">Mahableshwarkar 2015b</a>; <a href="./references#CD011520-bbs2-0011" title="MahableshwarkarAR , JacobsenPL , SerenkoM , ChenY , TrivediMH . A randomized, double‐blind, placebo‐controlled study of the efficacy and safety of 2 doses of vortioxetine in adults with major depressive disorder. Journal of Clinical Psychiatry2015;76(5):583‐91. NCT01179516 . A phase 3, randomized, double‐blind, parallel‐group, placebo‐controlled, fixed‐dose study comparing the efficacy and safety of 2 doses (10 and 15 mg) of Lu AA21004 in acute treatment of adults with major depressive disorder. clinicaltrials.gov/show/NCT01179516 Date first received: 9 August 2010. ">Mahableshwarkar 2015c</a>; <a href="./references#CD011520-bbs2-0013" title="Euctr2010‐022257‐41‐Lv . A multinational, randomized, double‐blind, placebo‐controlled, dose ranging study to assess the efficacy and safety of Lu AA21004 in patients with major depressive disorder ‐ efficacy and safety of Lu AA21004 for treatment of major depressive disorder. www.clinicaltrialsregister.eu/ctr‐search/search?query=eudract_number:2010‐022257‐412010. NCT01255787 . A multinational, randomized, double‐blind, placebo‐controlled, dose ranging study to assess the efficacy and safety of Lu AA21004 in patients with major depressive disorder. clinicaltrials.gov/show/NCT01255787 Date first received: 6 December 2010. ">NCT01255787</a>; <a href="./references#CD011520-bbs2-0014" title="Jprn‐Japiccti‐111492 . A randomized, double‐blind, placebo‐controlled, phase III study to assess the efficacy and safety of LuAA21004 in patients with major depressive disorder. www.clinicaltrials.jp/user/showCteDetailE.jsp?japicId=JapicCTI‐111492 Date first received: 9 May 2011. NCT01355081 . A randomized, double‐blind, placebo‐controlled, parallel‐group, phase III study to assess the efficacy and safety of Lu AA21004 in patients with major depressive disorder. clinicaltrials.gov/show/NCT01355081 Date first received: 16 May 2011. ">Takeda 2011</a>). In addition, five studies did not adequately describe allocation concealment (<a href="./references#CD011520-bbs2-0004" title="HenigsbergN , MahableshwarkarA , JacobsenP , ChenY , ThaseME . Efficacy and tolerability of multiple doses of LU AA21004 in an 8‐week trial of adults with major depressive disorder. European Neuropsychopharmacology2011;21(Suppl 3):S393. HenigsbergN , MahableshwarkarAR , JacobsenP , ChenY , ThaseME . A randomized, double‐blind, placebo‐controlled 8‐week trial of the efficacy and tolerability of multiple doses of Lu AA21004 in adults with major depressive disorder. Journal of Clinical Psychology2012;73(7):953‐9. NCT00707980 . A long‐term, open‐label, flexible‐dose, extension study evaluating the safety and tolerability of Lu AA21004 in subjects with major depressive disorder. clinicaltrials.gov/ct2/show/NCT00707980 Date first received: 27 June 2008. NCT00735709 . A randomized, double‐blind, parallel‐group, placebo‐controlled, fixed‐dose study comparing the efficacy and safety of 3 doses of Lu AA21004 in acute treatment of adults with major depressive disorder. clinicaltrials.gov/show/NCT00735709 Date first received: 14 August 2008. ">Henigsberg 2012</a>; <a href="./references#CD011520-bbs2-0005" title="JacobsenPL , MahableshwarkarAR , SerenkoM , ChanS , TrivediMH . A randomized, double‐blind, placebo‐controlled study of the efficacy and safety of vortioxetine 10 mg and 20 mg in adults with major depressive disorder. Journal of Clinical Psychiatry2015;76(5):575‐82. NCT01163266 . A phase 3, randomized, double‐blind, parallel‐group, placebo‐controlled, fixed‐dose study comparing the efficacy and safety of 2 doses (10 and 20 mg) of Lu AA21004 in acute treatment of adults with major depressive disorder. clinicaltrials.gov/show/NCT01163266 Date first received: 14 July 2010. ">Jacobsen 2015</a>; <a href="./references#CD011520-bbs2-0010" title="JacobsonW , HarveyP , MerikleE , ZhongW , NomikosG , OlsenCK , et al. Impact of vortioxetine on functional capacity in MDD patients with subjective cognitive dysfunction: performance on the University of California San Diego performance‐based skills assessment (UPSA). 54th Annual Meeting of the American College of Neuropsychopharmacology, ACNP; 2015 Dec 6‐10; Hollywood (FL). 2015:S150‐1. JacobsonW , OlsenC , MahableshwarkarA , YinzhongC , KeefeR . Effect of vortioxetine on functional capacity in patients with major depressive disorder with self‐reported cognitive dysfunction. 28th European College of Neuropsychopharmacology, ECNP Congress; 2015 29 Aug ‐ 1 Sept; Amsterdam Netherlands. 2015:S460. KeefeR , MahableshwarkarA , ZajeckaJ , JacobsonW , ChenY . Efficacy of vortioxetine on cognitive function in patients with major depressive disorder: cognitive test performance results: from a randomized, double‐blind, duloxetine‐referenced, placebo‐controlled. Neuropsychopharmacology2014;39:S389‐90. MahableshwarkarAR , ZajeckaJ , JacobsonW , ChenY , KeefeRS . A randomized, placebo‐controlled, active‐reference, double‐blind, flexible‐dose study of the efficacy of vortioxetine on cognitive function in major depressive disorder. Neuropsychopharmacology2015;40(8):2025‐37. NCT01564862 . A randomized, double‐blind, parallel‐group, placebo‐controlled, active‐referenced, flexible dose study on the efficacy of Lu AA21004 on cognitive dysfunction in adult subjects with major depressive disorder (MDD). clinicaltrials.gov/show/NCT01564862 Date first received: 26 March 2012. ">Mahableshwarkar 2015b</a>; <a href="./references#CD011520-bbs2-0013" title="Euctr2010‐022257‐41‐Lv . A multinational, randomized, double‐blind, placebo‐controlled, dose ranging study to assess the efficacy and safety of Lu AA21004 in patients with major depressive disorder ‐ efficacy and safety of Lu AA21004 for treatment of major depressive disorder. www.clinicaltrialsregister.eu/ctr‐search/search?query=eudract_number:2010‐022257‐412010. NCT01255787 . A multinational, randomized, double‐blind, placebo‐controlled, dose ranging study to assess the efficacy and safety of Lu AA21004 in patients with major depressive disorder. clinicaltrials.gov/show/NCT01255787 Date first received: 6 December 2010. ">NCT01255787</a>; <a href="./references#CD011520-bbs2-0014" title="Jprn‐Japiccti‐111492 . A randomized, double‐blind, placebo‐controlled, phase III study to assess the efficacy and safety of LuAA21004 in patients with major depressive disorder. www.clinicaltrials.jp/user/showCteDetailE.jsp?japicId=JapicCTI‐111492 Date first received: 9 May 2011. NCT01355081 . A randomized, double‐blind, placebo‐controlled, parallel‐group, phase III study to assess the efficacy and safety of Lu AA21004 in patients with major depressive disorder. clinicaltrials.gov/show/NCT01355081 Date first received: 16 May 2011. ">Takeda 2011</a>). </p> </section> <section id="CD011520-sec-0087"> <h4 class="title">Blinding</h4> <p>All RCTs were reported as double‐blind and so were at low risk of bias. All studies used at least identically appearing capsules for blinding. </p> </section> <section id="CD011520-sec-0088"> <h4 class="title">Incomplete outcome data</h4> <p>Nine studies had a dropout rate below 20% in all treatment arms and so were at low risk of attrition bias (<a href="./references#CD011520-bbs2-0001" title="AlvarezE , PerezV , DragheimM , LoftH , ArtigasF . A double‐blind, randomized, placebo‐controlled, active reference study of Lu AA21004 in patients with major depressive disorder. International Journal of Neuropsychopharmacology2012;15(5):589‐600. [Lundbeck 11492A; NCT00839423] NCT00839423 . Randomised placebo‐controlled venlafaxine‐referenced study of efficacy and safety of 5 and 10 mg of vortioxetine (Lu AA21004) in acute treatment of major depressive disorder in adults. clinicaltrials.gov/ct2/show/NCT00839423 Date first received: 6 February 2009. ">Alvarez 2012</a>; <a href="./references#CD011520-bbs2-0004" title="HenigsbergN , MahableshwarkarA , JacobsenP , ChenY , ThaseME . Efficacy and tolerability of multiple doses of LU AA21004 in an 8‐week trial of adults with major depressive disorder. European Neuropsychopharmacology2011;21(Suppl 3):S393. HenigsbergN , MahableshwarkarAR , JacobsenP , ChenY , ThaseME . A randomized, double‐blind, placebo‐controlled 8‐week trial of the efficacy and tolerability of multiple doses of Lu AA21004 in adults with major depressive disorder. Journal of Clinical Psychology2012;73(7):953‐9. NCT00707980 . A long‐term, open‐label, flexible‐dose, extension study evaluating the safety and tolerability of Lu AA21004 in subjects with major depressive disorder. clinicaltrials.gov/ct2/show/NCT00707980 Date first received: 27 June 2008. NCT00735709 . A randomized, double‐blind, parallel‐group, placebo‐controlled, fixed‐dose study comparing the efficacy and safety of 3 doses of Lu AA21004 in acute treatment of adults with major depressive disorder. clinicaltrials.gov/show/NCT00735709 Date first received: 14 August 2008. ">Henigsberg 2012</a>; <a href="./references#CD011520-bbs2-0005" title="JacobsenPL , MahableshwarkarAR , SerenkoM , ChanS , TrivediMH . A randomized, double‐blind, placebo‐controlled study of the efficacy and safety of vortioxetine 10 mg and 20 mg in adults with major depressive disorder. Journal of Clinical Psychiatry2015;76(5):575‐82. NCT01163266 . A phase 3, randomized, double‐blind, parallel‐group, placebo‐controlled, fixed‐dose study comparing the efficacy and safety of 2 doses (10 and 20 mg) of Lu AA21004 in acute treatment of adults with major depressive disorder. clinicaltrials.gov/show/NCT01163266 Date first received: 14 July 2010. ">Jacobsen 2015</a>; <a href="./references#CD011520-bbs2-0007" title="KatonaC , HansenT , OlsenCK . A randomised, double‐blind, placebo controlled, active‐referenced study of the multimodal antidepressant Lu AA21004 in the treatment of elderly depressed patients. European Neuropsychopharmacology2012;22:S258‐9. KatonaC , HansenT , OlsenCK . A randomized, double‐blind, placebo‐controlled, duloxetine‐referenced, fixed‐dose study comparing the efficacy and safety of Lu AA21004 in elderly patients with major depressive disorder. International Clinical Psychopharmacology2012;27(4):215‐23. [Lundbeck 12541A; NCT00811252] NCT00811252 . Randomised placebo‐controlled duloxetine‐referenced study of efficacy and safety of 5 mg of vortioxetine (Lu AA21004) in acute treatment of major depressive disorder in elderly patients. clinicaltrials.gov/ct2/show/NCT00811252 Date first received: 17 December 2008. ">Katona 2012</a>; <a href="./references#CD011520-bbs2-0010" title="JacobsonW , HarveyP , MerikleE , ZhongW , NomikosG , OlsenCK , et al. Impact of vortioxetine on functional capacity in MDD patients with subjective cognitive dysfunction: performance on the University of California San Diego performance‐based skills assessment (UPSA). 54th Annual Meeting of the American College of Neuropsychopharmacology, ACNP; 2015 Dec 6‐10; Hollywood (FL). 2015:S150‐1. JacobsonW , OlsenC , MahableshwarkarA , YinzhongC , KeefeR . Effect of vortioxetine on functional capacity in patients with major depressive disorder with self‐reported cognitive dysfunction. 28th European College of Neuropsychopharmacology, ECNP Congress; 2015 29 Aug ‐ 1 Sept; Amsterdam Netherlands. 2015:S460. KeefeR , MahableshwarkarA , ZajeckaJ , JacobsonW , ChenY . Efficacy of vortioxetine on cognitive function in patients with major depressive disorder: cognitive test performance results: from a randomized, double‐blind, duloxetine‐referenced, placebo‐controlled. Neuropsychopharmacology2014;39:S389‐90. MahableshwarkarAR , ZajeckaJ , JacobsonW , ChenY , KeefeRS . A randomized, placebo‐controlled, active‐reference, double‐blind, flexible‐dose study of the efficacy of vortioxetine on cognitive function in major depressive disorder. Neuropsychopharmacology2015;40(8):2025‐37. NCT01564862 . A randomized, double‐blind, parallel‐group, placebo‐controlled, active‐referenced, flexible dose study on the efficacy of Lu AA21004 on cognitive dysfunction in adult subjects with major depressive disorder (MDD). clinicaltrials.gov/show/NCT01564862 Date first received: 26 March 2012. ">Mahableshwarkar 2015b</a>; <a href="./references#CD011520-bbs2-0011" title="MahableshwarkarAR , JacobsenPL , SerenkoM , ChenY , TrivediMH . A randomized, double‐blind, placebo‐controlled study of the efficacy and safety of 2 doses of vortioxetine in adults with major depressive disorder. Journal of Clinical Psychiatry2015;76(5):583‐91. NCT01179516 . A phase 3, randomized, double‐blind, parallel‐group, placebo‐controlled, fixed‐dose study comparing the efficacy and safety of 2 doses (10 and 15 mg) of Lu AA21004 in acute treatment of adults with major depressive disorder. clinicaltrials.gov/show/NCT01179516 Date first received: 9 August 2010. ">Mahableshwarkar 2015c</a>; <a href="./references#CD011520-bbs2-0012" title="HarrisonJ . Assessment of cognitive dysfunction in patients with depression ‐ which test is best?. 28th European College of Neuropsychopharmacology, ECNP Congress; 2015 29 Aug ‐ 1 Sept; Amsterdam Netherlands. 2015:S669. McIntyreRS , LophavenS , OlsenCK . A randomized, double‐blind, placebo‐controlled study of vortioxetine on cognitive function in depressed adults. International Journal of Neuropsychopharmacology2014;17(10):1557‐67. [NCT01422213] McIntyreRS , LophavenS , OlsenCK . Randomized, double‐blind, placebo‐controlled study of the efficacy of vortioxetine on cognitive dysfunction in adult patients with major depressive disorder (MDD). 52nd Annual Meeting of the American College of Neuropsychopharmacology, ACNP; 2013 Dec 8‐12; Hollywood (FL). 2013:S380‐1. NCT01422213 . Randomised, double‐blind, parallel‐group, placebo‐controlled, fixed dose study on the efficacy of [vortioxetine] Lu AA21004 on cognitive dysfunction in adult patients with major depressive disorder (MDD). clinicaltrials.gov/show/NCT01422213 Date first received: 22 August 2011. ">McIntyre 2014</a>; <a href="./references#CD011520-bbs2-0013" title="Euctr2010‐022257‐41‐Lv . A multinational, randomized, double‐blind, placebo‐controlled, dose ranging study to assess the efficacy and safety of Lu AA21004 in patients with major depressive disorder ‐ efficacy and safety of Lu AA21004 for treatment of major depressive disorder. www.clinicaltrialsregister.eu/ctr‐search/search?query=eudract_number:2010‐022257‐412010. NCT01255787 . A multinational, randomized, double‐blind, placebo‐controlled, dose ranging study to assess the efficacy and safety of Lu AA21004 in patients with major depressive disorder. clinicaltrials.gov/show/NCT01255787 Date first received: 6 December 2010. ">NCT01255787</a>; <a href="./references#CD011520-bbs2-0014" title="Jprn‐Japiccti‐111492 . A randomized, double‐blind, placebo‐controlled, phase III study to assess the efficacy and safety of LuAA21004 in patients with major depressive disorder. www.clinicaltrials.jp/user/showCteDetailE.jsp?japicId=JapicCTI‐111492 Date first received: 9 May 2011. NCT01355081 . A randomized, double‐blind, placebo‐controlled, parallel‐group, phase III study to assess the efficacy and safety of Lu AA21004 in patients with major depressive disorder. clinicaltrials.gov/show/NCT01355081 Date first received: 16 May 2011. ">Takeda 2011</a>). Of the six remaining studies, two studies had a dropout rate above 20% in the vortioxetine arm (<a href="./references#CD011520-bbs2-0002" title="BaldwinD , LoftH , DragheimM . A randomised, double‐blind, placebo controlled, duloxetine‐referenced, fixed‐dose study of three dosages of Lu AA21004 in MDD treatment. European Neuropsychopharmacology2011;21(Suppl 3):S390. BaldwinDS , LoftH , DragheimM . A randomised, double‐blind, placebo controlled, duloxetine‐referenced, fixed‐dose study of three dosages of Lu AA21004 in acute treatment of major depressive disorder (MDD). European Neuropsychopharmacology2012;22(7):482‐91. [Lundbeck 11984A; NCT00635219] NCT00635219 . Randomised placebo‐controlled duloxetine‐referenced efficacy and safety study of 2.5, 5 and 10 mg of vortioxetine (Lu AA21004) in acute treatment of major depressive disorder. clinicaltrials.gov/ct2/show/NCT00635219 Date first received: 3 March 2008. ">Baldwin 2012</a>; <a href="./references#CD011520-bbs2-0003" title="BoulengerJ‐P , LoftH , OlsenCK . Efficacy and safety of vortioxetine (Lu AA21004), 15 and 20 mg/day: a randomized, double‐blind, placebo‐controlled, duloxetine‐referenced study in the acute treatment of adult patients with major depressive disorder. International Clinical Psychopharmacology2014;29(3):138‐49. [NCT01140906] NCT01140906 . A randomised, double‐blind, parallel‐group, placebo‐controlled, duloxetine‐referenced, fixed‐dose study evaluating the efficacy and safety of Lu AA21004 (15 and 20 mg/day) in the acute treatment of adult patients with major depressive disorder. clinicaltrials.gov/show/NCT01140906 Date first received: 9 June 2010. ">Boulenger 2014</a>), one study in the active control arm (<a href="./references#CD011520-bbs2-0015" title="Kct0000432 . Randomised, double‐blind, parallel‐group, active‐comparator (venlafaxine extended release), fixed‐dose study of LuAA21004 in major depressive disorder in Asian countries. cris.nih.go.kr/cris/en/search/search_result_st01.jsp?seq=2532 Date first approved: 16 August 2011. NCT01571453 . Randomised, double‐blind, parallel‐group, active‐comparator (venlafaxine extended release), fixed‐dose study of [vortioxetine] Lu AA21004 in major depressive disorder in Asian countries. clinicaltrials.gov/show/NCT01571453 Date first received: 28 March 2012. WangG , GislumM , FilippovG , MontgomeryS . Comparison of vortioxetine versus venlafaxine XR in adults in Asia with major depressive disorder: a randomized, double‐blind study. Current Medical Research and Opinion2015;31(4):785‐94. ">Wang 2015</a>), one study in the placebo arm (<a href="./references#CD011520-bbs2-0006" title="JainR , MahableshwarkarAR , JacobsenPL , ChenY , ThaseME . A randomized, double‐blind, placebo‐controlled 6‐wk trial of the efficacy and tolerability of 5 mg vortioxetine in adults with major depressive disorder. International Journal of Neuropsychopharmacology2013;16(2):313‐21. NCT00672958 . A randomized, double‐blind, parallel‐group, placebo‐controlled, fixed‐dose study comparing the efficacy and safety of Lu AA21004 versus placebo in acute treatment of adults with major depressive disorder. clinicaltrials.gov/show/NCT00672958 Date first received: 2 May 2008. ">Jain 2013</a>), one study in the vortioxetine and in the active control arm (<a href="./references#CD011520-bbs2-0009" title="MahableshwarkarAR , JacobsenPL , ChenY , SerenkoM , TrivediMH . A randomized, double‐blind, duloxetine‐referenced study comparing efficacy and tolerability of 2 fixed doses of vortioxetine in the acute treatment of adults with MDD. Psychopharmacology2015;232(12):2061‐70. NCT01153009 . A phase 3, randomized, double‐blind, parallel‐group, placebo‐controlled, duloxetine‐referenced, fixed‐dose study comparing the efficacy and safety of 2 doses (15 and 20 mg) of Lu AA21004 in acute treatment of adults with major depressive disorder. clinicaltrials.gov/show/NCT01153009 Date first received: 28 June 2010. ">Mahableshwarkar 2015a</a>), and one study in all arms (<a href="./references#CD011520-bbs2-0008" title="MahableshwarkarAR , JacobsenPL , ChenY . A randomized, double‐blind trial of 2.5mg and 5mg vortioxetine (Lu AA21004) versus placebo for 8 weeks in adults with major depressive disorder. Current Medical Research and Opinion2013;29(3):217‐26. [NCT00672620] NCT00672620 . A randomized, double‐blind, parallel‐group, placebo‐controlled, active‐referenced, fixed‐dose study comparing the efficacy and safety of 2 doses of Lu AA21004 in acute treatment of adults with major depressive disorder. clinicaltrials.gov/show/NCT00672620 Date first received: 2 May 2008. NCT00707980 . A long‐term, open‐label, flexible‐dose, extension study evaluating the safety and tolerability of Lu AA21004 in subjects with major depressive disorder. clinicaltrials.gov/ct2/show/NCT00707980 Date first received: 27 June 2008. ">Mahableshwarkar 2013</a>). The range in these six studies was from 20.1% to 27.4%. These studies were at unclear risk of attrition bias. </p> </section> <section id="CD011520-sec-0089"> <h4 class="title">Selective reporting</h4> <p>We rated all included studies at unclear risk of selective reporting bias, because published protocols were unavailable. However, publications and entries in clinical trial registers did not reveal discrepancies. </p> </section> <section id="CD011520-sec-0090"> <h4 class="title">Other potential sources of bias</h4> <p>All studies were sponsored by the pharmaceutical companies that manufactures vortioxetine (Lundbeck, Takeda) and were, therefore, assessed as having an unclear risk of bias. </p> </section> </section> <section id="CD011520-sec-0091"> <h3 class="title" id="CD011520-sec-0091">Effects of interventions</h3> <p>See: <a href="./full#CD011520-tbl-0001"><b>Summary of findings for the main comparison</b> Vortioxetine compared to Placebo for adults with Major Depressive Disorder</a>; <a href="./full#CD011520-tbl-0002"><b>Summary of findings 2</b> Vortioxetine compared to SNRIs for adults with Major Depressive Disorder</a> </p> <p>We have reported the results of the present systematic review by grouping the comparators into two classes: placebo and SNRIs. Specific comparators are presented in subgroups where possible. We could not identify relevant studies comparing vortioxetine with TCAs, heterocyclics, SSRIs, MAOIs or other antidepressants. </p> <section id="CD011520-sec-0092"> <h4 class="title">Comparison 1. Vortioxetine versus placebo</h4> <p>Fourteen studies including 6220 participants contributed data to the comparison of vortioxetine versus placebo (see <a href="./full#CD011520-tbl-0001">summary of findings Table for the main comparison</a>). The quality of evidence contributing to all outcomes was rated as moderate to very low, because of high dropout rates and statistical heterogeneity. </p> <section id="CD011520-sec-0093"> <h5 class="title">Primary outcomes</h5> <section id="CD011520-sec-0094"> <h6 class="title">1.1. Response to treatment</h6> <p>There was evidence that vortioxetine was more effective than placebo (Mantel‐Haenszel RR 1.35, 95% CI 1.22 to 1.49; P &lt; 0.001; 14 studies, 6220 participants). Statistical heterogeneity was substantial between studies (I<sup>2</sup> = 60%) (<a href="./references#CD011520-fig-0009" title="">Analysis 1.1</a>; <a href="#CD011520-fig-0005">Figure 5</a>). </p> <div class="figure" id="CD011520-fig-0005"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 5</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Vortioxetine versus placebo, outcome: 1.1 Response." data-id="CD011520-fig-0005" src="/cdsr/doi/10.1002/14651858.CD011520.pub2/media/CDSR/CD011520/image_n/nCD011520-AFig-FIG05.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Vortioxetine versus placebo, outcome: 1.1 Response.</p> </div> </div> </div> </section> <section id="CD011520-sec-0095"> <h6 class="title">1.2. Total number of dropouts</h6> <p>There was no evidence that vortioxetine was associated with a lower or higher total dropout rate than placebo (RR 1.05, 95% CI 0.93 to 1.19; P = 0.40; 14 studies, 6220 participants). There was no heterogeneity (I<sup>2</sup> = 0%) (<a href="./references#CD011520-fig-0010" title="">Analysis 1.2</a>; <a href="#CD011520-fig-0006">Figure 6</a>). </p> <div class="figure" id="CD011520-fig-0006"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 6</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Vortioxetine versus placebo, outcome: 1.2 Total number of dropouts." data-id="CD011520-fig-0006" src="/cdsr/doi/10.1002/14651858.CD011520.pub2/media/CDSR/CD011520/image_n/nCD011520-AFig-FIG06.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Vortioxetine versus placebo, outcome: 1.2 Total number of dropouts. </p> </div> </div> </div> </section> </section> <section id="CD011520-sec-0096"> <h5 class="title">Secondary outcomes</h5> <section id="CD011520-sec-0097"> <h6 class="title">1.3. Achieved remission</h6> <p>There was evidence that more participants achieved remission with vortioxetine than with placebo (RR 1.32, 95% CI 1.15 to 1.53; P &lt; 0.001; 14 studies, 6220 participants). Heterogeneity was substantial between studies (I<sup>2</sup> = 58%) (<a href="./references#CD011520-fig-0011" title="">Analysis 1.3</a>). </p> </section> <section id="CD011520-sec-0098"> <h6 class="title">1.4. Depressive symptoms</h6> <p>There was evidence that vortioxetine was significantly more effective in lowering MADRS score compared to placebo (MD ‐2.94, 95% CI ‐4.07 to ‐1.80, P &lt; 0.001; 14 studies, 5566 participants). Heterogeneity was high between studies (I<sup>2</sup> = 79%) (<a href="./references#CD011520-fig-0012" title="">Analysis 1.4</a>). </p> </section> <section id="CD011520-sec-0099"> <h6 class="title">1.5. Dropout due to adverse events</h6> <p>There was evidence that vortioxetine was associated with a higher dropout rate due to adverse events compared to placebo (RR 1.41, 95% CI 1.09 to 1.81; P = 0.008; 14 studies, 6220 participants). There was no heterogeneity (I<sup>2</sup> = 0%) (<a href="./references#CD011520-fig-0013" title="">Analysis 1.5</a>). </p> </section> <section id="CD011520-sec-0100"> <h6 class="title">1.6. Dropout due to inefficacy</h6> <p>There was evidence that vortioxetine was associated with a lower dropout rate due to inefficacy compared to placebo (RR 0.56, 95% CI 0.34 to 0.90; P = 0.02; 14 studies, 6220 participants). Heterogeneity between studies was moderate (I<sup>2</sup> = 41%) (see <a href="./references#CD011520-fig-0014" title="">Analysis 1.6</a>). </p> </section> <section id="CD011520-sec-0101"> <h6 class="title">1.7. Tolerability</h6> <p>There was evidence that more participants experienced adverse effects when treated with vortioxetine than when treated with placebo (RR 1.12, 95% CI 1.07 to 1.16; P &lt; 0.001; 14 studies, 6182 participants). Heterogeneity between studies was low (I<sup>2</sup> = 8%) (see <a href="./references#CD011520-fig-0015" title="">Analysis 1.7</a>). </p> <p>Specific adverse effects compared to placebo are reported descriptively in <a href="./references#CD011520-fig-0022" title="">Analysis 1.14</a>. One study reported all adverse effects mentioned (<a href="./references#CD011520-bbs2-0014" title="Jprn‐Japiccti‐111492 . A randomized, double‐blind, placebo‐controlled, phase III study to assess the efficacy and safety of LuAA21004 in patients with major depressive disorder. www.clinicaltrials.jp/user/showCteDetailE.jsp?japicId=JapicCTI‐111492 Date first received: 9 May 2011. NCT01355081 . A randomized, double‐blind, placebo‐controlled, parallel‐group, phase III study to assess the efficacy and safety of Lu AA21004 in patients with major depressive disorder. clinicaltrials.gov/show/NCT01355081 Date first received: 16 May 2011. ">Takeda 2011</a>). Due to the limits of graphs in Review Manager 5 and in line with the majority of studies, we only reported adverse effects with an incidence of 2% or greater in one of the treatment arms for this study. Serious adverse events are reported in <a href="./references#CD011520-fig-0023" title="">Analysis 1.15</a>. </p> <p>This analysis was not conducted with ITT data according to our conservative approach (see <a href="#CD011520-sec-0057">Measures of treatment effect</a>), but with ITT data as reported in the trials. </p> </section> </section> </section> <section id="CD011520-sec-0102"> <h4 class="title">Comparison 2. Vortioxetine versus serotonin‐norepinephrine reuptake inhibitors</h4> <p>Eight studies including 3159 participants contributed data to the comparison of vortioxetine versus SNRIs (see <a href="./full#CD011520-tbl-0002">summary of findings Table 2</a>). The quality of evidence contributing to all outcomes was very low because of high dropout rates and substantial statistical heterogeneity. </p> <section id="CD011520-sec-0103"> <h5 class="title">Primary outcomes</h5> <section id="CD011520-sec-0104"> <h6 class="title">2.1. Response to treatment</h6> <p>There was no evidence that vortioxetine was less or more effective than SNRIs as a whole (RR 0.91, 95% CI 0.82 to 1.00; P = 0.06; 8 studies, 3159 participants). Heterogeneity was substantial between studies (I<sup>2</sup> = 61%) (<a href="./references#CD011520-fig-0024" title="">Analysis 2.1</a>; <a href="#CD011520-fig-0007">Figure 7</a>). </p> <div class="figure" id="CD011520-fig-0007"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 7</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 3. Vortioxetine versus serotonin‐norepinephrine reuptake inhibitors, outcome: 3.1 Response." data-id="CD011520-fig-0007" src="/cdsr/doi/10.1002/14651858.CD011520.pub2/media/CDSR/CD011520/image_n/nCD011520-AFig-FIG07.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 3. Vortioxetine versus serotonin‐norepinephrine reuptake inhibitors, outcome: 3.1 Response. </p> </div> </div> </div> <p>Although there was no statistically significant difference between the specific comparators (Chi<sup>2</sup> = 2.84, degrees of freedom (df) = 1, P = 0.09), response rates were significantly lower for vortioxetine compared to duloxetine (RR 0.86, 95% CI 0.79 to 0.94; P = 0.001; 6 studies, 2392 participants; I<sup>2</sup> = 28%) while there was no difference in response rates compared to venlafaxine (RR 1.03, 95% CI 0.85 to 1.25; P = 0.73; 2 studies, 767 participants; I<sup>2</sup> = 69%). </p> </section> <section id="CD011520-sec-0105"> <h6 class="title">2.2. Total number of dropouts</h6> <p>There was no evidence that vortioxetine was associated with a lower or higher total dropout rate than SNRIs as a whole (RR 0.89, 95% CI 0.73 to 1.08; P = 0.25; 8 studies, 3159 participants). Heterogeneity between studies was moderate (I<sup>2</sup> = 44%) (<a href="./references#CD011520-fig-0025" title="">Analysis 2.2</a>; <a href="#CD011520-fig-0008">Figure 8</a>). </p> <div class="figure" id="CD011520-fig-0008"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 8</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 3. Vortioxetine versus serotonin‐norepinephrine reuptake inhibitors, outcome: 3.2 Total number of dropouts." data-id="CD011520-fig-0008" src="/cdsr/doi/10.1002/14651858.CD011520.pub2/media/CDSR/CD011520/image_n/nCD011520-AFig-FIG08.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 3. Vortioxetine versus serotonin‐norepinephrine reuptake inhibitors, outcome: 3.2 Total number of dropouts. </p> </div> </div> </div> <p>There was no significant difference between trials comparing vortioxetine to duloxetine or venlafaxine (Chi<sup>2</sup> = 2.87, df = 1, P = 0.09), but total dropout rates were significantly lower for vortioxetine compared to venlafaxine (RR 0.70, 95% CI 0.52 to 0.93; P = 0.02; 2 studies, 767 participants; I<sup>2</sup> = 0%). There was no statistically significant difference between vortioxetine and duloxetine for total dropouts (RR 0.96, 95% CI 0.76 to 1.21; P = 0.74; 6 studies, 2392 participants; I<sup>2</sup> = 45%). </p> </section> </section> <section id="CD011520-sec-0106"> <h5 class="title">Secondary outcomes</h5> <section id="CD011520-sec-0107"> <h6 class="title">2.3. Achieved remission</h6> <p>There was no significant difference in the number of participants who achieved remission between vortioxetine and SNRIs as a whole (RR 0.89, 95% CI 0.77 to 1.03; P = 0.11; 8 studies, 3155 participants). Heterogeneity between studies was substantial (I<sup>2</sup> = 57%) (<a href="./references#CD011520-fig-0026" title="">Analysis 2.3</a>). </p> <p>There was no statistically significant difference between the specific comparators (Chi<sup>2</sup> = 1.15, df = 1, P = 0.28) and there were no statistically significant differences in remission rates between vortioxetine and venlafaxine (RR 0.99, 95% CI 0.81 to 1.20, P = 0.88; 2 studies, 767 participants; I<sup>2</sup> = 37%) or vortioxetine and duloxetine (RR 0.85, 95% CI 0.70 to 1.02; P = 0.09; 6 studies, 2388 participants; I<sup>2</sup> = 58%). </p> </section> <section id="CD011520-sec-0108"> <h6 class="title">2.4. Depressive symptoms</h6> <p>There was evidence that vortioxetine was less effective in lowering depression scores compared to SNRIs as a whole (MD 1.52, 95% CI 0.50 to 2.53; P = 0.003; 8 studies, 2807 participants). Heterogeneity between studies was moderate (I<sup>2</sup> = 50%) (<a href="./references#CD011520-fig-0027" title="">Analysis 2.4</a>). </p> <p>There was no significant difference between trials comparing vortioxetine to duloxetine or venlafaxine (Chi<sup>2</sup> = 2.11, df = 1, P = 0.15). Comparing vortioxetine to duloxetine, the depression scores were significantly more reduced by duloxetine (MD 1.99, 95% CI 1.15 to 2.83; P &lt; 0.001; 6 studies, 2106 participants; I<sup>2</sup> = 6%). There was no significant difference for this outcome between vortioxetine and venlafaxine (MD 0.02, 95% CI ‐2.49 to 2.54; P = 0.99; 2 studies, 701 participants; I<sup>2</sup> = 65%). </p> </section> <section id="CD011520-sec-0109"> <h6 class="title">2.5. Dropout due to adverse events</h6> <p>There was no evidence that vortioxetine was associated with a lower or higher dropout rate due to adverse events compared to SNRIs as a whole (RR 0.74, 95% CI 0.51 to 1.08; P = 0.12; 8 studies, 3159 participants). Heterogeneity between studies was moderate (I<sup>2</sup> = 55%) (<a href="./references#CD011520-fig-0028" title="">Analysis 2.5</a>). </p> <p>There was a statistically significant difference between the comparators (Chi<sup>2</sup> = 7.07, df = 1, P = 0.008). Dropout rates due to adverse events were significantly lower for vortioxetine compared to venlafaxine (RR 0.42, 95% CI 0.26 to 0.67; P &lt; 0.001; 2 studies; 767 participants; I<sup>2</sup> = 0%). There was no statistically significant difference between vortioxetine and duloxetine (RR 0.92, 95% CI 0.65 to 1.31; P = 0.65; 6 studies, 2392 participants; I<sup>2</sup> = 30%). </p> </section> <section id="CD011520-sec-0110"> <h6 class="title">2.6. Dropout due to inefficacy</h6> <p>There was no evidence that vortioxetine was associated with a lower or higher dropout rate due to inefficacy compared to SNRIs as a whole (RR 1.52, 95% CI 0.70 to 3.30; P = 0.29; 8 studies, 3159 participants). Heterogeneity between studies was moderate (I<sup>2</sup> = 30%) (<a href="./references#CD011520-fig-0029" title="">Analysis 2.6</a>). </p> <p>There was no significant difference between trials comparing vortioxetine to duloxetine or venlafaxine (Chi<sup>2</sup> = 1.29, df = 1, P = 0.26). Furthermore, there were no significant differences in dropout rates due to inefficacy between vortioxetine and venlafaxine (RR 2.68, 95% CI 0.99 to 7.24; P = 0.05; 2 studies, 767 participants; I<sup>2</sup> = 0%) or vortioxetine and duloxetine (RR 1.16, 95% CI 0.41 to 3.31; P = 0.78; 6 studies, 2392 participants; I<sup>2</sup> = 34%). </p> </section> <section id="CD011520-sec-0111"> <h6 class="title">2.7. Tolerability</h6> <p>There was evidence that fewer participants experienced adverse effects when treated with vortioxetine than when treated with SNRIs as a whole (RR 0.90, 95% CI 0.86 to 0.94; P &lt; 0.001; 8 studies, 3139 participants). There was no heterogeneity (I<sup>2</sup> = 0%) (<a href="./references#CD011520-fig-0030" title="">Analysis 2.7</a>). </p> <p>There was no statistically significant difference between the specific comparators (Chi<sup>2</sup> = 0.09, df = 1, P = 0.76). The comparison between vortioxetine and duloxetine showed that fewer participants experienced adverse effects when treated with vortioxetine (RR 0.89, 95% CI 0.84 to 0.95; P &lt; 0.001; 6 studies, 2376 participants; I<sup>2</sup> = 18%). There was no significant difference between vortioxetine and venlafaxine (RR 0.91, 95% CI 0.82 to 1.00; P = 0.06; 2 studies, 758 participants; I<sup>2</sup> = 0%). </p> <p>Specific adverse effects compared to SNRIs are reported descriptively in <a href="./references#CD011520-fig-0039" title="">Analysis 2.16</a>. Specific serious adverse events are reported in <a href="./references#CD011520-fig-0040" title="">Analysis 2.17</a>. </p> <p>This analysis used ITT data as reported in the trials.</p> </section> </section> </section> <section id="CD011520-sec-0112"> <h4 class="title">Subgroup analyses</h4> </section> <section id="CD011520-sec-0113"> <h4 class="title">Comparison 1. Vortioxetine versus placebo</h4> <section id="CD011520-sec-0114"> <h5 class="title">Fixed versus flexible dosing schemes</h5> <p>Two studies compared placebo to a flexible dose of vortioxetine (<a href="./references#CD011520-bbs2-0001" title="AlvarezE , PerezV , DragheimM , LoftH , ArtigasF . A double‐blind, randomized, placebo‐controlled, active reference study of Lu AA21004 in patients with major depressive disorder. International Journal of Neuropsychopharmacology2012;15(5):589‐600. [Lundbeck 11492A; NCT00839423] NCT00839423 . Randomised placebo‐controlled venlafaxine‐referenced study of efficacy and safety of 5 and 10 mg of vortioxetine (Lu AA21004) in acute treatment of major depressive disorder in adults. clinicaltrials.gov/ct2/show/NCT00839423 Date first received: 6 February 2009. ">Alvarez 2012</a>; <a href="./references#CD011520-bbs2-0010" title="JacobsonW , HarveyP , MerikleE , ZhongW , NomikosG , OlsenCK , et al. Impact of vortioxetine on functional capacity in MDD patients with subjective cognitive dysfunction: performance on the University of California San Diego performance‐based skills assessment (UPSA). 54th Annual Meeting of the American College of Neuropsychopharmacology, ACNP; 2015 Dec 6‐10; Hollywood (FL). 2015:S150‐1. JacobsonW , OlsenC , MahableshwarkarA , YinzhongC , KeefeR . Effect of vortioxetine on functional capacity in patients with major depressive disorder with self‐reported cognitive dysfunction. 28th European College of Neuropsychopharmacology, ECNP Congress; 2015 29 Aug ‐ 1 Sept; Amsterdam Netherlands. 2015:S460. KeefeR , MahableshwarkarA , ZajeckaJ , JacobsonW , ChenY . Efficacy of vortioxetine on cognitive function in patients with major depressive disorder: cognitive test performance results: from a randomized, double‐blind, duloxetine‐referenced, placebo‐controlled. Neuropsychopharmacology2014;39:S389‐90. MahableshwarkarAR , ZajeckaJ , JacobsonW , ChenY , KeefeRS . A randomized, placebo‐controlled, active‐reference, double‐blind, flexible‐dose study of the efficacy of vortioxetine on cognitive function in major depressive disorder. Neuropsychopharmacology2015;40(8):2025‐37. NCT01564862 . A randomized, double‐blind, parallel‐group, placebo‐controlled, active‐referenced, flexible dose study on the efficacy of Lu AA21004 on cognitive dysfunction in adult subjects with major depressive disorder (MDD). clinicaltrials.gov/show/NCT01564862 Date first received: 26 March 2012. ">Mahableshwarkar 2015b</a>). There were no significant differences between the subgroups in terms of treatment response (test for subgroup differences: Chi<sup>2</sup> = 0.05, df = 1, P = 0.82; <a href="./references#CD011520-fig-0016" title="">Analysis 1.8</a>) and total number of dropouts (Chi<sup>2</sup> = 0.70, df = 1, P = 0.40; <a href="./references#CD011520-fig-0017" title="">Analysis 1.9</a>). </p> </section> <section id="CD011520-sec-0115"> <h5 class="title">Treatment setting: primary care versus inpatient care versus outpatient care</h5> <p>We found no studies in primary care settings and all studies including inpatients also included outpatients, so it was impossible to conduct this subgroup analysis. </p> </section> <section id="CD011520-sec-0116"> <h5 class="title">Older people (aged greater than 65 years): included versus excluded</h5> <p>We excluded four studies from this subgroup analysis, because it was unclear if older participants were included (<a href="./references#CD011520-bbs2-0004" title="HenigsbergN , MahableshwarkarA , JacobsenP , ChenY , ThaseME . Efficacy and tolerability of multiple doses of LU AA21004 in an 8‐week trial of adults with major depressive disorder. European Neuropsychopharmacology2011;21(Suppl 3):S393. HenigsbergN , MahableshwarkarAR , JacobsenP , ChenY , ThaseME . A randomized, double‐blind, placebo‐controlled 8‐week trial of the efficacy and tolerability of multiple doses of Lu AA21004 in adults with major depressive disorder. Journal of Clinical Psychology2012;73(7):953‐9. NCT00707980 . A long‐term, open‐label, flexible‐dose, extension study evaluating the safety and tolerability of Lu AA21004 in subjects with major depressive disorder. clinicaltrials.gov/ct2/show/NCT00707980 Date first received: 27 June 2008. NCT00735709 . A randomized, double‐blind, parallel‐group, placebo‐controlled, fixed‐dose study comparing the efficacy and safety of 3 doses of Lu AA21004 in acute treatment of adults with major depressive disorder. clinicaltrials.gov/show/NCT00735709 Date first received: 14 August 2008. ">Henigsberg 2012</a>; <a href="./references#CD011520-bbs2-0006" title="JainR , MahableshwarkarAR , JacobsenPL , ChenY , ThaseME . A randomized, double‐blind, placebo‐controlled 6‐wk trial of the efficacy and tolerability of 5 mg vortioxetine in adults with major depressive disorder. International Journal of Neuropsychopharmacology2013;16(2):313‐21. NCT00672958 . A randomized, double‐blind, parallel‐group, placebo‐controlled, fixed‐dose study comparing the efficacy and safety of Lu AA21004 versus placebo in acute treatment of adults with major depressive disorder. clinicaltrials.gov/show/NCT00672958 Date first received: 2 May 2008. ">Jain 2013</a>; <a href="./references#CD011520-bbs2-0008" title="MahableshwarkarAR , JacobsenPL , ChenY . A randomized, double‐blind trial of 2.5mg and 5mg vortioxetine (Lu AA21004) versus placebo for 8 weeks in adults with major depressive disorder. Current Medical Research and Opinion2013;29(3):217‐26. [NCT00672620] NCT00672620 . A randomized, double‐blind, parallel‐group, placebo‐controlled, active‐referenced, fixed‐dose study comparing the efficacy and safety of 2 doses of Lu AA21004 in acute treatment of adults with major depressive disorder. clinicaltrials.gov/show/NCT00672620 Date first received: 2 May 2008. NCT00707980 . A long‐term, open‐label, flexible‐dose, extension study evaluating the safety and tolerability of Lu AA21004 in subjects with major depressive disorder. clinicaltrials.gov/ct2/show/NCT00707980 Date first received: 27 June 2008. ">Mahableshwarkar 2013</a>; <a href="./references#CD011520-bbs2-0014" title="Jprn‐Japiccti‐111492 . A randomized, double‐blind, placebo‐controlled, phase III study to assess the efficacy and safety of LuAA21004 in patients with major depressive disorder. www.clinicaltrials.jp/user/showCteDetailE.jsp?japicId=JapicCTI‐111492 Date first received: 9 May 2011. NCT01355081 . A randomized, double‐blind, placebo‐controlled, parallel‐group, phase III study to assess the efficacy and safety of Lu AA21004 in patients with major depressive disorder. clinicaltrials.gov/show/NCT01355081 Date first received: 16 May 2011. ">Takeda 2011</a>). Four studies excluded older participants (<a href="./references#CD011520-bbs2-0001" title="AlvarezE , PerezV , DragheimM , LoftH , ArtigasF . A double‐blind, randomized, placebo‐controlled, active reference study of Lu AA21004 in patients with major depressive disorder. International Journal of Neuropsychopharmacology2012;15(5):589‐600. [Lundbeck 11492A; NCT00839423] NCT00839423 . Randomised placebo‐controlled venlafaxine‐referenced study of efficacy and safety of 5 and 10 mg of vortioxetine (Lu AA21004) in acute treatment of major depressive disorder in adults. clinicaltrials.gov/ct2/show/NCT00839423 Date first received: 6 February 2009. ">Alvarez 2012</a>; <a href="./references#CD011520-bbs2-0010" title="JacobsonW , HarveyP , MerikleE , ZhongW , NomikosG , OlsenCK , et al. Impact of vortioxetine on functional capacity in MDD patients with subjective cognitive dysfunction: performance on the University of California San Diego performance‐based skills assessment (UPSA). 54th Annual Meeting of the American College of Neuropsychopharmacology, ACNP; 2015 Dec 6‐10; Hollywood (FL). 2015:S150‐1. JacobsonW , OlsenC , MahableshwarkarA , YinzhongC , KeefeR . Effect of vortioxetine on functional capacity in patients with major depressive disorder with self‐reported cognitive dysfunction. 28th European College of Neuropsychopharmacology, ECNP Congress; 2015 29 Aug ‐ 1 Sept; Amsterdam Netherlands. 2015:S460. KeefeR , MahableshwarkarA , ZajeckaJ , JacobsonW , ChenY . Efficacy of vortioxetine on cognitive function in patients with major depressive disorder: cognitive test performance results: from a randomized, double‐blind, duloxetine‐referenced, placebo‐controlled. Neuropsychopharmacology2014;39:S389‐90. MahableshwarkarAR , ZajeckaJ , JacobsonW , ChenY , KeefeRS . A randomized, placebo‐controlled, active‐reference, double‐blind, flexible‐dose study of the efficacy of vortioxetine on cognitive function in major depressive disorder. Neuropsychopharmacology2015;40(8):2025‐37. NCT01564862 . A randomized, double‐blind, parallel‐group, placebo‐controlled, active‐referenced, flexible dose study on the efficacy of Lu AA21004 on cognitive dysfunction in adult subjects with major depressive disorder (MDD). clinicaltrials.gov/show/NCT01564862 Date first received: 26 March 2012. ">Mahableshwarkar 2015b</a>; <a href="./references#CD011520-bbs2-0012" title="HarrisonJ . Assessment of cognitive dysfunction in patients with depression ‐ which test is best?. 28th European College of Neuropsychopharmacology, ECNP Congress; 2015 29 Aug ‐ 1 Sept; Amsterdam Netherlands. 2015:S669. McIntyreRS , LophavenS , OlsenCK . A randomized, double‐blind, placebo‐controlled study of vortioxetine on cognitive function in depressed adults. International Journal of Neuropsychopharmacology2014;17(10):1557‐67. [NCT01422213] McIntyreRS , LophavenS , OlsenCK . Randomized, double‐blind, placebo‐controlled study of the efficacy of vortioxetine on cognitive dysfunction in adult patients with major depressive disorder (MDD). 52nd Annual Meeting of the American College of Neuropsychopharmacology, ACNP; 2013 Dec 8‐12; Hollywood (FL). 2013:S380‐1. NCT01422213 . Randomised, double‐blind, parallel‐group, placebo‐controlled, fixed dose study on the efficacy of [vortioxetine] Lu AA21004 on cognitive dysfunction in adult patients with major depressive disorder (MDD). clinicaltrials.gov/show/NCT01422213 Date first received: 22 August 2011. ">McIntyre 2014</a>; <a href="./references#CD011520-bbs2-0013" title="Euctr2010‐022257‐41‐Lv . A multinational, randomized, double‐blind, placebo‐controlled, dose ranging study to assess the efficacy and safety of Lu AA21004 in patients with major depressive disorder ‐ efficacy and safety of Lu AA21004 for treatment of major depressive disorder. www.clinicaltrialsregister.eu/ctr‐search/search?query=eudract_number:2010‐022257‐412010. NCT01255787 . A multinational, randomized, double‐blind, placebo‐controlled, dose ranging study to assess the efficacy and safety of Lu AA21004 in patients with major depressive disorder. clinicaltrials.gov/show/NCT01255787 Date first received: 6 December 2010. ">NCT01255787</a>). One study recruited only older participants (<a href="./references#CD011520-bbs2-0007" title="KatonaC , HansenT , OlsenCK . A randomised, double‐blind, placebo controlled, active‐referenced study of the multimodal antidepressant Lu AA21004 in the treatment of elderly depressed patients. European Neuropsychopharmacology2012;22:S258‐9. KatonaC , HansenT , OlsenCK . A randomized, double‐blind, placebo‐controlled, duloxetine‐referenced, fixed‐dose study comparing the efficacy and safety of Lu AA21004 in elderly patients with major depressive disorder. International Clinical Psychopharmacology2012;27(4):215‐23. [Lundbeck 12541A; NCT00811252] NCT00811252 . Randomised placebo‐controlled duloxetine‐referenced study of efficacy and safety of 5 mg of vortioxetine (Lu AA21004) in acute treatment of major depressive disorder in elderly patients. clinicaltrials.gov/ct2/show/NCT00811252 Date first received: 17 December 2008. ">Katona 2012</a>). There were no differences in response rates between the subgroups (Chi<sup>2</sup> = 0.52, df = 1, P = 0.47; <a href="./references#CD011520-fig-0018" title="">Analysis 1.10</a>), but dropout rates differed significantly (Chi<sup>2</sup> = 5.02, df = 1, P = 0.02; <a href="./references#CD011520-fig-0019" title="">Analysis 1.11</a>). In the studies including older participants, the dropout rates were significantly lower in the placebo groups (RR 1.25, 95% CI 1.05 to 1.49; P = 0.01; I<sup>2</sup> = 0%). The number of total dropouts was not significantly different compared to placebo in the studies excluding older participants (RR 0.90, 95% CI 0.71 to 1.13; P = 0.36; I<sup>2</sup> = 0%). </p> </section> </section> <section id="CD011520-sec-0117"> <h4 class="title">Comparison 2. Vortioxetine versus serotonin‐norepinephrine reuptake inhibitors</h4> <section id="CD011520-sec-0118"> <h5 class="title">Fixed versus flexible dosing schemes</h5> <p>One study compared a flexible dose of vortioxetine 10 mg to 20 mg versus a fixed dose of duloxetine 60 mg/day (<a href="./references#CD011520-bbs2-0010" title="JacobsonW , HarveyP , MerikleE , ZhongW , NomikosG , OlsenCK , et al. Impact of vortioxetine on functional capacity in MDD patients with subjective cognitive dysfunction: performance on the University of California San Diego performance‐based skills assessment (UPSA). 54th Annual Meeting of the American College of Neuropsychopharmacology, ACNP; 2015 Dec 6‐10; Hollywood (FL). 2015:S150‐1. JacobsonW , OlsenC , MahableshwarkarA , YinzhongC , KeefeR . Effect of vortioxetine on functional capacity in patients with major depressive disorder with self‐reported cognitive dysfunction. 28th European College of Neuropsychopharmacology, ECNP Congress; 2015 29 Aug ‐ 1 Sept; Amsterdam Netherlands. 2015:S460. KeefeR , MahableshwarkarA , ZajeckaJ , JacobsonW , ChenY . Efficacy of vortioxetine on cognitive function in patients with major depressive disorder: cognitive test performance results: from a randomized, double‐blind, duloxetine‐referenced, placebo‐controlled. Neuropsychopharmacology2014;39:S389‐90. MahableshwarkarAR , ZajeckaJ , JacobsonW , ChenY , KeefeRS . A randomized, placebo‐controlled, active‐reference, double‐blind, flexible‐dose study of the efficacy of vortioxetine on cognitive function in major depressive disorder. Neuropsychopharmacology2015;40(8):2025‐37. NCT01564862 . A randomized, double‐blind, parallel‐group, placebo‐controlled, active‐referenced, flexible dose study on the efficacy of Lu AA21004 on cognitive dysfunction in adult subjects with major depressive disorder (MDD). clinicaltrials.gov/show/NCT01564862 Date first received: 26 March 2012. ">Mahableshwarkar 2015b</a>). All other studies used a fixed dose scheme. The study with a flexible dose found no significant differences in terms of response rates (Chi<sup>2</sup> = 0.03, df = 1, P = 0.86; <a href="./references#CD011520-fig-0031" title="">Analysis 2.8</a>) and total dropouts (Chi<sup>2</sup> = 0.04, df = 1, P = 0.84; <a href="./references#CD011520-fig-0032" title="">Analysis 2.9</a>), as compared to the fixed‐dose studies. </p> </section> <section id="CD011520-sec-0119"> <h5 class="title">Treatment setting: primary care versus inpatient care versus outpatient care</h5> <p>We found no studies in primary care settings and all studies including inpatients also included outpatients, so it was impossible to conduct this subgroup analysis. </p> </section> <section id="CD011520-sec-0120"> <h5 class="title">Older participants (aged greater than 65 years): included versus excluded</h5> <p>We excluded one study from this analysis, because it was unclear if older participants were included in the study population (<a href="./references#CD011520-bbs2-0008" title="MahableshwarkarAR , JacobsenPL , ChenY . A randomized, double‐blind trial of 2.5mg and 5mg vortioxetine (Lu AA21004) versus placebo for 8 weeks in adults with major depressive disorder. Current Medical Research and Opinion2013;29(3):217‐26. [NCT00672620] NCT00672620 . A randomized, double‐blind, parallel‐group, placebo‐controlled, active‐referenced, fixed‐dose study comparing the efficacy and safety of 2 doses of Lu AA21004 in acute treatment of adults with major depressive disorder. clinicaltrials.gov/show/NCT00672620 Date first received: 2 May 2008. NCT00707980 . A long‐term, open‐label, flexible‐dose, extension study evaluating the safety and tolerability of Lu AA21004 in subjects with major depressive disorder. clinicaltrials.gov/ct2/show/NCT00707980 Date first received: 27 June 2008. ">Mahableshwarkar 2013</a>). Three studies comparing vortioxetine to an SNRI excluded older participants (<a href="./references#CD011520-bbs2-0001" title="AlvarezE , PerezV , DragheimM , LoftH , ArtigasF . A double‐blind, randomized, placebo‐controlled, active reference study of Lu AA21004 in patients with major depressive disorder. International Journal of Neuropsychopharmacology2012;15(5):589‐600. [Lundbeck 11492A; NCT00839423] NCT00839423 . Randomised placebo‐controlled venlafaxine‐referenced study of efficacy and safety of 5 and 10 mg of vortioxetine (Lu AA21004) in acute treatment of major depressive disorder in adults. clinicaltrials.gov/ct2/show/NCT00839423 Date first received: 6 February 2009. ">Alvarez 2012</a>; <a href="./references#CD011520-bbs2-0010" title="JacobsonW , HarveyP , MerikleE , ZhongW , NomikosG , OlsenCK , et al. Impact of vortioxetine on functional capacity in MDD patients with subjective cognitive dysfunction: performance on the University of California San Diego performance‐based skills assessment (UPSA). 54th Annual Meeting of the American College of Neuropsychopharmacology, ACNP; 2015 Dec 6‐10; Hollywood (FL). 2015:S150‐1. JacobsonW , OlsenC , MahableshwarkarA , YinzhongC , KeefeR . Effect of vortioxetine on functional capacity in patients with major depressive disorder with self‐reported cognitive dysfunction. 28th European College of Neuropsychopharmacology, ECNP Congress; 2015 29 Aug ‐ 1 Sept; Amsterdam Netherlands. 2015:S460. KeefeR , MahableshwarkarA , ZajeckaJ , JacobsonW , ChenY . Efficacy of vortioxetine on cognitive function in patients with major depressive disorder: cognitive test performance results: from a randomized, double‐blind, duloxetine‐referenced, placebo‐controlled. Neuropsychopharmacology2014;39:S389‐90. MahableshwarkarAR , ZajeckaJ , JacobsonW , ChenY , KeefeRS . A randomized, placebo‐controlled, active‐reference, double‐blind, flexible‐dose study of the efficacy of vortioxetine on cognitive function in major depressive disorder. Neuropsychopharmacology2015;40(8):2025‐37. NCT01564862 . A randomized, double‐blind, parallel‐group, placebo‐controlled, active‐referenced, flexible dose study on the efficacy of Lu AA21004 on cognitive dysfunction in adult subjects with major depressive disorder (MDD). clinicaltrials.gov/show/NCT01564862 Date first received: 26 March 2012. ">Mahableshwarkar 2015b</a>; <a href="./references#CD011520-bbs2-0015" title="Kct0000432 . Randomised, double‐blind, parallel‐group, active‐comparator (venlafaxine extended release), fixed‐dose study of LuAA21004 in major depressive disorder in Asian countries. cris.nih.go.kr/cris/en/search/search_result_st01.jsp?seq=2532 Date first approved: 16 August 2011. NCT01571453 . Randomised, double‐blind, parallel‐group, active‐comparator (venlafaxine extended release), fixed‐dose study of [vortioxetine] Lu AA21004 in major depressive disorder in Asian countries. clinicaltrials.gov/show/NCT01571453 Date first received: 28 March 2012. WangG , GislumM , FilippovG , MontgomeryS . Comparison of vortioxetine versus venlafaxine XR in adults in Asia with major depressive disorder: a randomized, double‐blind study. Current Medical Research and Opinion2015;31(4):785‐94. ">Wang 2015</a>). There was no significant difference between the subgroups in response rates (test for subgroup differences: Chi<sup>2</sup> = 2.52, df = 1, P = 0.11; <a href="./references#CD011520-fig-0033" title="">Analysis 2.10</a>) and total dropout rates (test for subgroup differences: Chi<sup>2</sup> = 2.38, df = 1, P = 0.12; <a href="./references#CD011520-fig-0034" title="">Analysis 2.11</a>). </p> </section> </section> <section id="CD011520-sec-0121"> <h4 class="title">Sensitivity analyses</h4> <p>The following sensitivity analyses were defined a priori.</p> <section id="CD011520-sec-0122"> <h5 class="title">Exclusion of trials with unequal dosing</h5> <p>This sensitivity analysis is only meaningful for the comparisons of vortioxetine with active comparators. </p> <p>In six studies, vortioxetine and control antidepressants were compared using unequal doses. Two studies compared vortioxetine 5 mg/day (25% of the maximum dose) to duloxetine 60 mg/day (50% of the maximum dose) (<a href="./references#CD011520-bbs2-0007" title="KatonaC , HansenT , OlsenCK . A randomised, double‐blind, placebo controlled, active‐referenced study of the multimodal antidepressant Lu AA21004 in the treatment of elderly depressed patients. European Neuropsychopharmacology2012;22:S258‐9. KatonaC , HansenT , OlsenCK . A randomized, double‐blind, placebo‐controlled, duloxetine‐referenced, fixed‐dose study comparing the efficacy and safety of Lu AA21004 in elderly patients with major depressive disorder. International Clinical Psychopharmacology2012;27(4):215‐23. [Lundbeck 12541A; NCT00811252] NCT00811252 . Randomised placebo‐controlled duloxetine‐referenced study of efficacy and safety of 5 mg of vortioxetine (Lu AA21004) in acute treatment of major depressive disorder in elderly patients. clinicaltrials.gov/ct2/show/NCT00811252 Date first received: 17 December 2008. ">Katona 2012</a>; <a href="./references#CD011520-bbs2-0008" title="MahableshwarkarAR , JacobsenPL , ChenY . A randomized, double‐blind trial of 2.5mg and 5mg vortioxetine (Lu AA21004) versus placebo for 8 weeks in adults with major depressive disorder. Current Medical Research and Opinion2013;29(3):217‐26. [NCT00672620] NCT00672620 . A randomized, double‐blind, parallel‐group, placebo‐controlled, active‐referenced, fixed‐dose study comparing the efficacy and safety of 2 doses of Lu AA21004 in acute treatment of adults with major depressive disorder. clinicaltrials.gov/show/NCT00672620 Date first received: 2 May 2008. NCT00707980 . A long‐term, open‐label, flexible‐dose, extension study evaluating the safety and tolerability of Lu AA21004 in subjects with major depressive disorder. clinicaltrials.gov/ct2/show/NCT00707980 Date first received: 27 June 2008. ">Mahableshwarkar 2013</a>), and one compared vortioxetine 5 mg/day or 10 mg/day (50% of the maximum dose) to venlafaxine 225 mg/day (100% of the maximum dose for moderately depressed outpatients) (<a href="./references#CD011520-bbs2-0001" title="AlvarezE , PerezV , DragheimM , LoftH , ArtigasF . A double‐blind, randomized, placebo‐controlled, active reference study of Lu AA21004 in patients with major depressive disorder. International Journal of Neuropsychopharmacology2012;15(5):589‐600. [Lundbeck 11492A; NCT00839423] NCT00839423 . Randomised placebo‐controlled venlafaxine‐referenced study of efficacy and safety of 5 and 10 mg of vortioxetine (Lu AA21004) in acute treatment of major depressive disorder in adults. clinicaltrials.gov/ct2/show/NCT00839423 Date first received: 6 February 2009. ">Alvarez 2012</a>). Two studies used higher vortioxetine doses and compared vortioxetine 15 mg/day or 20 mg/day (100% of the maximum dose) to duloxetine 60 mg/day (50% of the maximum dose) (<a href="./references#CD011520-bbs2-0003" title="BoulengerJ‐P , LoftH , OlsenCK . Efficacy and safety of vortioxetine (Lu AA21004), 15 and 20 mg/day: a randomized, double‐blind, placebo‐controlled, duloxetine‐referenced study in the acute treatment of adult patients with major depressive disorder. International Clinical Psychopharmacology2014;29(3):138‐49. [NCT01140906] NCT01140906 . A randomised, double‐blind, parallel‐group, placebo‐controlled, duloxetine‐referenced, fixed‐dose study evaluating the efficacy and safety of Lu AA21004 (15 and 20 mg/day) in the acute treatment of adult patients with major depressive disorder. clinicaltrials.gov/show/NCT01140906 Date first received: 9 June 2010. ">Boulenger 2014</a>; <a href="./references#CD011520-bbs2-0009" title="MahableshwarkarAR , JacobsenPL , ChenY , SerenkoM , TrivediMH . A randomized, double‐blind, duloxetine‐referenced study comparing efficacy and tolerability of 2 fixed doses of vortioxetine in the acute treatment of adults with MDD. Psychopharmacology2015;232(12):2061‐70. NCT01153009 . A phase 3, randomized, double‐blind, parallel‐group, placebo‐controlled, duloxetine‐referenced, fixed‐dose study comparing the efficacy and safety of 2 doses (15 and 20 mg) of Lu AA21004 in acute treatment of adults with major depressive disorder. clinicaltrials.gov/show/NCT01153009 Date first received: 28 June 2010. ">Mahableshwarkar 2015a</a>). One study compared flexible dosing of vortioxetine to a fixed dose of duloxetine (<a href="./references#CD011520-bbs2-0010" title="JacobsonW , HarveyP , MerikleE , ZhongW , NomikosG , OlsenCK , et al. Impact of vortioxetine on functional capacity in MDD patients with subjective cognitive dysfunction: performance on the University of California San Diego performance‐based skills assessment (UPSA). 54th Annual Meeting of the American College of Neuropsychopharmacology, ACNP; 2015 Dec 6‐10; Hollywood (FL). 2015:S150‐1. JacobsonW , OlsenC , MahableshwarkarA , YinzhongC , KeefeR . Effect of vortioxetine on functional capacity in patients with major depressive disorder with self‐reported cognitive dysfunction. 28th European College of Neuropsychopharmacology, ECNP Congress; 2015 29 Aug ‐ 1 Sept; Amsterdam Netherlands. 2015:S460. KeefeR , MahableshwarkarA , ZajeckaJ , JacobsonW , ChenY . Efficacy of vortioxetine on cognitive function in patients with major depressive disorder: cognitive test performance results: from a randomized, double‐blind, duloxetine‐referenced, placebo‐controlled. Neuropsychopharmacology2014;39:S389‐90. MahableshwarkarAR , ZajeckaJ , JacobsonW , ChenY , KeefeRS . A randomized, placebo‐controlled, active‐reference, double‐blind, flexible‐dose study of the efficacy of vortioxetine on cognitive function in major depressive disorder. Neuropsychopharmacology2015;40(8):2025‐37. NCT01564862 . A randomized, double‐blind, parallel‐group, placebo‐controlled, active‐referenced, flexible dose study on the efficacy of Lu AA21004 on cognitive dysfunction in adult subjects with major depressive disorder (MDD). clinicaltrials.gov/show/NCT01564862 Date first received: 26 March 2012. ">Mahableshwarkar 2015b</a>). To increase the usability of the analysis, the analysis was conducted by grouping the comparisons into subgroups according to the direction of the imbalance in dosing. </p> <p>The analysis of response rates revealed statistically significant differences between the groups (Chi² = 14.99, df = 3, P = 0.002; <a href="./references#CD011520-fig-0035" title="">Analysis 2.12</a>). The two trials with fair (or comparable) dosing found no differences between vortioxetine and SNRIs (RR 1.09, 95% CI 0.97 to 1.22; P = 0.13; 912 participants; I<sup>2</sup> = 0%), but the studies using higher and lower vortioxetine doses than comparator showed significantly higher response rates in participants treated with SNRIs (higher: RR 0.80, 95% CI 0.72 to 0.90; P &lt; 0.001; 2 studies, 903 participants; I<sup>2</sup> = 0%; lower: RR 0.87, 95% CI 0.78 to 0.98; P = 0.02; 3 studies, 936 participants; I<sup>2</sup> = 9%). </p> <p>The analysis of the total number of dropouts found no statistically significant differences between the subgroups (Chi<sup>2</sup> = 3.68, df = 3, P = 0.30; <a href="./references#CD011520-fig-0036" title="">Analysis 2.13</a>). In the trials with fair (or comparable) dosing, vortioxetine showed statistically significant lower total dropout rate than SNRIs as a whole (RR 0.75, 95% CI 0.59 to 0.96; P = 0.02; 2 studies, 912 participants; I<sup>2</sup> = 0%). The studies using higher vortioxetine doses, lower vortioxetine doses and flexible versus fixed dosing found no statistically significant dropout rates between vortioxetine and SNRIs (higher dose: RR 1.33, 95% CI 0.74 to 2.39; P = 0.33; 2 studies, 903 participants; I<sup>2</sup> = 72%; lower vortioxetine dose: RR 0.77, 95% CI 0.59 to 1.02; P = 0.06; 3 studies, 936 participants; I<sup>2</sup> = 0%; flexible versus fixed dosing: RR 0.94, 95% CI 0.60 to 1.47; P = 0.77; 1 study, 408 participants). </p> </section> <section id="CD011520-sec-0123"> <h5 class="title">Exclusion of studies that did not employ a double‐blind approach</h5> <p>All our included studies were double‐blinded.</p> </section> <section id="CD011520-sec-0124"> <h5 class="title">Exclusion of studies with subsets of participants with bipolar disorders</h5> <p>None of the included studies randomised people with bipolar disorder.</p> </section> <section id="CD011520-sec-0125"> <h5 class="title">Exclusion of trials with dropout rates of more than 20% in one of the treatment arm included </h5> <p>This sensitivity analyses were performed for the comparisons of vortioxetine with placebo and vortioxetine with SNRIs. </p> <p>Six studies reported overall dropout rates of more than 20% and were excluded (<a href="./references#CD011520-bbs2-0002" title="BaldwinD , LoftH , DragheimM . A randomised, double‐blind, placebo controlled, duloxetine‐referenced, fixed‐dose study of three dosages of Lu AA21004 in MDD treatment. European Neuropsychopharmacology2011;21(Suppl 3):S390. BaldwinDS , LoftH , DragheimM . A randomised, double‐blind, placebo controlled, duloxetine‐referenced, fixed‐dose study of three dosages of Lu AA21004 in acute treatment of major depressive disorder (MDD). European Neuropsychopharmacology2012;22(7):482‐91. [Lundbeck 11984A; NCT00635219] NCT00635219 . Randomised placebo‐controlled duloxetine‐referenced efficacy and safety study of 2.5, 5 and 10 mg of vortioxetine (Lu AA21004) in acute treatment of major depressive disorder. clinicaltrials.gov/ct2/show/NCT00635219 Date first received: 3 March 2008. ">Baldwin 2012</a>; <a href="./references#CD011520-bbs2-0003" title="BoulengerJ‐P , LoftH , OlsenCK . Efficacy and safety of vortioxetine (Lu AA21004), 15 and 20 mg/day: a randomized, double‐blind, placebo‐controlled, duloxetine‐referenced study in the acute treatment of adult patients with major depressive disorder. International Clinical Psychopharmacology2014;29(3):138‐49. [NCT01140906] NCT01140906 . A randomised, double‐blind, parallel‐group, placebo‐controlled, duloxetine‐referenced, fixed‐dose study evaluating the efficacy and safety of Lu AA21004 (15 and 20 mg/day) in the acute treatment of adult patients with major depressive disorder. clinicaltrials.gov/show/NCT01140906 Date first received: 9 June 2010. ">Boulenger 2014</a>; <a href="./references#CD011520-bbs2-0006" title="JainR , MahableshwarkarAR , JacobsenPL , ChenY , ThaseME . A randomized, double‐blind, placebo‐controlled 6‐wk trial of the efficacy and tolerability of 5 mg vortioxetine in adults with major depressive disorder. International Journal of Neuropsychopharmacology2013;16(2):313‐21. NCT00672958 . A randomized, double‐blind, parallel‐group, placebo‐controlled, fixed‐dose study comparing the efficacy and safety of Lu AA21004 versus placebo in acute treatment of adults with major depressive disorder. clinicaltrials.gov/show/NCT00672958 Date first received: 2 May 2008. ">Jain 2013</a>; <a href="./references#CD011520-bbs2-0008" title="MahableshwarkarAR , JacobsenPL , ChenY . A randomized, double‐blind trial of 2.5mg and 5mg vortioxetine (Lu AA21004) versus placebo for 8 weeks in adults with major depressive disorder. Current Medical Research and Opinion2013;29(3):217‐26. [NCT00672620] NCT00672620 . A randomized, double‐blind, parallel‐group, placebo‐controlled, active‐referenced, fixed‐dose study comparing the efficacy and safety of 2 doses of Lu AA21004 in acute treatment of adults with major depressive disorder. clinicaltrials.gov/show/NCT00672620 Date first received: 2 May 2008. NCT00707980 . A long‐term, open‐label, flexible‐dose, extension study evaluating the safety and tolerability of Lu AA21004 in subjects with major depressive disorder. clinicaltrials.gov/ct2/show/NCT00707980 Date first received: 27 June 2008. ">Mahableshwarkar 2013</a>; <a href="./references#CD011520-bbs2-0009" title="MahableshwarkarAR , JacobsenPL , ChenY , SerenkoM , TrivediMH . A randomized, double‐blind, duloxetine‐referenced study comparing efficacy and tolerability of 2 fixed doses of vortioxetine in the acute treatment of adults with MDD. Psychopharmacology2015;232(12):2061‐70. NCT01153009 . A phase 3, randomized, double‐blind, parallel‐group, placebo‐controlled, duloxetine‐referenced, fixed‐dose study comparing the efficacy and safety of 2 doses (15 and 20 mg) of Lu AA21004 in acute treatment of adults with major depressive disorder. clinicaltrials.gov/show/NCT01153009 Date first received: 28 June 2010. ">Mahableshwarkar 2015a</a>; <a href="./references#CD011520-bbs2-0015" title="Kct0000432 . Randomised, double‐blind, parallel‐group, active‐comparator (venlafaxine extended release), fixed‐dose study of LuAA21004 in major depressive disorder in Asian countries. cris.nih.go.kr/cris/en/search/search_result_st01.jsp?seq=2532 Date first approved: 16 August 2011. NCT01571453 . Randomised, double‐blind, parallel‐group, active‐comparator (venlafaxine extended release), fixed‐dose study of [vortioxetine] Lu AA21004 in major depressive disorder in Asian countries. clinicaltrials.gov/show/NCT01571453 Date first received: 28 March 2012. WangG , GislumM , FilippovG , MontgomeryS . Comparison of vortioxetine versus venlafaxine XR in adults in Asia with major depressive disorder: a randomized, double‐blind study. Current Medical Research and Opinion2015;31(4):785‐94. ">Wang 2015</a>). </p> <p>The analyses of response rates showed no significant differences between dropout rates below and above 20% for the comparison between vortioxetine and placebo (Chi<sup>2</sup> = 1.00, df = 1, P = 0.32; <a href="./references#CD011520-fig-0020" title="">Analysis 1.12</a>) and the comparison between vortioxetine and SNRIs (Chi<sup>2</sup> = 0, df = 1, P = 0.95; <a href="./references#CD011520-fig-0037" title="">Analysis 2.14</a>). </p> <p>The analyses of the total number of dropouts found no statistically significant differences between the subgroups for the comparison between vortioxetine and placebo (Chi<sup>2</sup> = 0.21, df = 1, P = 0.64; <a href="./references#CD011520-fig-0021" title="">Analysis 1.13</a>) and the comparison between vortioxetine and SNRIs (Chi<sup>2</sup> = 0.11, df = 1, P = 0.74; <a href="./references#CD011520-fig-0038" title="">Analysis 2.15</a>). </p> </section> <section id="CD011520-sec-0126"> <h5 class="title">Exclusion of studies with imputed data</h5> <p>There is no need for this sensitivity analysis, because the analysis did not include imputed data. </p> </section> <section id="CD011520-sec-0127"> <h5 class="title">Exclusion of studied sponsored by the manufacturer of vortioxetine</h5> <p>All studies were conducted by the manufacturers of vortioxetine, therefore this sensitivity analysis is not meaningful. </p> </section> </section> <section id="CD011520-sec-0128"> <h4 class="title">Reporting bias</h4> <p>We examined the funnel plot for the primary outcomes for the comparison of vortioxetine and placebo only, because the comparison with SNRIs did not contain more than 10 studies. Both funnel plots were inconclusive. We were able to identify two unpublished trials (<a href="./references#CD011520-bbs2-0013" title="Euctr2010‐022257‐41‐Lv . A multinational, randomized, double‐blind, placebo‐controlled, dose ranging study to assess the efficacy and safety of Lu AA21004 in patients with major depressive disorder ‐ efficacy and safety of Lu AA21004 for treatment of major depressive disorder. www.clinicaltrialsregister.eu/ctr‐search/search?query=eudract_number:2010‐022257‐412010. NCT01255787 . A multinational, randomized, double‐blind, placebo‐controlled, dose ranging study to assess the efficacy and safety of Lu AA21004 in patients with major depressive disorder. clinicaltrials.gov/show/NCT01255787 Date first received: 6 December 2010. ">NCT01255787</a>; <a href="./references#CD011520-bbs2-0014" title="Jprn‐Japiccti‐111492 . A randomized, double‐blind, placebo‐controlled, phase III study to assess the efficacy and safety of LuAA21004 in patients with major depressive disorder. www.clinicaltrials.jp/user/showCteDetailE.jsp?japicId=JapicCTI‐111492 Date first received: 9 May 2011. NCT01355081 . A randomized, double‐blind, placebo‐controlled, parallel‐group, phase III study to assess the efficacy and safety of Lu AA21004 in patients with major depressive disorder. clinicaltrials.gov/show/NCT01355081 Date first received: 16 May 2011. ">Takeda 2011</a>). </p> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD011520-sec-0129" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD011520-sec-0129"></div> <section id="CD011520-sec-0130"> <h3 class="title" id="CD011520-sec-0130">Summary of main results</h3> <p>Our review included 15 studies (7746 participants). Statistically, vortioxetine was more effective than placebo. This advantage was consistent across the three efficacy outcomes of response, remission and depressive symptoms, although the quality of the evidence was low for response and remission and very low for depressive symptoms (see <a href="./full#CD011520-tbl-0001">summary of findings Table for the main comparison</a>). Clinically, there is uncertainty on the relevance of these differences. According to some authors, statistically significant differences in response and remission rates should be accepted as clinically relevant (<a href="./references#CD011520-bbs2-0073" title="MontgomerySA , MollerH‐J . Is the significant superiority of escitalopram compared with other antidepressants clinically relevant?. International Clinical Psychopharmacology2009;24(3):111‐8. ">Montgomery 2009</a>), but in the present review we estimated a RR of 1.35 for response and 1.32 for remission, which correspond to a number needed to treat for an additional beneficial outcome (NNTB) of 8 (95% CI 5 to 12) for response and 13 (95% CI 8 to 29) for remission (assuming a baseline response and remission rate of 356/1000 for response and 224/1000 for remission; see <a href="./full#CD011520-tbl-0001">summary of findings Table for the main comparison</a>). Thus, doctors would need to treat 8 (95% CI 5 to 12) people with vortioxetine, rather than placebo, for one additional responding patient and 13 people (95% CI 8 to 29) for one additional remitting patient. Furthermore, the difference in change scores between vortioxetine and placebo was estimated to be fewer than 3 points on the MADRS at study endpoint. Some authors suggested that a difference of 2 points on HAM‐D or MADRS is already clinically relevant (<a href="./references#CD011520-bbs2-0073" title="MontgomerySA , MollerH‐J . Is the significant superiority of escitalopram compared with other antidepressants clinically relevant?. International Clinical Psychopharmacology2009;24(3):111‐8. ">Montgomery 2009</a>), but others have shown that an improvement of up to 3 points on the HAM‐D‐17 corresponded to "no change" on CGI (<a href="./references#CD011520-bbs2-0069" title="LeuchtS , FennemaH , EngelR , Kaspers‐JanssenM , LeppingP , SzegediA . What does the HAMD mean?. Journal of Affective Disorders2013;148(2‐3):243‐8. ">Leucht 2013</a>). Clearly, this casts uncertainty on the real added value of vortioxetine. We found no statistically significant difference in terms of total dropout rates, although more participants discontinued vortioxetine because of adverse effects, while significantly more participants discontinued placebo because of inefficacy. The subgroup or sensitivity analysis revealed no factors that significantly influenced the results. </p> <p>In comparison with other antidepressants, very low quality of evidence found no clinically significant advantage in efficacy of vortioxetine over the SNRIs as a class (see <a href="./full#CD011520-tbl-0002">summary of findings Table 2</a>). Against individual antidepressants, the analyses of response rates and change in depressive symptoms scores suggested that vortioxetine may be less effective than duloxetine, although in terms of remission rates, there was no difference. Against venlafaxine, meta‐analysis of two studies found no statistically significant differences. In terms of tolerability, our analyses of total dropout rates and dropouts due to adverse events or inefficacy found no significant differences between vortioxetine and the SNRIs as a class. In terms of number of participants reporting at least one adverse effect, vortioxetine was better than the SNRIs as a class and duloxetine. However, the sensitivity analysis casts some doubts on this result, as only two studies used comparable dosing. </p> </section> <section id="CD011520-sec-0131"> <h3 class="title" id="CD011520-sec-0131">Overall completeness and applicability of evidence</h3> <p>All studies included were conducted in highly selected populations, excluding, for example, people with psychiatric comorbidities and suicidal ideation, which are commonly seen in everyday practice. Thus, the external validity of our results may be limited. Furthermore, we were unable to identify studies that compared vortioxetine to pharmacological classes other than SNRI, which is a major limitation in terms of applicability of the evidence in routine care, as the SSRIs are the most commonly prescribed antidepressants as first‐line treatment. </p> <p>In accordance with the protocol, we did not conduct meta‐analysis on adverse events and did not include scales assessing accompanying symptoms, although these aspects may be of paramount relevance in clinical practice, often guiding the selection of an antidepressant (<a href="./references#CD011520-bbs2-0056" title="GartlehnerG , ThalerK , HillS , HansenRA . How should primary care doctors select which antidepressants to administer?. Current Psychiatry Reports2012;14(4):360‐9. ">Gartlehner 2012</a>). Our list of adverse events shows that there is considerable variance in naming, grouping and reporting adverse events; similarly, functional outcomes or accompanying symptoms were erratically assessed and reported. Thus, meta‐analyses of these outcomes cannot be informative and may rather be misleading in informing clinical practice. </p> </section> <section id="CD011520-sec-0132"> <h3 class="title" id="CD011520-sec-0132">Quality of the evidence</h3> <p>We chose seven outcomes for assessing the quality of evidence and to construct the 'Summary of findings' tables (the chosen outcomes being: response, total number of dropouts, remission, depressive symptoms, dropouts due to adverse events, dropouts due to inefficacy, tolerability expressed as patient experiencing as least one adverse event). We constructed two separate 'Summary of findings' tables: one for vortioxetine compared to placebo (<a href="./full#CD011520-tbl-0001">summary of findings Table for the main comparison</a>), and one for vortioxetine compared to SNRIs (<a href="./full#CD011520-tbl-0002">summary of findings Table 2</a>). </p> <p>The quality of the evidence for the comparisons of vortioxetine and placebo was low for remission and response rates and very low for the analysis of depressive symptoms, showing uncertainty in the magnitude of effect. The quality was downgraded because of high dropout rates in some of the trials or because of statistical heterogeneity. We rated the quality of the evidence with respect to treatment discontinuation as moderate for all three outcomes in studies of vortioxetine versus placebo (<a href="./full#CD011520-tbl-0001">summary of findings Table for the main comparison</a>). </p> <p>For studies comparing vortioxetine versus the SNRIs, the quality of the evidence was very low for all outcomes (<a href="./full#CD011520-tbl-0002">summary of findings Table 2</a>). The quality was downgraded because of high dropout rates and substantial statistical heterogeneity. </p> <section id="CD011520-sec-0133"> <h4 class="title">Study limitations (risk of bias)</h4> <p>All studies employed proper double‐blind procedures and adequate masking of the outcome assessment. However, we judged that all outcomes in studies comparing vortioxetine versus placebo had a serious risk of bias, as about 30% of studies showed an overall dropout rate above 20%. We downgraded the quality of evidence by one level accordingly. In studies comparing vortioxetine versus the SNRIs, the risk of bias was very serious for all outcomes, as about 60% of studies had a dropout rate above 20%. </p> </section> <section id="CD011520-sec-0134"> <h4 class="title">Consistency of effect</h4> <p>In studies comparing vortioxetine versus placebo, there was a moderate degree of heterogeneity (I<sup>2</sup> = 30% to 60%) (<a href="./references#CD011520-bbs2-0080" title="SchünemannH , BrożekJ , GuyattG , OxmanA , editor(s) . GRADE handbook. Handbook for grading the quality of evidence and the strength of recommendations using the GRADE approach. [updated October 2013]. The GRADE Working Group, 2013. Available from gdt.guidelinedevelopment.org/app/handbook/handbook.html. ">Schünemann 2013</a>) for the outcomes 'response' and 'remission.' The quality of evidence was downgraded by one level. There was a substantial degree of heterogeneity (I<sup>2</sup> = 60% to 90%) for the outcome 'depressive symptoms.' For this reason, we downgraded the quality of evidence by two levels for these outcomes. In the comparison vortioxetine versus SNRIs, there was a moderate degree of heterogeneity for four outcomes, namely 'response,' 'remission,' 'depressive symptoms' and 'dropouts due to adverse events.' We downgraded the quality of evidence by one level. Reasons underpinning this statistical heterogeneity are uncertain. In general, included studies were homogeneous in terms of clinical features of participants, as the vast majority enrolled participants with the same diagnosis and within the same range of age. Also trial duration was very similar between studies, while the characteristics of the setting differed between studies (see <a href="#CD011520-sec-0074">Included studies</a>). </p> </section> <section id="CD011520-sec-0135"> <h4 class="title">Indirectness</h4> <p>We judged that there was no serious risk of indirectness, as the diagnostic criteria, the characteristics of participants, type of interventions and outcomes largely matched those of interest. Most studies were conducted in high‐ and middle‐income countries, especially in the US. Evidence for people from large parts of the world, for example, Africa, South America and the Middle East was lacking (see <a href="#CD011520-fig-0002">Figure 2</a>). </p> </section> <section id="CD011520-sec-0136"> <h4 class="title">Imprecision</h4> <p>For studies comparing vortioxetine versus placebo, there was no serious risk of imprecision, because of the relatively large number of participants and events. However, for studies comparing vortioxetine versus SNRIs, we downgraded the outcomes 'total dropouts' and 'dropouts due to adverse events' by one level for serious risk of imprecision, as the 95% CI crossed both 1 (no differences) and 0.75 (appreciable benefit for vortioxetine) (according to <a href="./references#CD011520-bbs2-0063" title="GuyattGH , OxmanAD , KunzR , BrozekJ , Alonso‐CoelloP , RindD , et al. GRADE guidelines 6. Rating the quality of evidence ‐ imprecision. Journal of Clinical Epidemiology2011;64(12):1283‐93. [DOI: 10.1016/j.jclinepi.2011.01.012] ">Guyatt 2011</a>). The outcome 'dropouts due to inefficacy' was downgraded by two levels for very serious risk of imprecision, as the 95% CI crossed 1 (no differences), 0.75 (appreciable benefit for vortioxetine) and 1.25 (appreciable benefit for SNRIs). </p> </section> <section id="CD011520-sec-0137"> <h4 class="title">Publication bias</h4> <p>Visual inspection of the funnel plot did not suggest a relevant risk of publication bias. Our review included some unpublished studies and this may have reduced the impact of publication bias. As experts in the field were contacted during the search phase, it is unlikely that relevant studies were overlooked. However, although the search was thorough, there is still the possibility of not having identified unpublished studies, considering that standardised procedures to perform this type of search are lacking (<a href="./references#CD011520-bbs2-0039" title="ChanAW . Out of sight but not out of mind: how to search for unpublished clinical trial evidence. BMJ2012;3(344):d8013. ">Chan 2012</a>), and that all studies were sponsored by the pharmaceutical company. </p> </section> </section> <section id="CD011520-sec-0138"> <h3 class="title" id="CD011520-sec-0138">Potential biases in the review process</h3> <p>Although we judged our funnel plots to be inconclusive and we cannot rule out that we missed studies, we consider that our study sample is rather comprehensive and less prone to publication bias in comparison to, for example, reviews of agomelatine (<a href="./references#CD011520-bbs2-0060" title="GuaianaGiuseppe , GuptaSumeet , ChiodoDebbie , Davies SimonJ C , HaederleKatja , KoestersMarkus . Agomelatine versus other antidepressive agents for major depression. Cochrane Database of Systematic Reviews2013, Issue 12. [DOI: 10.1002/14651858.CD008851.pub2] ">Guaiana 2013</a>; <a href="./references#CD011520-bbs2-0067" title="KoestersM , GuaianaG , CiprianiA , BeckerT , BarbuiC . Agomelatine efficacy and acceptability revisited: systematic review and meta‐analysis of published and unpublished randomised trials. British Journal of Psychiatry2013;203(3):179‐87. ">Koesters 2013</a>). We included two unpublished trials only, but, for example, the failed trial and the three negative trials listed in the FDA medical review (<a href="./references#CD011520-bbs2-0038" title="Center for Drug Evaluation and Research. Application number: 204447Orig1s000. Medical review(s), 2013. www.accessdata.fda.gov/drugsatfda_docs/nda/2013/204447orig1s000medr.pdf (accessed 27 July 2016). ">CDER 2013</a>) have been published and are included in our review (<a href="./references#CD011520-bbs2-0002" title="BaldwinD , LoftH , DragheimM . A randomised, double‐blind, placebo controlled, duloxetine‐referenced, fixed‐dose study of three dosages of Lu AA21004 in MDD treatment. European Neuropsychopharmacology2011;21(Suppl 3):S390. BaldwinDS , LoftH , DragheimM . A randomised, double‐blind, placebo controlled, duloxetine‐referenced, fixed‐dose study of three dosages of Lu AA21004 in acute treatment of major depressive disorder (MDD). European Neuropsychopharmacology2012;22(7):482‐91. [Lundbeck 11984A; NCT00635219] NCT00635219 . Randomised placebo‐controlled duloxetine‐referenced efficacy and safety study of 2.5, 5 and 10 mg of vortioxetine (Lu AA21004) in acute treatment of major depressive disorder. clinicaltrials.gov/ct2/show/NCT00635219 Date first received: 3 March 2008. ">Baldwin 2012</a>; <a href="./references#CD011520-bbs2-0006" title="JainR , MahableshwarkarAR , JacobsenPL , ChenY , ThaseME . A randomized, double‐blind, placebo‐controlled 6‐wk trial of the efficacy and tolerability of 5 mg vortioxetine in adults with major depressive disorder. International Journal of Neuropsychopharmacology2013;16(2):313‐21. NCT00672958 . A randomized, double‐blind, parallel‐group, placebo‐controlled, fixed‐dose study comparing the efficacy and safety of Lu AA21004 versus placebo in acute treatment of adults with major depressive disorder. clinicaltrials.gov/show/NCT00672958 Date first received: 2 May 2008. ">Jain 2013</a>; <a href="./references#CD011520-bbs2-0008" title="MahableshwarkarAR , JacobsenPL , ChenY . A randomized, double‐blind trial of 2.5mg and 5mg vortioxetine (Lu AA21004) versus placebo for 8 weeks in adults with major depressive disorder. Current Medical Research and Opinion2013;29(3):217‐26. [NCT00672620] NCT00672620 . A randomized, double‐blind, parallel‐group, placebo‐controlled, active‐referenced, fixed‐dose study comparing the efficacy and safety of 2 doses of Lu AA21004 in acute treatment of adults with major depressive disorder. clinicaltrials.gov/show/NCT00672620 Date first received: 2 May 2008. NCT00707980 . A long‐term, open‐label, flexible‐dose, extension study evaluating the safety and tolerability of Lu AA21004 in subjects with major depressive disorder. clinicaltrials.gov/ct2/show/NCT00707980 Date first received: 27 June 2008. ">Mahableshwarkar 2013</a>; <a href="./references#CD011520-bbs2-0011" title="MahableshwarkarAR , JacobsenPL , SerenkoM , ChenY , TrivediMH . A randomized, double‐blind, placebo‐controlled study of the efficacy and safety of 2 doses of vortioxetine in adults with major depressive disorder. Journal of Clinical Psychiatry2015;76(5):583‐91. NCT01179516 . A phase 3, randomized, double‐blind, parallel‐group, placebo‐controlled, fixed‐dose study comparing the efficacy and safety of 2 doses (10 and 15 mg) of Lu AA21004 in acute treatment of adults with major depressive disorder. clinicaltrials.gov/show/NCT01179516 Date first received: 9 August 2010. ">Mahableshwarkar 2015c</a>). However, there is some evidence for a sponsorship bias in antidepressant research favouring the experimental drug (<a href="./references#CD011520-bbs2-0033" title='BarbuiC , CiprianiA , BrambillaP , HotopfM . "Wish bias" in antidepressant drug trials?. Journal of Clinical Psychopharmacology2004;24(2):126‐30. '>Barbui 2004</a>; <a href="./references#CD011520-bbs2-0085" title="WeinmannS , BeckerT , KoestersM . Re‐evaluation of the efficacy and tolerability of venlafaxine vs SSRI: meta‐analysis. Psychopharmacology2008;196(4):511‐20. ">Weinmann 2008</a>). Our analysis contained only trials conducted by the manufacturers, so we cannot rule out a sponsorship bias in favour of vortioxetine in our data. Furthermore, our analysis combined different doses of vortioxetine, which may have increased heterogeneity of the effects. However, considering that previous reviews found no significant dose‐response effects (<a href="./references#CD011520-bbs2-0071" title="MeekerAS , HerinkMC , HaxbyDG , HartungDM . The safety and efficacy of vortioxetine for acute treatment of major depressive disorder: a systematic review and meta‐analysis. Systematic Reviews2015;4:21. ">Meeker 2015</a>; <a href="./references#CD011520-bbs2-0083" title="ThaseME , MahableshwarkarAR , DragheimM , LoftH , VietaE . A meta‐analysis of randomized, placebo‐controlled trials of vortioxetine for the treatment of major depressive disorder in adults. European Neuropsychopharmacology2016;26(6):979‐93. ">Thase 2016</a>), this approach may be justified. Furthermore, doses may also vary considerably across participants within study arms and it therefore may be necessary to review these effects based on individual participant data. </p> </section> <section id="CD011520-sec-0139"> <h3 class="title" id="CD011520-sec-0139">Agreements and disagreements with other studies or reviews</h3> <p>Our review is in line with previous reviews of vortioxetine (e.g. <a href="./references#CD011520-bbs2-0071" title="MeekerAS , HerinkMC , HaxbyDG , HartungDM . The safety and efficacy of vortioxetine for acute treatment of major depressive disorder: a systematic review and meta‐analysis. Systematic Reviews2015;4:21. ">Meeker 2015</a>; <a href="./references#CD011520-bbs2-0083" title="ThaseME , MahableshwarkarAR , DragheimM , LoftH , VietaE . A meta‐analysis of randomized, placebo‐controlled trials of vortioxetine for the treatment of major depressive disorder in adults. European Neuropsychopharmacology2016;26(6):979‐93. ">Thase 2016</a>; <a href="./references#CD011520-bbs2-0089" title="ZhangJ , MathisMV , SellersJW , KordzakhiaG , JacksonAJ , DowA , et al. The US Food and Drug Administration's perspective on the new antidepressant vortioxetine. Journal of Clinical Psychiatry2015;76(1):8‐14. ">Zhang 2015</a>) showing that vortioxetine has a statistically significant advantage compared to placebo in terms of efficacy, but did not show an advantage compared to SNRIs. However, considering the quality of the evidence and other potential sources of bias, we suggest caution in the interpretation of efficacy data. This cautious interpretation is in line with findings from previous reviews, for example by not finding a clear dose‐response relationship (<a href="./references#CD011520-bbs2-0071" title="MeekerAS , HerinkMC , HaxbyDG , HartungDM . The safety and efficacy of vortioxetine for acute treatment of major depressive disorder: a systematic review and meta‐analysis. Systematic Reviews2015;4:21. ">Meeker 2015</a>; <a href="./references#CD011520-bbs2-0083" title="ThaseME , MahableshwarkarAR , DragheimM , LoftH , VietaE . A meta‐analysis of randomized, placebo‐controlled trials of vortioxetine for the treatment of major depressive disorder in adults. European Neuropsychopharmacology2016;26(6):979‐93. ">Thase 2016</a>), and the noteworthy finding that only high doses (20 mg/day) of vortioxetine were significantly superior to placebo in US populations (<a href="./references#CD011520-bbs2-0083" title="ThaseME , MahableshwarkarAR , DragheimM , LoftH , VietaE . A meta‐analysis of randomized, placebo‐controlled trials of vortioxetine for the treatment of major depressive disorder in adults. European Neuropsychopharmacology2016;26(6):979‐93. ">Thase 2016</a>; <a href="./references#CD011520-bbs2-0089" title="ZhangJ , MathisMV , SellersJW , KordzakhiaG , JacksonAJ , DowA , et al. The US Food and Drug Administration's perspective on the new antidepressant vortioxetine. Journal of Clinical Psychiatry2015;76(1):8‐14. ">Zhang 2015</a>). Furthermore, the findings that duloxetine was more effective than vortioxetine, and that there was no difference in terms of efficacy between vortioxetine and venlafaxine, are inconsistent with the evidence showing the superior efficacy of venlafaxine over duloxetine (<a href="./references#CD011520-bbs2-0041" title="CiprianiA , FurukawaTA , SalantiG , GeddesJR , HigginsJPT , ChurchillR , et al. Comparative efficacy and acceptability of 12 new‐generation antidepressants: a multiple‐treatments meta‐analysis. Lancet2009;373(9665):746‐58. ">Cipriani 2009</a>; <a href="./references#CD011520-bbs2-0079" title="SchuelerYB , KoestersM , WieselerB , GrouvenU , KrompM , KerekesMF , et al. A systematic review of duloxetine and venlafaxine in major depression, including unpublished data. Acta Psychiatrica Scandinavica2011;123(4):247‐65. ">Schueler 2011</a>). We are aware of the limitations of such an indirect comparison, but these inconsistencies raise some questions about the validity of the findings. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD011520-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011520.pub2/media/CDSR/CD011520/urn:x-wiley:14651858:media:CD011520:CD011520-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011520.pub2/media/CDSR/CD011520/image_t/tCD011520-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD011520-fig-0001" src="/cdsr/doi/10.1002/14651858.CD011520.pub2/media/CDSR/CD011520/image_n/nCD011520-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011520.pub2/full#CD011520-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011520.pub2/media/CDSR/CD011520/image_n/nCD011520-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011520-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011520.pub2/media/CDSR/CD011520/urn:x-wiley:14651858:media:CD011520:CD011520-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011520.pub2/media/CDSR/CD011520/image_t/tCD011520-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Countries participating in trials. The categories represent the number of studies randomising participants within a country." data-id="CD011520-fig-0002" src="/cdsr/doi/10.1002/14651858.CD011520.pub2/media/CDSR/CD011520/image_n/nCD011520-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Countries participating in trials. The categories represent the number of studies randomising participants within a country. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011520.pub2/full#CD011520-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011520.pub2/media/CDSR/CD011520/image_n/nCD011520-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011520-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011520.pub2/media/CDSR/CD011520/urn:x-wiley:14651858:media:CD011520:CD011520-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011520.pub2/media/CDSR/CD011520/image_t/tCD011520-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD011520-fig-0003" src="/cdsr/doi/10.1002/14651858.CD011520.pub2/media/CDSR/CD011520/image_n/nCD011520-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011520.pub2/full#CD011520-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011520.pub2/media/CDSR/CD011520/image_n/nCD011520-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011520-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011520.pub2/media/CDSR/CD011520/urn:x-wiley:14651858:media:CD011520:CD011520-AFig-FIG04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011520.pub2/media/CDSR/CD011520/image_t/tCD011520-AFig-FIG04.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD011520-fig-0004" src="/cdsr/doi/10.1002/14651858.CD011520.pub2/media/CDSR/CD011520/image_n/nCD011520-AFig-FIG04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011520.pub2/full#CD011520-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011520.pub2/media/CDSR/CD011520/image_n/nCD011520-AFig-FIG04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011520-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011520.pub2/media/CDSR/CD011520/urn:x-wiley:14651858:media:CD011520:CD011520-AFig-FIG05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011520.pub2/media/CDSR/CD011520/image_t/tCD011520-AFig-FIG05.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Vortioxetine versus placebo, outcome: 1.1 Response." data-id="CD011520-fig-0005" src="/cdsr/doi/10.1002/14651858.CD011520.pub2/media/CDSR/CD011520/image_n/nCD011520-AFig-FIG05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 5</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Vortioxetine versus placebo, outcome: 1.1 Response.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011520.pub2/full#CD011520-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011520.pub2/media/CDSR/CD011520/image_n/nCD011520-AFig-FIG05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011520-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011520.pub2/media/CDSR/CD011520/urn:x-wiley:14651858:media:CD011520:CD011520-AFig-FIG06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011520.pub2/media/CDSR/CD011520/image_t/tCD011520-AFig-FIG06.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Vortioxetine versus placebo, outcome: 1.2 Total number of dropouts." data-id="CD011520-fig-0006" src="/cdsr/doi/10.1002/14651858.CD011520.pub2/media/CDSR/CD011520/image_n/nCD011520-AFig-FIG06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 6</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Vortioxetine versus placebo, outcome: 1.2 Total number of dropouts. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011520.pub2/full#CD011520-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011520.pub2/media/CDSR/CD011520/image_n/nCD011520-AFig-FIG06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011520-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011520.pub2/media/CDSR/CD011520/urn:x-wiley:14651858:media:CD011520:CD011520-AFig-FIG07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011520.pub2/media/CDSR/CD011520/image_t/tCD011520-AFig-FIG07.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 3. Vortioxetine versus serotonin‐norepinephrine reuptake inhibitors, outcome: 3.1 Response." data-id="CD011520-fig-0007" src="/cdsr/doi/10.1002/14651858.CD011520.pub2/media/CDSR/CD011520/image_n/nCD011520-AFig-FIG07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 7</div> <div class="figure-caption"> <p>Forest plot of comparison: 3. Vortioxetine versus serotonin‐norepinephrine reuptake inhibitors, outcome: 3.1 Response. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011520.pub2/full#CD011520-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011520.pub2/media/CDSR/CD011520/image_n/nCD011520-AFig-FIG07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011520-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011520.pub2/media/CDSR/CD011520/urn:x-wiley:14651858:media:CD011520:CD011520-AFig-FIG08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011520.pub2/media/CDSR/CD011520/image_t/tCD011520-AFig-FIG08.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 3. Vortioxetine versus serotonin‐norepinephrine reuptake inhibitors, outcome: 3.2 Total number of dropouts." data-id="CD011520-fig-0008" src="/cdsr/doi/10.1002/14651858.CD011520.pub2/media/CDSR/CD011520/image_n/nCD011520-AFig-FIG08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 8</div> <div class="figure-caption"> <p>Forest plot of comparison: 3. Vortioxetine versus serotonin‐norepinephrine reuptake inhibitors, outcome: 3.2 Total number of dropouts. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011520.pub2/full#CD011520-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011520.pub2/media/CDSR/CD011520/image_n/nCD011520-AFig-FIG08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011520-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011520.pub2/media/CDSR/CD011520/urn:x-wiley:14651858:media:CD011520:CD011520-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011520.pub2/media/CDSR/CD011520/image_t/tCD011520-CMP-001-01.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Vortioxetine versus placebo, Outcome 1 Response." data-id="CD011520-fig-0009" src="/cdsr/doi/10.1002/14651858.CD011520.pub2/media/CDSR/CD011520/image_n/nCD011520-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Vortioxetine versus placebo, Outcome 1 Response.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011520.pub2/references#CD011520-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011520.pub2/media/CDSR/CD011520/image_n/nCD011520-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011520-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011520.pub2/media/CDSR/CD011520/urn:x-wiley:14651858:media:CD011520:CD011520-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011520.pub2/media/CDSR/CD011520/image_t/tCD011520-CMP-001-02.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Vortioxetine versus placebo, Outcome 2 Total number of dropouts." data-id="CD011520-fig-0010" src="/cdsr/doi/10.1002/14651858.CD011520.pub2/media/CDSR/CD011520/image_n/nCD011520-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Vortioxetine versus placebo, Outcome 2 Total number of dropouts.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011520.pub2/references#CD011520-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011520.pub2/media/CDSR/CD011520/image_n/nCD011520-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011520-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011520.pub2/media/CDSR/CD011520/urn:x-wiley:14651858:media:CD011520:CD011520-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011520.pub2/media/CDSR/CD011520/image_t/tCD011520-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Vortioxetine versus placebo, Outcome 3 Remission." data-id="CD011520-fig-0011" src="/cdsr/doi/10.1002/14651858.CD011520.pub2/media/CDSR/CD011520/image_n/nCD011520-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Vortioxetine versus placebo, Outcome 3 Remission.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011520.pub2/references#CD011520-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011520.pub2/media/CDSR/CD011520/image_n/nCD011520-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011520-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011520.pub2/media/CDSR/CD011520/urn:x-wiley:14651858:media:CD011520:CD011520-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011520.pub2/media/CDSR/CD011520/image_t/tCD011520-CMP-001-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Vortioxetine versus placebo, Outcome 4 Depressive symptoms." data-id="CD011520-fig-0012" src="/cdsr/doi/10.1002/14651858.CD011520.pub2/media/CDSR/CD011520/image_n/nCD011520-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 Vortioxetine versus placebo, Outcome 4 Depressive symptoms.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011520.pub2/references#CD011520-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011520.pub2/media/CDSR/CD011520/image_n/nCD011520-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011520-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011520.pub2/media/CDSR/CD011520/urn:x-wiley:14651858:media:CD011520:CD011520-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011520.pub2/media/CDSR/CD011520/image_t/tCD011520-CMP-001-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Vortioxetine versus placebo, Outcome 5 Dropout due to adverse events." data-id="CD011520-fig-0013" src="/cdsr/doi/10.1002/14651858.CD011520.pub2/media/CDSR/CD011520/image_n/nCD011520-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 Vortioxetine versus placebo, Outcome 5 Dropout due to adverse events.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011520.pub2/references#CD011520-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011520.pub2/media/CDSR/CD011520/image_n/nCD011520-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011520-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011520.pub2/media/CDSR/CD011520/urn:x-wiley:14651858:media:CD011520:CD011520-CMP-001-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011520.pub2/media/CDSR/CD011520/image_t/tCD011520-CMP-001-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Vortioxetine versus placebo, Outcome 6 Dropout due to inefficacy." data-id="CD011520-fig-0014" src="/cdsr/doi/10.1002/14651858.CD011520.pub2/media/CDSR/CD011520/image_n/nCD011520-CMP-001-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1 Vortioxetine versus placebo, Outcome 6 Dropout due to inefficacy.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011520.pub2/references#CD011520-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011520.pub2/media/CDSR/CD011520/image_n/nCD011520-CMP-001-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011520-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011520.pub2/media/CDSR/CD011520/urn:x-wiley:14651858:media:CD011520:CD011520-CMP-001-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011520.pub2/media/CDSR/CD011520/image_t/tCD011520-CMP-001-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Vortioxetine versus placebo, Outcome 7 Tolerability." data-id="CD011520-fig-0015" src="/cdsr/doi/10.1002/14651858.CD011520.pub2/media/CDSR/CD011520/image_n/nCD011520-CMP-001-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1 Vortioxetine versus placebo, Outcome 7 Tolerability.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011520.pub2/references#CD011520-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011520.pub2/media/CDSR/CD011520/image_n/nCD011520-CMP-001-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011520-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011520.pub2/media/CDSR/CD011520/urn:x-wiley:14651858:media:CD011520:CD011520-CMP-001-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011520.pub2/media/CDSR/CD011520/image_t/tCD011520-CMP-001-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Vortioxetine versus placebo, Outcome 8 Subgroup analysis: fixed vs flexible dosing ‐ response." data-id="CD011520-fig-0016" src="/cdsr/doi/10.1002/14651858.CD011520.pub2/media/CDSR/CD011520/image_n/nCD011520-CMP-001-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1 Vortioxetine versus placebo, Outcome 8 Subgroup analysis: fixed vs flexible dosing ‐ response. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011520.pub2/references#CD011520-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011520.pub2/media/CDSR/CD011520/image_n/nCD011520-CMP-001-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011520-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011520.pub2/media/CDSR/CD011520/urn:x-wiley:14651858:media:CD011520:CD011520-CMP-001-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011520.pub2/media/CDSR/CD011520/image_t/tCD011520-CMP-001-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Vortioxetine versus placebo, Outcome 9 Subgroup analysis: fixed vs flexible dosing ‐ total number of dropouts." data-id="CD011520-fig-0017" src="/cdsr/doi/10.1002/14651858.CD011520.pub2/media/CDSR/CD011520/image_n/nCD011520-CMP-001-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1 Vortioxetine versus placebo, Outcome 9 Subgroup analysis: fixed vs flexible dosing ‐ total number of dropouts. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011520.pub2/references#CD011520-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011520.pub2/media/CDSR/CD011520/image_n/nCD011520-CMP-001-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011520-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011520.pub2/media/CDSR/CD011520/urn:x-wiley:14651858:media:CD011520:CD011520-CMP-001-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011520.pub2/media/CDSR/CD011520/image_t/tCD011520-CMP-001-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Vortioxetine versus placebo, Outcome 10 Subgroup analysis: inclusion of older (aged &gt; 65 years) participants ‐ response." data-id="CD011520-fig-0018" src="/cdsr/doi/10.1002/14651858.CD011520.pub2/media/CDSR/CD011520/image_n/nCD011520-CMP-001-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.10</div> <div class="figure-caption"> <p>Comparison 1 Vortioxetine versus placebo, Outcome 10 Subgroup analysis: inclusion of older (aged &gt; 65 years) participants ‐ response. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011520.pub2/references#CD011520-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011520.pub2/media/CDSR/CD011520/image_n/nCD011520-CMP-001-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011520-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011520.pub2/media/CDSR/CD011520/urn:x-wiley:14651858:media:CD011520:CD011520-CMP-001-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011520.pub2/media/CDSR/CD011520/image_t/tCD011520-CMP-001-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Vortioxetine versus placebo, Outcome 11 Subgroup analysis: inclusion of older (aged &gt; 65 years) participants ‐ total number of dropouts." data-id="CD011520-fig-0019" src="/cdsr/doi/10.1002/14651858.CD011520.pub2/media/CDSR/CD011520/image_n/nCD011520-CMP-001-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.11</div> <div class="figure-caption"> <p>Comparison 1 Vortioxetine versus placebo, Outcome 11 Subgroup analysis: inclusion of older (aged &gt; 65 years) participants ‐ total number of dropouts. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011520.pub2/references#CD011520-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011520.pub2/media/CDSR/CD011520/image_n/nCD011520-CMP-001-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011520-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011520.pub2/media/CDSR/CD011520/urn:x-wiley:14651858:media:CD011520:CD011520-CMP-001-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011520.pub2/media/CDSR/CD011520/image_t/tCD011520-CMP-001-12.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Vortioxetine versus placebo, Outcome 12 Sensitivity analysis ‐ exclusion &gt; 20% dropouts ‐ response." data-id="CD011520-fig-0020" src="/cdsr/doi/10.1002/14651858.CD011520.pub2/media/CDSR/CD011520/image_n/nCD011520-CMP-001-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.12</div> <div class="figure-caption"> <p>Comparison 1 Vortioxetine versus placebo, Outcome 12 Sensitivity analysis ‐ exclusion &gt; 20% dropouts ‐ response. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011520.pub2/references#CD011520-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011520.pub2/media/CDSR/CD011520/image_n/nCD011520-CMP-001-12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011520-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011520.pub2/media/CDSR/CD011520/urn:x-wiley:14651858:media:CD011520:CD011520-CMP-001-13" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011520.pub2/media/CDSR/CD011520/image_t/tCD011520-CMP-001-13.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Vortioxetine versus placebo, Outcome 13 Sensitivity analysis ‐ exclusion &gt; 20% dropouts ‐ total number of dropouts." data-id="CD011520-fig-0021" src="/cdsr/doi/10.1002/14651858.CD011520.pub2/media/CDSR/CD011520/image_n/nCD011520-CMP-001-13.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.13</div> <div class="figure-caption"> <p>Comparison 1 Vortioxetine versus placebo, Outcome 13 Sensitivity analysis ‐ exclusion &gt; 20% dropouts ‐ total number of dropouts. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011520.pub2/references#CD011520-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011520.pub2/media/CDSR/CD011520/image_n/nCD011520-CMP-001-13.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011520-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011520.pub2/media/CDSR/CD011520/urn:x-wiley:14651858:media:CD011520:CD011520-CMP-001-14" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011520.pub2/media/CDSR/CD011520/image_t/tCD011520-CMP-001-14.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Vortioxetine versus placebo, Outcome 14 Adverse events." data-id="CD011520-fig-0022" src="/cdsr/doi/10.1002/14651858.CD011520.pub2/media/CDSR/CD011520/image_n/nCD011520-CMP-001-14.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.14</div> <div class="figure-caption"> <p>Comparison 1 Vortioxetine versus placebo, Outcome 14 Adverse events.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011520.pub2/references#CD011520-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011520.pub2/media/CDSR/CD011520/image_n/nCD011520-CMP-001-14.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011520-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011520.pub2/media/CDSR/CD011520/urn:x-wiley:14651858:media:CD011520:CD011520-CMP-001-15" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011520.pub2/media/CDSR/CD011520/image_t/tCD011520-CMP-001-15.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Vortioxetine versus placebo, Outcome 15 Serious adverse events." data-id="CD011520-fig-0023" src="/cdsr/doi/10.1002/14651858.CD011520.pub2/media/CDSR/CD011520/image_n/nCD011520-CMP-001-15.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.15</div> <div class="figure-caption"> <p>Comparison 1 Vortioxetine versus placebo, Outcome 15 Serious adverse events.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011520.pub2/references#CD011520-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011520.pub2/media/CDSR/CD011520/image_n/nCD011520-CMP-001-15.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011520-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011520.pub2/media/CDSR/CD011520/urn:x-wiley:14651858:media:CD011520:CD011520-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011520.pub2/media/CDSR/CD011520/image_t/tCD011520-CMP-002-01.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Vortioxetine versus serotonin‐norepinephrine reuptake inhibitors (SNRIs), Outcome 1 Response." data-id="CD011520-fig-0024" src="/cdsr/doi/10.1002/14651858.CD011520.pub2/media/CDSR/CD011520/image_n/nCD011520-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 Vortioxetine versus serotonin‐norepinephrine reuptake inhibitors (SNRIs), Outcome 1 Response. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011520.pub2/references#CD011520-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011520.pub2/media/CDSR/CD011520/image_n/nCD011520-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011520-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011520.pub2/media/CDSR/CD011520/urn:x-wiley:14651858:media:CD011520:CD011520-CMP-002-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011520.pub2/media/CDSR/CD011520/image_t/tCD011520-CMP-002-02.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Vortioxetine versus serotonin‐norepinephrine reuptake inhibitors (SNRIs), Outcome 2 Total number of dropouts." data-id="CD011520-fig-0025" src="/cdsr/doi/10.1002/14651858.CD011520.pub2/media/CDSR/CD011520/image_n/nCD011520-CMP-002-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2 Vortioxetine versus serotonin‐norepinephrine reuptake inhibitors (SNRIs), Outcome 2 Total number of dropouts. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011520.pub2/references#CD011520-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011520.pub2/media/CDSR/CD011520/image_n/nCD011520-CMP-002-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011520-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011520.pub2/media/CDSR/CD011520/urn:x-wiley:14651858:media:CD011520:CD011520-CMP-002-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011520.pub2/media/CDSR/CD011520/image_t/tCD011520-CMP-002-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Vortioxetine versus serotonin‐norepinephrine reuptake inhibitors (SNRIs), Outcome 3 Remission." data-id="CD011520-fig-0026" src="/cdsr/doi/10.1002/14651858.CD011520.pub2/media/CDSR/CD011520/image_n/nCD011520-CMP-002-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2 Vortioxetine versus serotonin‐norepinephrine reuptake inhibitors (SNRIs), Outcome 3 Remission. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011520.pub2/references#CD011520-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011520.pub2/media/CDSR/CD011520/image_n/nCD011520-CMP-002-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011520-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011520.pub2/media/CDSR/CD011520/urn:x-wiley:14651858:media:CD011520:CD011520-CMP-002-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011520.pub2/media/CDSR/CD011520/image_t/tCD011520-CMP-002-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Vortioxetine versus serotonin‐norepinephrine reuptake inhibitors (SNRIs), Outcome 4 Depressive symptoms." data-id="CD011520-fig-0027" src="/cdsr/doi/10.1002/14651858.CD011520.pub2/media/CDSR/CD011520/image_n/nCD011520-CMP-002-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2 Vortioxetine versus serotonin‐norepinephrine reuptake inhibitors (SNRIs), Outcome 4 Depressive symptoms. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011520.pub2/references#CD011520-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011520.pub2/media/CDSR/CD011520/image_n/nCD011520-CMP-002-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011520-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011520.pub2/media/CDSR/CD011520/urn:x-wiley:14651858:media:CD011520:CD011520-CMP-002-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011520.pub2/media/CDSR/CD011520/image_t/tCD011520-CMP-002-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Vortioxetine versus serotonin‐norepinephrine reuptake inhibitors (SNRIs), Outcome 5 Dropout due to adverse events." data-id="CD011520-fig-0028" src="/cdsr/doi/10.1002/14651858.CD011520.pub2/media/CDSR/CD011520/image_n/nCD011520-CMP-002-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2 Vortioxetine versus serotonin‐norepinephrine reuptake inhibitors (SNRIs), Outcome 5 Dropout due to adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011520.pub2/references#CD011520-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011520.pub2/media/CDSR/CD011520/image_n/nCD011520-CMP-002-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011520-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011520.pub2/media/CDSR/CD011520/urn:x-wiley:14651858:media:CD011520:CD011520-CMP-002-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011520.pub2/media/CDSR/CD011520/image_t/tCD011520-CMP-002-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Vortioxetine versus serotonin‐norepinephrine reuptake inhibitors (SNRIs), Outcome 6 Dropout due to inefficacy." data-id="CD011520-fig-0029" src="/cdsr/doi/10.1002/14651858.CD011520.pub2/media/CDSR/CD011520/image_n/nCD011520-CMP-002-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.6</div> <div class="figure-caption"> <p>Comparison 2 Vortioxetine versus serotonin‐norepinephrine reuptake inhibitors (SNRIs), Outcome 6 Dropout due to inefficacy. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011520.pub2/references#CD011520-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011520.pub2/media/CDSR/CD011520/image_n/nCD011520-CMP-002-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011520-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011520.pub2/media/CDSR/CD011520/urn:x-wiley:14651858:media:CD011520:CD011520-CMP-002-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011520.pub2/media/CDSR/CD011520/image_t/tCD011520-CMP-002-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Vortioxetine versus serotonin‐norepinephrine reuptake inhibitors (SNRIs), Outcome 7 Tolerability." data-id="CD011520-fig-0030" src="/cdsr/doi/10.1002/14651858.CD011520.pub2/media/CDSR/CD011520/image_n/nCD011520-CMP-002-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.7</div> <div class="figure-caption"> <p>Comparison 2 Vortioxetine versus serotonin‐norepinephrine reuptake inhibitors (SNRIs), Outcome 7 Tolerability. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011520.pub2/references#CD011520-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011520.pub2/media/CDSR/CD011520/image_n/nCD011520-CMP-002-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011520-fig-0031"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011520.pub2/media/CDSR/CD011520/urn:x-wiley:14651858:media:CD011520:CD011520-CMP-002-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011520.pub2/media/CDSR/CD011520/image_t/tCD011520-CMP-002-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Vortioxetine versus serotonin‐norepinephrine reuptake inhibitors (SNRIs), Outcome 8 Subgroup analysis: fixed vs flexible dosing ‐ response." data-id="CD011520-fig-0031" src="/cdsr/doi/10.1002/14651858.CD011520.pub2/media/CDSR/CD011520/image_n/nCD011520-CMP-002-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.8</div> <div class="figure-caption"> <p>Comparison 2 Vortioxetine versus serotonin‐norepinephrine reuptake inhibitors (SNRIs), Outcome 8 Subgroup analysis: fixed vs flexible dosing ‐ response. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011520.pub2/references#CD011520-fig-0031">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011520.pub2/media/CDSR/CD011520/image_n/nCD011520-CMP-002-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011520-fig-0032"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011520.pub2/media/CDSR/CD011520/urn:x-wiley:14651858:media:CD011520:CD011520-CMP-002-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011520.pub2/media/CDSR/CD011520/image_t/tCD011520-CMP-002-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Vortioxetine versus serotonin‐norepinephrine reuptake inhibitors (SNRIs), Outcome 9 Subgroup analysis: fixed vs flexible dosing ‐ total number of dropouts." data-id="CD011520-fig-0032" src="/cdsr/doi/10.1002/14651858.CD011520.pub2/media/CDSR/CD011520/image_n/nCD011520-CMP-002-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.9</div> <div class="figure-caption"> <p>Comparison 2 Vortioxetine versus serotonin‐norepinephrine reuptake inhibitors (SNRIs), Outcome 9 Subgroup analysis: fixed vs flexible dosing ‐ total number of dropouts. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011520.pub2/references#CD011520-fig-0032">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011520.pub2/media/CDSR/CD011520/image_n/nCD011520-CMP-002-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011520-fig-0033"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011520.pub2/media/CDSR/CD011520/urn:x-wiley:14651858:media:CD011520:CD011520-CMP-002-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011520.pub2/media/CDSR/CD011520/image_t/tCD011520-CMP-002-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Vortioxetine versus serotonin‐norepinephrine reuptake inhibitors (SNRIs), Outcome 10 Subgroup analysis: inclusion of older (aged &gt; 65 years) participants ‐ response." data-id="CD011520-fig-0033" src="/cdsr/doi/10.1002/14651858.CD011520.pub2/media/CDSR/CD011520/image_n/nCD011520-CMP-002-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.10</div> <div class="figure-caption"> <p>Comparison 2 Vortioxetine versus serotonin‐norepinephrine reuptake inhibitors (SNRIs), Outcome 10 Subgroup analysis: inclusion of older (aged &gt; 65 years) participants ‐ response. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011520.pub2/references#CD011520-fig-0033">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011520.pub2/media/CDSR/CD011520/image_n/nCD011520-CMP-002-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011520-fig-0034"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011520.pub2/media/CDSR/CD011520/urn:x-wiley:14651858:media:CD011520:CD011520-CMP-002-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011520.pub2/media/CDSR/CD011520/image_t/tCD011520-CMP-002-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Vortioxetine versus serotonin‐norepinephrine reuptake inhibitors (SNRIs), Outcome 11 Subgroup analysis: inclusion of older (aged &gt; 65 years) participants ‐ total number of dropouts." data-id="CD011520-fig-0034" src="/cdsr/doi/10.1002/14651858.CD011520.pub2/media/CDSR/CD011520/image_n/nCD011520-CMP-002-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.11</div> <div class="figure-caption"> <p>Comparison 2 Vortioxetine versus serotonin‐norepinephrine reuptake inhibitors (SNRIs), Outcome 11 Subgroup analysis: inclusion of older (aged &gt; 65 years) participants ‐ total number of dropouts. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011520.pub2/references#CD011520-fig-0034">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011520.pub2/media/CDSR/CD011520/image_n/nCD011520-CMP-002-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011520-fig-0035"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011520.pub2/media/CDSR/CD011520/urn:x-wiley:14651858:media:CD011520:CD011520-CMP-002-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011520.pub2/media/CDSR/CD011520/image_t/tCD011520-CMP-002-12.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Vortioxetine versus serotonin‐norepinephrine reuptake inhibitors (SNRIs), Outcome 12 Sensitivity analysis ‐ unequal dosing ‐ response." data-id="CD011520-fig-0035" src="/cdsr/doi/10.1002/14651858.CD011520.pub2/media/CDSR/CD011520/image_n/nCD011520-CMP-002-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.12</div> <div class="figure-caption"> <p>Comparison 2 Vortioxetine versus serotonin‐norepinephrine reuptake inhibitors (SNRIs), Outcome 12 Sensitivity analysis ‐ unequal dosing ‐ response. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011520.pub2/references#CD011520-fig-0035">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011520.pub2/media/CDSR/CD011520/image_n/nCD011520-CMP-002-12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011520-fig-0036"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011520.pub2/media/CDSR/CD011520/urn:x-wiley:14651858:media:CD011520:CD011520-CMP-002-13" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011520.pub2/media/CDSR/CD011520/image_t/tCD011520-CMP-002-13.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Vortioxetine versus serotonin‐norepinephrine reuptake inhibitors (SNRIs), Outcome 13 Sensitivity analysis ‐ unequal dosing ‐ total number of dropouts." data-id="CD011520-fig-0036" src="/cdsr/doi/10.1002/14651858.CD011520.pub2/media/CDSR/CD011520/image_n/nCD011520-CMP-002-13.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.13</div> <div class="figure-caption"> <p>Comparison 2 Vortioxetine versus serotonin‐norepinephrine reuptake inhibitors (SNRIs), Outcome 13 Sensitivity analysis ‐ unequal dosing ‐ total number of dropouts. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011520.pub2/references#CD011520-fig-0036">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011520.pub2/media/CDSR/CD011520/image_n/nCD011520-CMP-002-13.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011520-fig-0037"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011520.pub2/media/CDSR/CD011520/urn:x-wiley:14651858:media:CD011520:CD011520-CMP-002-14" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011520.pub2/media/CDSR/CD011520/image_t/tCD011520-CMP-002-14.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Vortioxetine versus serotonin‐norepinephrine reuptake inhibitors (SNRIs), Outcome 14 Sensitivity analysis ‐ exclusion &gt; 20% dropouts ‐ response." data-id="CD011520-fig-0037" src="/cdsr/doi/10.1002/14651858.CD011520.pub2/media/CDSR/CD011520/image_n/nCD011520-CMP-002-14.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.14</div> <div class="figure-caption"> <p>Comparison 2 Vortioxetine versus serotonin‐norepinephrine reuptake inhibitors (SNRIs), Outcome 14 Sensitivity analysis ‐ exclusion &gt; 20% dropouts ‐ response. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011520.pub2/references#CD011520-fig-0037">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011520.pub2/media/CDSR/CD011520/image_n/nCD011520-CMP-002-14.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011520-fig-0038"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011520.pub2/media/CDSR/CD011520/urn:x-wiley:14651858:media:CD011520:CD011520-CMP-002-15" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011520.pub2/media/CDSR/CD011520/image_t/tCD011520-CMP-002-15.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Vortioxetine versus serotonin‐norepinephrine reuptake inhibitors (SNRIs), Outcome 15 Sensitivity analysis ‐ exclusion &gt; 20% dropouts ‐ total number of dropouts." data-id="CD011520-fig-0038" src="/cdsr/doi/10.1002/14651858.CD011520.pub2/media/CDSR/CD011520/image_n/nCD011520-CMP-002-15.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.15</div> <div class="figure-caption"> <p>Comparison 2 Vortioxetine versus serotonin‐norepinephrine reuptake inhibitors (SNRIs), Outcome 15 Sensitivity analysis ‐ exclusion &gt; 20% dropouts ‐ total number of dropouts. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011520.pub2/references#CD011520-fig-0038">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011520.pub2/media/CDSR/CD011520/image_n/nCD011520-CMP-002-15.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011520-fig-0039"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011520.pub2/media/CDSR/CD011520/urn:x-wiley:14651858:media:CD011520:CD011520-CMP-002-16" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011520.pub2/media/CDSR/CD011520/image_t/tCD011520-CMP-002-16.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Vortioxetine versus serotonin‐norepinephrine reuptake inhibitors (SNRIs), Outcome 16 Adverse events." data-id="CD011520-fig-0039" src="/cdsr/doi/10.1002/14651858.CD011520.pub2/media/CDSR/CD011520/image_n/nCD011520-CMP-002-16.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.16</div> <div class="figure-caption"> <p>Comparison 2 Vortioxetine versus serotonin‐norepinephrine reuptake inhibitors (SNRIs), Outcome 16 Adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011520.pub2/references#CD011520-fig-0039">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011520.pub2/media/CDSR/CD011520/image_n/nCD011520-CMP-002-16.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011520-fig-0040"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011520.pub2/media/CDSR/CD011520/urn:x-wiley:14651858:media:CD011520:CD011520-CMP-002-17" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011520.pub2/media/CDSR/CD011520/image_t/tCD011520-CMP-002-17.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Vortioxetine versus serotonin‐norepinephrine reuptake inhibitors (SNRIs), Outcome 17 Serious adverse events." data-id="CD011520-fig-0040" src="/cdsr/doi/10.1002/14651858.CD011520.pub2/media/CDSR/CD011520/image_n/nCD011520-CMP-002-17.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.17</div> <div class="figure-caption"> <p>Comparison 2 Vortioxetine versus serotonin‐norepinephrine reuptake inhibitors (SNRIs), Outcome 17 Serious adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011520.pub2/references#CD011520-fig-0040">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011520.pub2/media/CDSR/CD011520/image_n/nCD011520-CMP-002-17.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD011520-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Vortioxetine compared to Placebo for adults with Major Depressive Disorder</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Vortioxetine compared to Placebo for adults with Major Depressive Disorder</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> adults with Major Depressive Disorder<br/> <b>Setting:</b> Inpatients and outpatients<br/> <b>Intervention:</b> Vortioxetine<br/> <b>Comparison:</b> Placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with Placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with Vortioxetine</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Response<br/> assessed with: reduction of at least 50% on the HAMD scale or MADRS scale, or any other score 1 or 2 on CGI‐I<br/> follow up: range 6 weeks to 8 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.35<br/> (1.22 to 1.49) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>6220<br/> (14 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>All studies were sponsored by the pharmaceutical companies that manufacture vortioxetine. Small difference favouring vortioxetine. </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>356 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>480 per 1,000<br/> (434 to 530) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Total number of drop‐outs<br/> follow up: range 6 weeks to 8 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.05<br/> (0.93 to 1.19) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>6220<br/> (14 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>No difference between vortioxetine and placebo.</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>160 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>168 per 1,000<br/> (149 to 190) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Remission<br/> assessed with: 7 points or less on the 17‐item HAM‐D and 8 points or less for longer HAM‐D versions; 10 or less points on the MADRS; score 1 or 2 on CGI‐S<br/> follow up: range 6 weeks to 8 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.33<br/> (1.15 to 1.53) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>6217<br/> (14 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Small difference favouring vortioxetine.</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>224 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>299 per 1,000<br/> (258 to 343) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Depressive Symptoms<br/> assessed with: MADRS score (score range: 0‐34; higher score means worse outcome)<br/> follow up: range 6 weeks to 8 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The change in depressive symptoms score ranged from 10.8 to 15.9 points</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The change was 2.94 points higher<br/> (1.8 higher to 4.07 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5566<br/> (14 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>1 3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Small difference favouring vortioxetine.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Drop‐out due to adverse events<br/> follow up: range 6 weeks to 8 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.41<br/> (1.09 to 1.81) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>6220<br/> (14 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Small difference favouring placebo.</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>38 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>53 per 1,000<br/> (41 to 68) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Drop‐out due to inefficacy<br/> follow up: range 6 weeks to 8 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.56<br/> (0.34 to 0.90) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>6220<br/> (14 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Small difference favouring vortioxetine.</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>31 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>18 per 1,000<br/> (11 to 28) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Tolerability</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.12<br/> (1.07 to 1.16) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>6182<br/> (14 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Small difference favouring placebo</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>564 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>632 per 1,000<br/> (603 to 654) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; <b>OR:</b> Odds ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> A serious risk of bias is present, as about 30% of the studies showed an overall dropout rate above 20%, evidence was downgraded by one level </p> <p><sup>2</sup> A moderate degree of heterogeneity (I‐squared 30‐60%) is present, evidence was downgraded by one level </p> <p><sup>3</sup> A substantial degree of heterogeneity (I‐squared 60‐90%) is present, evidence was downgraded by two levels </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Vortioxetine compared to Placebo for adults with Major Depressive Disorder</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011520.pub2/full#CD011520-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD011520-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Vortioxetine compared to SNRIs for adults with Major Depressive Disorder</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Vortioxetine compared to SNRIs for adults with Major Depressive Disorder</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> adults with Major Depressive Disorder<br/> <b>Setting:</b> Inpatients and outpatients<br/> <b>Intervention:</b> Vortioxetine<br/> <b>Comparison:</b> SNRIs </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with SNRIs</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with Vortioxetine</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Response<br/> assessed with: assessed with: reduction of at least 50% on the HAMD scale or MADRS scale, or any other score 1 or 2 on CGI‐I<br/> follow up: range 6 weeks to 8 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.91<br/> (0.82 to 1.00) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>3159<br/> (8 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>1 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>All studies were sponsored by the pharmaceutical companies that manufacture vortioxetine. No difference between vortioxetine and SNRIs. </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>577 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>525 per 1,000<br/> (473 to 577) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Total number of drop‐outs<br/> follow up: range 6 weeks to 8 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.89<br/> (0.73 to 1.08) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>3159<br/> (8 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>1 3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>No difference between vortioxetine and SNRIs.</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>212 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>189 per 1,000<br/> (155 to 229) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Remission<br/> assessed with: 7 points or less on the 17‐item HAM‐D and 8 points or less for longer HAM‐D versions; 10 or less points on the MADRS; score 1 or 2 on CGI‐S<br/> follow up: range 6 weeks to 8 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.89<br/> (0.77 to 1.03) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>3155<br/> (8 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>1 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>No difference between vortioxetine and SNRIs.</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>370 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>329 per 1,000<br/> (285 to 381) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Depressive Symptoms<br/> assessed with: MADRS score (score range: 0‐34; higher score means worse outcome)<br/> follow up: range 6 weeks to 8 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The change in depressive symptoms score ranged from 14.1 to 23.4 points</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The change was 1.52 points lower<br/> (0.5 lower to 2.53 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2807<br/> (8 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>1 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Small difference favouring SNRIs.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Drop‐out due to adverse events<br/> follow up: range 6 weeks to 8 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.74<br/> (0.51 to 1.08) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>3159<br/> (8 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>1 2 3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>No difference between vortioxetine and SNRIs.</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>97 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>72 per 1,000<br/> (50 to 105) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Drop‐out due to inefficacy<br/> follow up: range 6 weeks to 8 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.52<br/> (0.70 to 3.30) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>3159<br/> (8 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>1 4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>No difference between vortioxetine and SNRIs.</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>14 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>21 per 1,000<br/> (10 to 45) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Tolerability</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.90<br/> (0.86 to 0.94) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>3134<br/> (8 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Small difference favouring vortioxetine</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>690 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>621 per 1,000<br/> (593 to 648) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; <b>OR:</b> Odds ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> A very serious risk of bias is present as 60% of the studies had more than 20% dropouts overall, evidence was downgraded by two levels </p> <p><sup>2</sup> A moderate degree of heterogeneity (I‐squared 30‐60%) is present, evidence was downgraded by one level </p> <p><sup>3</sup> The 95% CI crossed both 1 (no differences) and 0.75 (appreciable benefit for vortioxetine), evidence was downgraded by one level </p> <p><sup>4</sup> The 95% CI crossed 1 (no differences), 0.75 (appreciable benefit for vortioxetine) and 1.25 (appreciable benefit for SNRIs). Outcome is very imprecise: evidence was downgraded by two levels </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Vortioxetine compared to SNRIs for adults with Major Depressive Disorder</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011520.pub2/full#CD011520-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011520-tbl-0003"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Vortioxetine versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Response <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6220</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.35 [1.22, 1.49]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Total number of dropouts <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6220</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.05 [0.93, 1.19]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Remission <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6220</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.32 [1.15, 1.53]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Depressive symptoms <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5566</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.94 [‐4.07, ‐1.80]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Dropout due to adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6220</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.41 [1.09, 1.81]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Dropout due to inefficacy <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6220</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.56 [0.34, 0.90]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Tolerability <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6182</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.12 [1.07, 1.16]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Subgroup analysis: fixed vs flexible dosing ‐ response <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6220</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.35 [1.22, 1.49]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 Fixed dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5513</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.35 [1.19, 1.52]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.2 Flexible dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>707</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.38 [1.16, 1.63]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Subgroup analysis: fixed vs flexible dosing ‐ total number of dropouts <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6220</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.05 [0.93, 1.19]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1 Fixed dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5513</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.07 [0.94, 1.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.2 Flexible dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>707</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.64, 1.30]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Subgroup analysis: inclusion of older (aged &gt; 65 years) participants ‐ response <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4525</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.38 [1.24, 1.54]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.1 Older participants included</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2616</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.34 [1.15, 1.55]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.2 Older participants excluded</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1909</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.45 [1.23, 1.71]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Subgroup analysis: inclusion of older (aged &gt; 65 years) participants ‐ total number of dropouts <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4528</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.11 [0.96, 1.28]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.1 Older participants included</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2619</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.25 [1.05, 1.49]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.2 Older participants excluded</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1909</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.71, 1.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 Sensitivity analysis ‐ exclusion &gt; 20% dropouts ‐ response <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6220</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.35 [1.22, 1.49]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.1 &lt; 20% dropouts</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3927</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.41 [1.26, 1.57]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.2 &gt; 20% dropouts</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2293</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.26 [1.03, 1.52]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13 Sensitivity analysis ‐ exclusion &gt; 20% dropouts ‐ total number of dropouts <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6220</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.05 [0.93, 1.19]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.1 &lt; 20% dropout</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3927</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.86, 1.21]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.2 &gt; 20% dropout</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2293</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.08 [0.91, 1.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14 Adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.1 Constipation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.2 Nausea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.3 Diarrhoea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.4 Dry mouth</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.5 Vomiting</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.6 Abdominal pain upper</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.7 Dyspepsia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.8 Gastro‐oesophageal reflux disease</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.9 Abdominal discomfort</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.10 Abdominal pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.11 Stomach discomfort</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.12 Flatulence</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.13 Fatigue</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.14 Pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.15 Thirst</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.16 Irritability</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.17 Decreased appetite</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.18 Increased appetite</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.19 Anorexia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.20 Headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.21 Dizziness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.22 Somnolence</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.23 Tremor</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.24 Sedation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.25 Dysgeusia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.26 Hypoaesthesia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.27 Poor‐quality sleep</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.28 Ejaculation delayed (men)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.29 Erectile dysfunction (men)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.30 Dysmenorrhoea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.31 Hyperhidrosis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.32 Pruritus generalised</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.33 Pruritus</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.34 Vision blurred</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.35 Nasopharyngitis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.36 Influenza</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.37 Respiratory tract infection</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.38 Gastroenteritis viral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.39 Sinusitis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.40 Urinary tract infection</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.41 Bronchitis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.42 Anorgasmia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.43 Insomnia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.44 Restlessness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.45 Abnormal dreams</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.46 Anxiety</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.47 Depression</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.48 Libido decreased</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.49 Orgasm abnormal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.50 Nightmare</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.51 Middle insomnia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.52 Suicidal ideation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.53 Tachycardia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.54 Palpitations</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.55 Tinnitus</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.56 Back pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.57 Arthralgia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.58 Myalgia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.59 Musculoskeletal pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.60 Muscle spasms</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.61 Pain in extremity</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.62 Hypertension</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.63 Hot flush</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.64 Fall</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.65 Ligament sprain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.66 Muscle strain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.67 Accidental overdose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.68 Road traffic accident</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.69 Nasal congestion</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.70 Yawning</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.71 Rhinorrhoea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.72 Oropharyngeal pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.73 Weight decreased</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.74 Blood pressure increased</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.75 Hepatic function abnormal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15 Serious adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.1 Varicella zoster infection</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.2 Kidney infection</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.3 Herpes zoster infection</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.4 Puncture site infection</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.5 Gastroenteritis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.6 Pyelonephritis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.7 Brain tumour</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.8 Gallbladder cancer</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.9 Colon cancer</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.10 Laryngeal cancer</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.11 Renal cell carcinoma</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.12 Bile duct cancer</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.13 Prostate cancer</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.14 Breast cancer recurrent</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.15 Worsening of major depressive disorder</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.16 Suicidal ideation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.17 Suicide attempt</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.18 Intentional self‐injury</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.19 Self‐injurious behaviour</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.20 Panic attack</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.21 Suicidal behaviour</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.22 Middle ear effusion</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.23 Jaundice cholestatic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.24 Cholecystitis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.25 Pelvic fracture</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.26 Intentional overdose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.27 Lumbar vertebral fracture</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.28 Injury</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.29 Hip fracture</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.30 Head injury</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.31 Stress fracture</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.32 Craniocerebral injury</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.33 Subdural haematoma</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.34 Brain contusion</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.35 Road traffic accident</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.36 Serotonin syndrome</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.37 Dizziness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.38 Cerebrovascular accident</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.39 Convulsion</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.40 Transient ischaemic attack</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.41 Lumbar radiculopathy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.42 Syncope</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.43 Cerebral haematoma</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.44 Subarachnoid haemorrhage</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.45 Adenomyosis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.46 Vaginal haemorrhage</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.47 Pulmonary embolism</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.48 Blood pressure decreased</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.49 Tachycardia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.50 Acute myocardial infarction</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.51 Atrial fibrillation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.52 Coronary artery disease</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.53 Pancreatitis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.54 Hiatus hernia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.55 Drug hypersensitivity</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.56 Abortion spontaneous</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.57 Ectopic pregnancy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.58 Abortion missed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.59 Abortion induced</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.60 Type 1 diabetes mellitus</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.61 Hypertension</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.62 Renal colic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Vortioxetine versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011520.pub2/references#CD011520-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011520-tbl-0004"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Vortioxetine versus serotonin‐norepinephrine reuptake inhibitors (SNRIs)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Response <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3159</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.82, 1.00]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Vortioxetine vs venlafaxine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>767</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.85, 1.25]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Vortioxetine vs duloxetine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2392</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.86 [0.79, 0.94]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Total number of dropouts <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3159</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.73, 1.08]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Vortioxetine vs venlafaxine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>767</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.70 [0.52, 0.93]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Vortioxetine vs duloxetine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2392</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.76, 1.21]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Remission <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3155</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.77, 1.03]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Vortioxetine vs venlafaxine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>767</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.81, 1.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Vortioxetine vs duloxetine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2388</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.85 [0.70, 1.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Depressive symptoms <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2807</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.52 [0.50, 2.53]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Vortioxetine vs venlafaxine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>701</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.02 [‐2.49, 2.54]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Vortioxetine vs duloxetine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2106</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.99 [1.15, 2.83]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Dropout due to adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3159</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.74 [0.51, 1.08]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Vortioxetine vs venlafaxine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>767</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.42 [0.26, 0.67]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 Vortioxetine vs duloxetine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2392</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.65, 1.31]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Dropout due to inefficacy <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3159</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.52 [0.70, 3.30]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 Vortioxetine vs venlafaxine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>767</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.68 [0.99, 7.24]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 Vortioxetine vs duloxetine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2392</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.16 [0.41, 3.31]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Tolerability <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3134</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.86, 0.94]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 Vortioxetine vs venlafaxine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>758</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.82, 1.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2 Vortioxetine vs duloxetine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2376</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.84, 0.95]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Subgroup analysis: fixed vs flexible dosing ‐ response <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3159</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.82, 1.00]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 Fixed dosing</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2751</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.81, 1.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.2 Flexible dosing</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>408</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.75, 1.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Subgroup analysis: fixed vs flexible dosing ‐ total number of dropouts <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3159</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.73, 1.08]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1 Fixed dosing</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2751</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.71, 1.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.2 Flexible dosing</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>408</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.60, 1.47]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Subgroup analysis: inclusion of older (aged &gt; 65 years) participants ‐ response <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2850</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.83, 1.03]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.1 Older participants included</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1675</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.77, 0.98]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.2 Older participants excluded</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1175</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.88, 1.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Subgroup analysis: inclusion of older (aged &gt; 65 years) participants ‐ total number of dropouts <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2854</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.74, 1.15]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.1 Older participants included</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1679</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.05 [0.76, 1.45]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.2 Older participants excluded</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1175</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.76 [0.60, 0.97]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 Sensitivity analysis ‐ unequal dosing ‐ response <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3159</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.82, 1.00]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.1 Equal dosing</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>912</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.09 [0.97, 1.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.2 Vortioxetine dose higher</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>903</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.80 [0.72, 0.90]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.3 Vortioxetine dose lower</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>936</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.78, 0.98]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.4 Flexible vs fixed dosing</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>408</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.75, 1.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13 Sensitivity analysis ‐ unequal dosing ‐ total number of dropouts <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3159</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.73, 1.08]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.1 Equal dosing</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>912</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.75 [0.59, 0.96]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.2 Vortioxetine dose higher</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>903</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.33 [0.74, 2.39]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.3 Vortioxetine dose lower</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>936</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.77 [0.59, 1.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.4 Flexible vs fixed dosing</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>408</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.60, 1.47]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14 Sensitivity analysis ‐ exclusion &gt; 20% dropouts ‐ response <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3159</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.82, 1.00]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.1 &lt; 20% dropouts</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1039</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.82, 1.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.2 &gt; 20% dropouts</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2120</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.77, 1.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15 Sensitivity analysis ‐ exclusion &gt; 20% dropouts ‐ total number of dropouts <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3159</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.73, 1.08]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.1 &lt; 20% dropouts</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1039</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.86 [0.64, 1.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.2 &gt; 20% dropouts</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2120</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.68, 1.24]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">16 Adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.1 Constipation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.2 Diarrhoea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.3 Dry mouth</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.4 Nausea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.5 Vomiting</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.6 Abdominal pain upper</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.7 Dyspepsia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.8 Abdominal discomfort</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.9 Abdominal pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.10 Stomach discomfort</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.11 Flatulence</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.12 Fatigue</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.13 Irritability</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.14 Decreased appetite</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.15 Anorexia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.16 Dizziness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.17 Headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.18 Somnolence</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.19 Tremor</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.20 Sedation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.21 Dysgeusia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.22 Poor quality sleep</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.23 Ejaculation delayed (men)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.24 Erectile dysfunction (men)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.25 Hyperhidrosis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.26 Vision blurred</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.27 Nasopharyngitis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.28 Upper respiratory tract infection</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.29 Gastroenteritis viral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.30 Urinary tract infection bacterial</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.31 Anorgasmia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.32 Insomnia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.33 Restlessness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.34 Abnormal dreams</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.35 Anxiety</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.36 Depression</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.37 Libido decreased</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.38 Orgasm abnormal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.39 Nightmare</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.40 Middle insomnia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.41 Palpitations</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.42 Tinnitus</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.43 Back pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.44 Arthralgia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.45 Myalgia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.46 Musculoskeletal pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.47 Muscle spasms</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.48 Pain in extremity</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.49 Hot flush</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.50 Fall</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.51 Muscle strain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.52 Accidental overdose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.53 Yawning</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.54 Rhinorrhoea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.55 Weight decreased</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.56 Blood pressure increased</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.57 Heart rate increased</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">17 Serious adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.1 Varicella zoster infection</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.2 Brain tumour</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.3 Gallbladder cancer</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.4 Bile duct cancer</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.5 Prostate cancer</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.6 Worsening of major depressive disorder</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.7 Suicidal ideation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.8 Suicide attempt</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.9 Intentional self‐injury</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.10 Self‐injurious behaviour</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.11 Panic attack</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.12 Anxiety</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.13 Middle ear effusion</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.14 Vertigo positional</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.15 Jaundice cholestatic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.16 Pelvic fracture</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.17 Intentional overdose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.18 Lumbar vertebral fracture</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.19 Hip fracture</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.20 Head injury</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.21 Stress fracture</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.22 Craniocerebral injury</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.23 Subdural haematoma</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.24 Asthenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.25 Serotonin syndrome</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.26 Dizziness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.27 Convulsion</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.28 Transient ischaemic attack</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.29 Adenomyosis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.30 Vaginal haemorrhage</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.31 Varicocele</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.32 Pulmonary embolism</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.33 Blood pressure decreased</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.34 Acute myocardial infarction</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.35 Atrial fibrillation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.36 Coronary artery disease</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.37 Abortion induced</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.38 Ligament sprain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Vortioxetine versus serotonin‐norepinephrine reuptake inhibitors (SNRIs)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011520.pub2/references#CD011520-tbl-0004">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD011520.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD011520-note-0006">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD011520-note-0012">فارسی</a> </li> <li class="section-language"> <a class="" href="hr#CD011520-note-0004">Hrvatski</a> </li> <li class="section-language"> <a class="" href="ms#CD011520-note-0003">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="pl#CD011520-note-0005">Polski</a> </li> <li class="section-language"> <a class="" href="ru#CD011520-note-0002">Русский</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD011520-note-0001">简体中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738735355000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738735355000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011520\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011520\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011520\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011520\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011520\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011520\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011520\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011520\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011520\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011520\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011520\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011520\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011520\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011520\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011520\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011520\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011520\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011520\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=zCmos3jT&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011520.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD011520.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD011520.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD011520.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011520.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740725520373"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD011520.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740725520377"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD011520.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918e7d3ece8ff4b8',t:'MTc0MDcyNTUyMC4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 